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ABSTRACT.
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease 
characterized serologically by B cell hyperactivity and a panoply of autoantibodies against 
nuclear, cytoplasmic and cell surface antigens. It is thought that T cells are involved in this 
process and more recently it has been suggested that the CD4' CD8\ i.e.double negative (DN) 
T cells, might be important.
As a start to understanding the contribution of DN T cells to disease pathogenesis in 
SLE, the percentages of DN T cells were determined and it was found that a p  but not y5 DNT 
cells were significantly increased in patients with SLE when compared to rheumatoid arthritis 
(RA) (autoimmune controls) and healthy controls.
To further establish their participation in the autoimmune reactions in SLE, the 
activation markers expressed by the DN T cells were examined. It was found that HLA-DR 
and CD69, and co-stimulatory molecules CD28 and CTLA-4 were all expressed by 
significantly higher percentages of DNT cells from patients with SLE, than those with RA or 
healthy controls (HC). More DN T cells from SLE patients were CD45RA+ than from 
controls, while CD45R0+ were reduced. DN T cells in patients with SLE also showed a more 
activated phenotype than their CD4+/ CD8+ counterparts.
To understand the functional significance in SLE DNT cells, the percentages of SLE 
a p  TCR+ DN T cells containing intracellular IL-4, a Th2 cytokine was determined. Higher 
percentages of SLE ap  TCR DN+ T cells contained DL-4 constitutively than RA or HC.
DN T cell populations from patients with SLE showed greater resistance to apoptosis 
in culture than the conventional CD4/CD8+ cells and DN T cells from healthy controls. High 
Bcl-2/Bax ratios and higher levels of Bcl-x observed in the DN T cells from patients with SLE 
could explain their resistance to apoptosis compared to the conventional T cells and DN T 
cells from healthy controls.
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Chapter 1. 
General Introduction.
15
1.1: Systemic lupus erythematosus.
Systemic lupus erythematosus is considered to be the prototypic systemic autoimmune 
rheumatic disease (Kotzin, 1996). It is a syndrome of complex multifactorial origin 
characterised by inflammation and has the potential to involve any of the body’s organs or 
systems (Isenberg, 1993). The American Congress of Rheumatology (ACR) revised 
classification criteria were originally formulated to classify the heterogenous population of 
SLE patients: it is widely used as a diagnostic standard. A patient can be diagnosed with SLE 
if they serially or simultaneously exhibit four of these criteria. This classification ‘set’ gives a 
correct definition of SLE with 95% sensitivity and 85% specificity (Hahn, 1998). The criteria 
are summarised in table 1.1:
• Malar rash
• Discoid rash
• Photosensitivity
• Oral ulcers
• Arthritis
• Serositis 
--pleuritis
or pericarditis
• Renal disorder
--proteinuria .0.5g/24 h or 3+, persistently 
or cellular casts
• Neurological disorder
— seizures
or psychosis (having excluded other causes e.g. drugs)
• Haematological disorder
— haemolytic anaemia
or leucopenia of < 4xl09/l on two or more occasions 
or lymphopenia of < 1.5x109/l on two or more occasions 
or thrombocytopenia< 1 OOx 109/l
• Immunological disorders
— positive LE cell
or raised anti-native DNA antibody binding 
or false positive serological tests for syphilis, present for 
atleast six months
• Antinuclear antibody in raised titre
Table 1.1: Criteria for the diagnosis of SLE: A person shall be said to have SLE if four 
or more of the eleven criteria are present serially or simultaneously, during any interval of 
observation (Tan et al., 1982).
16
SLE is a disease that affects predominantly women (female to male ratio- 9:1) of 
childbearing age (peak age of onset is between 20 and 40) with an incidence of approximately 
1:4000 in Caucasians. The incidence of SLE displays wide ethnic variations. For example, 
in the Birmingham area (circa 1995) the prevalence of SLE in females was 20.6:10,000 in 
Afro-Caribbeans, 9.1:10,000 in Asians and 3.6:10,000 in Caucasians (Johnston et al., 1995). 
The equivalent ratios for males were 0.93:10,000, 2.6:10,000 and 3.4:10,000 respectively. 
Similar ratios have been described by other groups who sampled patient populations in the 
USA and Europe (Fessel, 1974; Hochberg and Petri, 1993). Studies in twins suggest a 
concordance rate of between 30-70% for monozygotic twins compared to 3-15% for dizygotic 
twins. The fact that the concordance rate for monozygotic twins is not 100%, suggests that 
environmental factors have a role to play in addition to genetic factors in disease development 
(Isenberg, 1993; Isenberg and Horsfall, 1998).
1.1.1: Genetic Factors.
The genetic basis of lupus-like disease is remarkably complex, involving contributions 
from multiple genes in addition to the Class II MHC genes (Kotzin, 1996)
Multiple ethnic populations have been analysed for SLE susceptibility genes and three 
principles have emerged:-
a) For most ethnic populations, many susceptibility genes differ from those of 
other populations.
b) There are some single genes that predispose to disease across various ethnic
groups.
c) Genetic predisposition is linked to auto antibody repertoires and clinical 
subsets of disease (Wakeland et al., 2001 ).
The best-defined genes linked to SLE in humans are located on Chromosome 6 in the 
region that encodes the HLA genes. For example: -
HLA alleles A l, B8, DR3 -  associated with lupus in Caucasians.
HLA DR2 -  associated with lupus in Japanese
Some non- HLA genes and inherited complement deficiencies also predispose to lupus, 
as does IgA deficiency (Isenberg and Horsfall, 1998). Deficiencies in the early classical 
pathway complement components C lq , C2 and C4 are strongly associated with the
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development of a lupus like disease (Haq et al., 2002). Immunoglobulin G (IgG) receptors on 
mononuclear cells clear IgG and IgG containing immune complexes from the circulation. In 
Afro-American patients, associations have been found between SLE and the presence of low- 
affinity IgG receptors (Haq et al., 2002).
A list of modified genes that have been reported to mediate some component of 
systemic autoimmunity in human SLE and murine models is provided in table 1.2. As seen in 
the table these genes can be organized into broadly defined pathways impacting immune 
function relevant to systemic autoimmunity. A hypothetical model of the roles the various 
genetic pathways play in the initiation of SLE pathogenesis has been proposed in a recent 
review by Wakeland et al., and outlined in figure 1.1. The development of SLE can be viewed 
as involving interactions between the genes of the three pathways namely, loss of tolerance to 
nuclear antigens, dysregulation of the immune system and end organ targeting (Wakeland et 
a l,  2001).
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Proposed Mechanism Murine SLE Human SLE
Antigen/Immune complex 
clearance
Lymphoid signalling
Apoptosis
Epitope modification
C lq  knockout
C2, C3 knockout
SAP knockout
DNAase I knockout
Serum IgM knockout
Fey common chain
knockout
Mer Knockout
SHP-1 knockout
Lyn Knockout
Lyn/Fyn double knockout
CD22 knockout
BlyS transgenic
PD1 knockout
IL-2 knockout
CD45 E613R point
mutation
G2A knockout
IFN-y transgenic
Fas knockout
Fas-L knockout
Bcl-2 transgenic
Pten heterozygous
deficiency
P21 cyclin dependent 
kinase knockout 
a-Mannoside II knockout
C lq
C2, C3, C4
Mannose binding protein
FcyRIIA
FCyRIIIA
DNAase I
T cell receptor £ chain
TNF-a
IL-10
Table 1.2: Candidate genes and pathways implicated in SLE. 
(Wakeland et al., 2001)
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Susceptible individuals
Pathway 1 
Loss of tolerance to nuclear antigens
Slel, C lq , C4, SAP, DNAase
f
Anti-nuclear antibodies
Pathway 2 
Dysregulation of the immune system
V
Sle2, Sle3, Fas, Fas-L, Yaa, Lyn, BlyS, 
IL-2, PD-1
Pathogenic autoimmunity
Pathway 3 
End organ targeting
Vasculitis V
FcvIII, Sleld, Sle6
Nephritis
Neurological Arthritis 
disorders
Figure 1.1: Hypothetical pathway proposed by Wakeland et al., illustrating the manner
in which individual susceptibility genes interact to potentiate severe autoimmunity.
Sle: Systemic lupus erythematosus susceptibility foci.
C: complement protein.
SAP: Serum amyloid P component.
Yaa: Y-linked autoimmune accelerator.
Lyn: Src family tyrosine kinase.
BlyS: B lymphocyte stimulator.
PD -1: Programmed death 1 receptor.
IL-2: Interleukin 2.
Fc: Receptor for Fc region of immunoglobulin.
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1.1.2: Environmental factors.
Environmental influences on the expression of disease manifestations are clearly seen 
in SLE and those that may play a role are summarised in table 1.3. Of these factors the two 
most influential are UV light and sex hormones. It has been reported that up to 70% of SLE 
patients have disease flared by exposure to UV light (Kelley, 1990). A possible explanation 
for this is that UV light increases thymine dimerisation, which renders the DNA more 
immunogenic. More recently the ability of UV light to trigger apoptosis has been highlighted 
(discussed in section 1.9.3).
The predisposition of the disease to affecting women of child bearing age is not well 
understood. Estrogens are believed to play a role in the etiology of both human and murine 
SLE (Lahita, 1999). Sex hormones have been shown to augment CD8 and CD4 lymphocyte- 
mediated cytolysis, to enhance production of IFN-y and IL-10 by Thl and Th2 cells, 
respectively (Kammer et al., 1998). Rider et al, have reported that T cells from patients with 
SLE, but not normal or disease control cells, responded to estrogen by significantly increasing 
the amounts of calcineurin transcripts and calcineurin phosphatase (CN) activities (Rider et 
al., 1998). Calcineurin is a pivotal phosphatase in the biochemical cascade that conveys a signal 
from the T cell antigen receptor to the nucleus. The hypothesis proposed is that altered 
calcineurin regulation is a component of a primary T cell disorder encoded by multiple 
abnormal genes, manifested by T cell dysfunction, and resulting in increased autoimmunity 
(Kammer et a l, 1998). Recent research also suggests that estrogen acting through the estrogen 
receptor, enhances T cell activation in women with lupus resulting in amplified T-B cell 
interactions, B cell activation and autoantibody production (Rider and Abdou, 2001). Studies 
in mice also show that estrogen administration activates extrathymic T cell differentiation in 
the liver (Okuyama et al., 1992). The resulting T cells have unique characteristics such as 
autoreactivity and might in part, explain the female predominance of autoimmune diseases 
(Okuyama et al., 1992).
Drug-induced lupus was first recognised almost 50 years ago in association with 
hydralazine therapy, and numerous medications have been implicated in the de novo induction 
of rheumatological symptoms (Rubin, 1999). Drug-induced lupus has some features common 
with SLE and characteristically develops in people who have no history of systemic rheumatic 
disease. Medications currently in use and associated with at least several reports of lupus like 
syndrome are listed in table 1.3. The highest risk drugs are procainamide and hydralazine
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(Rubin, 1999, Ioannou et al., 2002). In vivo metabolites of the drugs rather than ingested 
medication are thought to be responsible for the initiation of autoimmunity. The proposed 
mechanisms for autoantibody induction by lupus-inducing drugs include-
•  Drug-altered B cell and/or T cell autoepitope,
• Drug directly activates B and /or T lymphocytes,
• Drug-specific T cells activate autoreactive B cells presenting drugs, and
• Drug prevents establishment of immune self-tolerance (Rubin, 1999).
Viral infections may be one of the factors that induce the production of autoreactive 
antibodies in patients with SLE, although the involved mechanisms are still incompletely 
understood. One proposed mechanism for virus-induced production of autoantibodies is 
molecular mimicry (Marilyn et al., 2003). Another mechanism derives from studies with the 
human polyomavirus BK. In these studies, in vivo binding of the polyomaviruses large T- 
antigen to chromatin of infected cells may render chromatin immunogenic. The large T- 
antigen-chromatin complex may thus function as a hapten-carrier model with subsequent 
production of anti-chromatin antibodies, including anti-dsDNA and anti-histone antibodies 
(Marilyn et al., 2003).
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Definite
Ultraviolet B light 
Sex hormones 
In humans ,
female:male ratio is 9:1 between 
menarche and menopause,
3:1 in young and old
Possible
Dietary factors
Alfalfa and related sprout foods (L-Canavanine)
High-calorie diets
High intake of saturated fats
Infectious agents
Retroviruses
Bacterial Lipopolysaccharides
Exposure to certain drugs:
Hydralazine
Procainamide
Isoniazid
Hydantoins
Chlorpromazine
Methyldopa
D- Pencillamine
Interferon-a
Table 1.3: Environmental factors that may play a role in SLE (Kelley, 1990)
1.2: Clinical assessment o f  SLE.
SLE is a complex multi-system disease. This complexity makes the disease difficult to 
monitor. In particular, there are problems in quantifying disease activity in the various 
organs/systems, and in differentiating potentially reversible organ dysfunction (due to active 
disease) from irreversible organ damage (Hay et al., 1993). More than 60 scales for measuring 
clinical disease activity in patients with SLE have been developed and used in a variety of 
studies but few have been validated ot shown to be reliable (Hay et al., 1993). Some of the 
most frequently used, validated global score systems are: the European Consensus lupus 
activity measure (ECLAM), systemic lupus erythematosus disease activity index (SLEDAI), 
systemic lupus activation measure (SLAM), and lupus activity index (LAI). In contrast the
23
British Isles Lupus Assessment group (BILAG) index provides an ‘at a glance’ view of activity 
in eight organs/systems. It is based on the ‘physicians intention to treat’ principle.
A number of studies of the SLEDAI, SLAM and BILAG disease activity indices have 
shown that the three indices are comparable and reproducible for evaluating disease in SLE 
(Gladman et al., 1992; Vitali et al., 1992). Most recently, when all these scores were used to 
assess a cohort of 19 patients, who were assessed fortnightly for 40 weeks, there was a 
statistically significant correlation between the results obtained from each score. During the 
study, 16 of the patients experienced a 96% or greater change in their disease activity as 
measured by the BILAG score (Ward et al., 2000).The BILAG score was used to assess each 
patient included in this thesis (Hay et al., 1993). The BILAG index is a computerised index for 
measuring clinical disease activity in SLE. The index allocates alphabetic scores (A-E) to each 
of the eight organs/systems (general, muco-cutaneous, neurological, musculoskeletal, 
cardiorespiratory, vasculitis and thrombosis, renal, haematological). The most active state is 
given an A grade while the complete absence of disease activity during the course of the 
disease gets an E. These individual organ grades were converted into a global score, with grade 
A=9, B=3, C=1 and D&E =0. A patient with a global score of more than or equal to 6 is 
regarded as having active disease and 0-5 inactive disease.
1.2.1: Clinical feature o f SLE.
SLE has the potential to involve multiple organ systems directly, and its clinical 
manifestations are extremely diverse and variable. Musculoskeletal and dermatological 
involvement are the most common manifestations of lupus, with more than 90% of the patients 
having one or both systems affected (Haq et al., 2002).
Arthralgia (90%), myalgia (50%), and tenosynovitis (20%) are common features in the 
musculoskeletal system. Avascular necrosis of the bone causes major morbidity in SLE and is 
associated with corticosteroid use. Osteoporosis is another major complication of SLE. It may 
result from lack of vitamin D caused by sun avoidance, menstrual cycle dysfunction from 
disease or treatment, corticosteroid use or lack of exercise (Haq et al., 2002).
The heart and lungs are often involved -  shortness of breath, pleurisy and pleural 
effusions are seen in about half of patients (Kelley, 1990). Pulmonary hypertension in SLE 
may result from multiple factors such as vasculitis, thrombosis and pulmonary artery 
vasoconstriction (Haq et al., 2002). The prognosis is relatively poor. Thromboembolic disease
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is associated with the presence of lupus anticoagulant and antiphospholipid antibodies and 
patients may need lifelong anticoagulation (Haq et al., 2002).
Gastrointestinal system symptoms are common in SLE. Anorexia, nausea and vomiting 
occur in up to half of the patients (Haq et al., 2002). Sjogren’s syndrome may coexist with 
SLE and can cause gingivitis, accelerated dental caries and oral infections such as candidiasis 
(Haq et al., 2002). Patients with SLE are at risk of peptic ulcer disease from the use of non­
steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (Haq et al., 2002).
Until recently, renal disease was the major cause of death in SLE, and 30% of patients 
develop significant renal disease (Haq et al., 2002). Symptoms can be minimal until substantial 
kidney damage has occurred (Haq et al., 2002). The immunosuppressive therapies used to treat 
the involvement of the kidneys add greatly to the morbidity and mortality of SLE patients 
(Zimmerman et al., 2001).
Skin involvement is another common occurrence and up to 40% of patients have 
characteristic butterfly rash- essentially a photosensitive vasculitis over the malar bones and 
bridge of the nose. Patients also show maculopapular discoid lesions and vasculitis lesions on 
fingers and toes (Haq et al., 2002). The commonest causes of death from SLE are infection, 
malignancy or atherosclerosis (Kelley, 1990).
1.2.2: Immunopathology.
The result of interactions between susceptibility genes and triggering environmental 
factors is the development of an abnormal immune response characteristic of SLE. The 
primary pathogenic components responsible for causing SLE are elusive, because the primary 
immunogens that trigger the auto-immune response in the disease have not been clearly 
identified (Datta, 1998).
The common denominator among SLE patients is Immunoglobulin G (IgG) 
autoantibody production, and in particular the elevated serum levels of antibodies to nuclear 
constituents (i.e., anti-nuclear antibodies or ANAs)(Kotzin, 1996). Raised dsDNA antibody 
titres were found in 60% of the patients in a study of a cohort of 300 patients by Isenberg et al 
(Haq et al., 2002). dsDNA antibodies are closely related to renal disease and an increase in 
titre, particularly if it is associated with decreasing C3 levels, alerts the clinician to a possible 
flare of disease (Haq et al., 2002). These pathogenic autoantibodies are an effect of hyper
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activity of auto-reactive B and T cells and the failure of the immunoregulatory circuits to 
control their activity (Kotzin, 1996).
1.2.3: Treatment o f patients with SLE.
Successful therapy of patients with SLE depends upon targeting both the symptoms and 
the underlying infection. Both pharmacological and non-pharmocological therapies are used to 
treat patients with SLE (Ioannou et al., 2002). The pharmacological management of patients 
with SLE presently revolves around four main classes of drugs, often in combination. These 
are:
•  Non-steroidal anti-inflammatory drugs (NSAIDs).
• Anti-malarial s.
•  Corticosteroids.
• Cytotoxic drugs.
Patients with mild lupus are generally treated with a combination of NSAIDs and antimalarial 
drugs such as a hydroxychloroquine (Plaquenil) (Ioannou et al., 2002). Low doses of 
corticosteroids are used when NSAIDs and antimalarials have failed to control symptoms of 
arthralgia/arthritis or rash sufficiently (Ioannou et al., 2002). Treatment of patients with major 
organ involvement involves broad spectrum immunosuppression with cytotoxic agents 
(Zimmerman et al., 2001). The drugs most frequently employed are azathioprine or 
cyclophosphamide together with corticosteroids, often in high doses. The use of 
cyclophosphamide, however, is limited by its side effect profile of profound nausea, alopecia, 
infertility especially in patients over the age of 30 and bone marrow suppression (Ioannou et 
al., 2002). The Bloomsbury rheumatology clinic, attended by patients studied in this thesis 
were treated with oral prednisolone, with azathioprine in mild to moderately active lupus, 
reserving pulsed cyclophosphamide (intravenous pulses of cyclophosphamide) for severe renal 
involvement (Ioannou et al., 2002).
Other treatments regimens used include plasmapheresis, dietary therapy, intravenous 
high dose gammaglobulins and cyclosporin therapy (Ioannou et al., 2002). Plasmapheresis or 
plasma exchange was thought to benefit the patient by the removal of autoreactive antibodies, 
antigens, and immune complexes from the circulation (Zimmerman et al., 2001). No
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conclusive advantage of this form of treatment has emerged from clinical studies, and 
limitations in its use include a “rebound” synthesis of autoantibodies, technical difficulties 
requiring central venous access with associated complications, patient discomfort and being an 
expensive form of therapy (Zimmerman et al., 2001, Ioannou et al., 2002). Dietary therapy in 
the form of calorific and in particular fat restriction is beneficial to patients, as is total zinc 
reduction (Ioannou et al., 2002). Studies have also shown the beneficial effects of a diet low in 
saturated fat combined with fish oil supplementation over a six-month period (Walton et al., 
1991). Calorie restriction, however, has no place in the patient with severely active lupus with 
major organ damage, as these patients tend to be acutely unwell and hence in a hypercatabolic 
state (Ioannou et al., 2002). Intravenous immunoglobulin therapy has an established role in 
lupus patients with severe thrombocytopenia or immune neutropenia (Ioannou et al., 2002). 
The intravenous administration of human immunoglobulin (Ig) could ameliorate symptoms by 
solubilizing immune complexes deposited in the kidney or by blocking Fc receptors on 
immune effector cells or mesangial cells of the kidney glomerulus (Zimmerman et al., 2001). 
Recent evidence has also demonstrated that cyclosporin (CsA) in low doses (2.5-5mg/kg/day) 
may provide reasonable disease control and offer the opportunity for reduction in steroid over 
long term follow up (Ioannou et al., 2002). Cyclosporin selectively inhibits T-cell function by 
blocking transcription of specific cytokines such as IL-2 and IFN-y (Marilyn et al., 2002). The 
primary concern about the use of cyclosporin has been the potential for long-term 
nephrotoxicity, although other reversible side effects include hypertension, gingival 
hyperplasia and hypertrichosis (Zimmerman et al., 2001).
Greater understanding of the immunopathogenic dysregulation characterising lupus in 
recent years, has enabled the development of targeted therapy to interfere with this 
dysregulation at various levels. Reagents near or at clinical trial phase include biological 
treatments developed to modulate or inhibit T cell activation (CTLA-4Ig, anti-CD40 ligand, 
anti-B7 monoclonal antibodies), T and B cell collaboration, anti-dsDNA antibody production 
(anti-CD20 mouse/human chimeric antibody monoclonal antibody), deposition of anti-dsDNA 
antibody complexes (DNase), complement activation/deposition (anti-complement 5 
monoclonal antibody), and cytokine activation (anti-IL-10 antibody, recombinant IL-1) 
(Ioannou et al., 2002, Marilyn et al., 2002).
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1.3: Autoantibody production and disease manifestation.
The principle targets for the autoantibodies produced in SLE include protein-nucleic 
acid complexes, notably ds and ss DNA, histones and nucleosomes, the U 1 and Sm small 
nuclear ribonucleoprotein(snRNP) particles and the Ro/SSA and La/SSB RNP complexes(Tan,
1989). Autoantibodies to phospholipids (complexed to P2 glycoprotein 1) are also relatively 
frequent and associated with thrombotic complications. A separate group of autoantibodies in 
SLE are directed to cell surface molecules, causing haemolytic anaemia and platelet 
destruction (thrombocytopenia)(Kotzin, 1996). The mechanisms by which most autoantibodies 
in lupus may cause disease is unclear. Anti-nuclear antibodies may on occasion penetrate 
cellular membranes and cause disease by binding to their intracellular targets (Alarcon-Segovia 
et al., 1979). More often it is believed that, the disease manifestations such as lupus nephritis, 
arthritis, and vasculitis may due to the formation of immune complexes.
Antibody % prevalence
Anti-nuclear antibody 96
Anti-Ro 25
Anti-La 19
Anti-Sm 10
Anti-UIRNP 13
Anticardiolipin IgG 24
Anticardiolipin IgM 13
Anti-ds DNA 70
Table 1.4: Prevalence of autoantibodies in patients with SLE (Cervera et a l ,  1993).
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Anti-double stranded DNA (anti-ds DNA abs) antibodies are the most prevalent form 
of anti-nuclear antibody (ANA) in SLE patients (Table 1.4). Genetic studies indicate that anti- 
dsDNA antibodies derive from an antigen selective stimulus (Radic and Weigert, 1994). These 
antibodies are usually oligoclonal, somatically mutated, and their V regions contain structures 
that are selected by, and bind to, double stranded DNA (Rekvig et al., 1997). In contrast to 
anti-single stranded DNA antibodies (anti-ssDNA abs), anti-ds DNA antibodies are very rarely 
found in any disease other than SLE (Koffler et al., 1971; Isenberg and Collins, 1985). Since, 
anti-dsDNA antibodies are common in, and specific to, SLE they represent a good candidate 
as a pathogenic factor in SLE. Therefore, their structure and relationship with disease activity 
needs to be characterised. The association of anti-ds DNA antibodies as one of the pathogenic 
factors in SLE is well established although while some studies find a strong correlation, 
particularly with vasculitis and glomerulonephritis, others find a weaker link (Esdaile et al., 
1996; Petri et al., 1991). The disparity in the results of the various studies may be due to:
1. the differences in the detection methods used,
2. missing the expansion in antibody levels as they are sequestered to target organs (e.g., 
kidney) or
3. that in a particular cohort of patients tested there is no association.
It is however, generally agreed that rising anti-ds DNA titres increase the risk of disease 
exacerbation in the following 8-10 weeks by a factor of 2-3 (Hahn, 1998).
1.3.1: Anti-DNA antibodies.
Normal individuals produce “natural” anti-DNA antibodies of IgM class in high 
frequency (Datta et al., 1986). In drug-induced lupus or patients with macroglobulinaemia, 
high levels of anti-DNA antibodies usually binding to ssDNA rather than dsDNA are produced 
with no disease manifestations as in SLE (Lahita et al., 1979; Pisetsky et al., 1990). Anti- 
histone antibodies are also a common feature of drug-induced lupus (Rubin, 1999).
In contrast to the natural (IgM) antibodies, pathogenic (e.g., nephritogenic) anti-DNA 
antibodies are of the IgG class (Theofilopoulos et al., 1989). These IgG antibodies are cationic 
as described in murine models and accompany the onset of murine lupus nephritis (Furukawa, 
1997; Datta et al., 1987). The cationic anti-DNA antibodies and or cationic immune complexes
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may form persistent immune deposits in glomeruli when injected into normal mice whereas the 
anionic (or neutral) antibodies and immune complexes do not persist (Shivakumar et al., 1989). 
Thus, deposition of immune complexes consisting of cationic anti-DNA autoantibodies may 
initiate the renal lesions of lupus nephritis, which may then be followed by the deposition of 
anionic or neutral autoantibodies (Gavalchin and Datta, 1987). The nephritogenic potential of 
cationic anti-DNA antibodies or cationic immune complexes probably arises from their affinity 
for the glomerular anionic sites that are constituted by negatively charged proteoglycans (Datta 
et al., 1987). Deposition of antibodies on the glomerular basement membrane results in 
recruitment of complement components and engagement of Fc receptors either on renal cells or 
on circulating monocytes (Schiffer et al., 2002). This deposition precipitates an inflammatory 
cascade in which upregulation of adhesion molecules and renal inflammatory chemokines 
attracts more lymphoid cells upregulation of lymphoid derived chemokines enhances influx of 
cells into the kidney. Release of cytokines and other inflammatory mediators results in tissue 
damage that finally leads to irreversible cell death (Schiffer et al., 2002).
Isolated B cells from both active and inactive lupus patients spontaneously produced 
markedly increased levels of total polyclonal IgG as compared to normal subjects but only B 
cells from active patients could produce pathogenic (cationic) anti-DNA autoantibodies with 
the help of autologous T helper cells (Shivakumar et al., 1989). These cationic anti-DNA 
antibodies produced by B cells (cultured in-vitro) isolated from patients with SLE with active 
disease (lupus nephritis) are found to be strikingly restricted in spectrotype. This observation 
indicates that the Th cells (T helper cells) help an oligoclonal population of B cells that are 
committed to produce this pathogenic variety of autoantibodies in patients with active disease. 
Studies in murine models of lupus nephritis have also shown that the pathogenic (cationic) 
variety of anti-DNA antibodies share a common antigenic specificity pattern and cross-reactive 
idiotype. These antibodies are distinct from nonpathogenic (natural) autoantibodies, indicating 
that they are produced by a select and oligoclonal population of B cells (Gavalchin and Datta, 
1987; Hahn and Ebling, 1984). Thus, it has been concluded that in humans and mice with 
active SLE, complex cellular mechanisms specific for the induction of pathogenic anti-DNA 
antibodies are operative. This discreet immunoregulatory defect could involve select subsets of 
T (helper) cells and B cells (Shivakumar et al., 1989)
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1.4: Cellular abnormalities in SLE.
Studies show that the cellular immune disorder of SLE is complex including 
multicellular dysfunction of all mononuclear leukocytes, including monocytes, macrophages, 
natural killer cells, B lymphocytes and T lymphocytes (Dayal and Kammer, 1996). Some of 
the major cellular and cytokine abnormalities in SLE are briefly summarised in table 1.5. In 
general, T and B cells manifest evidence of intense in vivo activation, but are hypo-responsive 
to exogenous antigens in vitro (Cohen, 1993).
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Cells
Monocytes/Macrophages 
Lymphocytes 
B cells
T cells
Defect
Decreased TNF-a production
Increased numbers of activated B cells
Hypergammaglobulinaemia, with a wide 
range of autoantibodies
Increased CD25 expression
Decreased CR1 expression
Increased cytoplasmic and surface 
expression of hsp90
Decreased numbers of CD4+ 
CD45RA+cells
Increased numbers of activated T cells 
(HLADR+)
Increased numbers of a p  TCR+ DN 
(CD3+CD4 C D 8 ') T cells
Increased and prolonged expression of 
CD40L on T cells
Defective supression/regulation
Impaired cytotoxicity
Table 1.5: Some major cellular abnormalities in SLE. Table adapted from Isenberg, 
1993.
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1.4.1: Role o f B cells in SLE.
B cells play a pivotal role in SLE. They are the source of the pathogenic 
autoantibodies, some of which may be harmful, others may serve as potentially useful 
diagnostic markers (Cohen, 1993). Their role is not limited to secretion of autoantibodies and 
it seems unlikely that SLE is solely an immune complex mediated disease. Under certain 
conditions, B cells can activate memory T cells, and process and present self antigens to naive 
T cells, implying the existence of an antibody-independent mechanism for tissue injury in 
systemic autoimmune diseases, such as lupus (Zouali, 2002 ).
It is evident that switching of both antibody isotype and idiotype may be involved in 
the immunopathology of lupus. IgG antibodies are more pathogenic than IgM and certain 
idiotypes (e.g. Id 16/16) have been found in the serum of the majority of lupus patients and in 
many renal biopsies (Haq et al, 2002).
There is often a marked increase in the numbers of plasma cells in the peripheral blood 
and in the numbers of B cells at all stages of activation (Kelley, 1990). Studies of twins and 
family members have shown that such increased numbers can precede a clinical disease 
(Kelley, 1990).
In mice, polyclonal activation of B cells precedes the accumulation of high avidity 
single autoantigen specific B cell repertoire that characterises well-developed disease (Kelley,
1990). This suggests that B cells in mice are subject to both increased polyclonal and specific 
activation (Dziarski, 1988). Individual autoantibody repertoires vary from person to person- 
although all have ANA’s, some have anti-dsDNA antibodies, others have anti-Ro antibodies 
etc (Kelley, 1990). Hence it is likely that many B cells are activated by specific autoantigens 
although the basis for this hyperactivity is unknown. However, it has been reported that SLE B 
cells are more easily activated and driven to mature by cytokine stimulation than B cells from 
normal individuals. For example, B cells from SLE patients are more easily driven to 
differentiate by IL-6 than are normal B cells (Kelley, 1990).
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1.4.2: Role o fT  cells in SLE.
B cell hyperactivity and autoantibody production are considered to be central to the 
pathophysiology of SLE. T cells have been postulated to have a major role in driving the SLE 
associated B cell hyperactivity based on observations that:
• Much of the pathology in SLE is mediated by autoantibodies of the IgG class, a 
T cell dependent response (Cohen, 1993; Via et al., 1993; Spronk et al., 1996)
• In vivo manipulations in murine SLE which reduce or inhibit T cell numbers 
and /or function have been shown to improve disease parameters (Via et al., 1993; Wang et 
al. ,2002 )
•  There is an association of SLE with particular class II major histocompatability 
complex (MHC) alleles (Kotzin, 1996)
The specificities of the autoreactive T cells, however have not been well characterised 
and the nature of T cell help in SLE may differ from conventional responses. The emergence 
of these autoimmune T and B cells in SLE is probably determined by genetically programmed 
defects of the immune system. Environmental and other endogenous factors may play a 
secondary role in lupus as non-autoimmune subjects are also exposed to the same factors 
(Datta, 1998). The question remains whether the T cell dysfunction in SLE reflects an intrinsic 
disorder(s) and/or a faulty interaction between antigen presenting cell (APC) and T cell.
1.4.3: Primary T cell disorders in SLE.
Studies demonstrating both biochemical and functional abnormalities in T cells from 
patients with SLE have led to the hypothesis of a primary T cell disorder in SLE. This primary 
T cell disorder could result in altered regulation and/or expression of genes that impair T cell 
immune effector functions. Although substantial gaps in the knowledge of the primary T cell 
disorders remain, dysfunctional signalling has been identified in both the adenyl 
cyclase/cAMP/protein kinase A and phosphoinositide/Ca++/protein kinase C pathways in 
murine and human lupus (Dayal and Kammer, 1996). CD3-mediated increases in free 
intracytoplasmic calcium occur specifically in lupus T cells and lines. This finding provides 
additional evidence that cell signalling events are defective in patients with lupus (Tsokos, 
1996). The increased calcium responses in lupus T cells may account for the altered apoptosis,
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altered PKA function or decreased IL-2 production reported in SLE (Tsokos, 1996). The 
presence of these defects in the T cell signal transduction system could significantly modify the 
T cell’s capacity to express particular genes in response to certain stimuli resulting in altered 
gene expression. Altering gene expression of cytokines for example, could potentially lead to 
a shift in the predominant T cell cytokine pattern (e.g., ThO-» Th2 switch), hindering 
physiological T cell effector and regulatory function.
1.4.4: T cell -Antigen presenting cell (A P C ) interactions in SLE.
Defects in antigen presenting cell surface molecule expression and function 
have been reported in patients with SLE (Tsokos et al., 1996). Abnormal APC function has 
been supported by studies evaluating the response of T cells from patients with SLE to the 
recall antigen influenza virus and alloantigens (Via et al., 1993). Studies showing that the 
need for APC delivered co-stimulation is bypassed by effectively cross-linking CD28 or CD26 
T cell surface molecules also point to impaired APC function (Sfikakis et al., 1994; Plana et 
al., 1994). APCs from patients with SLE have also been found to be defective in their 
expression of the B7-1 (CD80) costimulatory molecule. Resting normal APCs do not express 
B7-1, but treatment with interferon gamma (IFN-y) induces its expression. APCs from SLE 
patients failed to express surface B7-1 following stimulation with IFN-y and this defective 
expression is thought to be responsible for the decreased response of lupus T cells to recall 
antigens (Tsokos et al., 1996; Scheinecker et a l.,).
1.5: Cytokines in SLE.
The development of an effective immune response involves lymphoid cells, 
inflammatory cells, and haematopoietic cells. The complex interactions among these cells are 
mediated by a group of secreted low-molecular weight proteins that are collectively called 
cytokines to denote their role in cell to cell communication.
Cytokines play an essential role in moulding the quality of immune response to foreign 
or self-antigens. These mediators have been classified according to their cellular source and 
effector functions, with the Thl and Th2 families best illustrating this division of labour. The 
Thl cytokines include IL-2 and interferon-y (IFN-y), which in general promote delayed-type 
hypersensitivity responses by induction of T cell proliferation and monocyte activation. The
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Th2 cytokines include IL-4, IL-5, IL-6 and IL-10 and promote humoral immune responses 
(Singh et al., 1999; Van Eden et al. , ). T cells expressing cytokines of both patterns have been 
designated ThO. ThO cells represent a heterogeneous population of partially differentiated 
effector cells comprising multiple discrete subsets that can secrete Thl and Th2 cytokines 
(Romagnani, 1997). Furthermore, T cells producing transforming growth factor-p (TGF-p), 
IL-4 and IL-10 have been described as Th3 cells, and are considered regulatory cells that can 
act to induce immune tolerance (Dean et al., 2000 )
Cytokines have been suggested to play an important role in the immune dysregulation 
observed in patients with SLE and murine lupus prone strains. The abundant data on the 
expression, activity, or response to different cytokines in patients or murine models have been 
controversial (Horwitz and Jacob, 1994; Singh et al., 1999; Dean et al., 2000 ).The analysis of 
cytokines in disease states, in general, has been complicated by variable results derived from 
studying serum levels, secretion into culture supernatants or ex vivo analysis of intracellular 
mRNA or proteins (Horwitz, Stohl,Gray, 1997). Cytokine abnormalities in patients with SLE 
were first documented in studies of IFN-a, the first cytokine to be described. IFN-a now has 
been shown by several groups to be elevated in sera from patients with SLE, although the 
cellular source and stimulus for the production of that cytokine are not yet defined (Hooks et 
al., 1982). It is important to note that cytokine production is not only changed in patients with 
SLE when compared with autoimmune disease controls (RA) or healthy subjects, but also 
changes with different disease phenotypes. For example, IL-6 seems to be increased in the 
cerebrospinal fluid (CSF) of patients with central nervous system (CNS) involvement in SLE 
but not in patients with SLE who lack neurological symptoms (Dean et al., 2000 ). It may be 
that as in other inflammatory diseases, the balance of cytokines is more important in 
determining disease phenotype or severity rather than determining disease susceptibility. 
Aberrant (increased or decreased) production of several cytokines including IL-1, TNF-a, IL- 
2, IL-3, IL-4, IL-5, IL-6, IL-10, IFN-y and IFN-a have been reported in patients with SLE and 
murine models of lupus (Dean et al., 2000).
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1.5.1: The Thl/Th2 paradigm: role in SLE.
Thl and Th2 T cells were first described by Mosmann et al., who discovered that T 
cells could be conveniently divided into two subsets, Thl and Th2, with distinct arrays of 
cytokine secretion patterns and functions (Mosmann et al., 1996; Mosmann et al., 1986). A 
hypothesis was subsequently formulated according to which cell-mediated autoimmune 
diseases such as insulin-dependent diabetes mellitus are induced by Thl cells and their 
cytokines and humoural-mediated autoimmune diseases are mediated by Th2 cells and their 
cytokines.
The respective contributions of Th 1 and Th2 cytokines to the pathogenesis of SLE are 
still a matter of debate. Several Th2 cytokines, e.g., EL-6 and IL-10, are known to promote 
antibody formation by B cells, supporting the hypothesis that Th2 cells play an active role in 
the development of autoantibody-mediated autoimmune diseases such as SLE (Romagnani, 
1997; Kirou and Crow, 1999; Horwitz and Jacob, 1994; Dean et al., 2000 ). Further, 
treatment of MRL-lpr lupus prone mice with IL-4R or anti-IL-4 antibodies resulted in reduced 
mortality and disease (Nakajima et al., 1997; Schorlemmer et al., 1995). In addition, 
administration of IL-6 promoted and anti IL-6 inhibited disease in the MRL-lpr lupus prone 
mice (Ryffel et al., 1994; Finck et al., 1994). However, immune responses involving the Thl 
phenotype have also been found in the both patients with SLE and in murine models of lupus 
(Theofilopoulos et al., 2001 ; Kirou and Crow, 1999). For example, exacerbation of SLE by 
repeated injections of IFN-y, and inhibition by anti-IFN-y antibodies in (NZBxNZW) Fi hybrid 
mice, suggest the involvement of Th-1 type cells in the spontaneous development and 
progression of SLE (Jacob et al., 1987). Further support for a pathogenic role for the Thl 
cytokine IFN-y was the demonstration that MRL/lpr mice lacking IFN-y or IFN-y receptor had 
no glomerulonephritis (Schwarting et al., 1998). A kinetic study of disease progression in 
various strains of MRL mice correlated disease with increased expression of IFN-y, a relative 
decrease in production of IL-4, and IgG2a and IgG3, compared with IgGl, autoantibody 
levels. (Takahashi et al., 1996; Reininger et al., 1996). Taken together these findings have led 
to the suggestion that Th 1 cytokines may initiate disease, followed by production of 
autoantibodies and secretion of proapoptotic and proinflammatory cytokines, mainly derived 
from monocytes. Th2 cytokines, while potentially protective, may be inadequate in lupus mice 
(Santiago et al., 1997).
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Recent studies in patients with SLE also indicate a role for monocytes in the generation 
of potentially pathogenic cytokines such as IL-6 and IL-10, known to enhance B cell growth 
and differentiation and contribute to autoantibody formation (Linker-Israeli et al., 1991; 
Linker-Israeli et al., 1999). Regulation of IL-6 expression is achieved through positive and 
negative signals. Studies have shown that some cytokines particularly IL-ip and TNF-a 
stimulate IL-6 while IL-4, IL-10 and TGF-p inhibit IL-6 secretion by PBMC from patients 
with SLE in vitro (Linker-Israeli et al., 1999).
Therefore it is likely that both Thl and Th2 cytokines can modify a given autoimmune 
disease such as SLE depending on various factors such as stage of disease, local versus 
systemic expression and genetic background and without strict adherence to the Th 1 versus 
Th2 dualism.
1.6: Nucleosomes as autoantigens in SLE
The cardinal feature of systemic lupus erythematosus is the formation of anti-nuclear 
antibodies notably those directed against DNA. Some of these antibodies react with the native 
(double-stranded) B helical form of DNA, while others only react with denatured (single­
stranded) DNA(ssDNA). Most healthy subjects have a natural autoantibody repertoire 
including anti-DNA antibodies (Pisetsky et al., 1990). The anti-DNA antibodies in healthy 
subjects show only a weak affinity for DNA and wide cross-reactivity for other antigens, and 
are mostly of the IgM isotype. In contrast, anti-DNA antibodies involved in the pathogenesis of 
SLE are of the IgG isotype and display high affinity for DNA. These antibodies bear all the 
characteristics of an antigen driven, T cell dependent immune response (Desai-Mehta et al., 
1995).
Although for a long time dsDNA has been believed to be a major autoantigen in SLE, 
dsDNA does not occur as such in vivo and also has poor immunogenicity in animal models. 
DNA outside the cell is generally present in the form of nucleosomes generated by apoptosis. 
Nucleosomes appear to be the particles that provide DNA in vivo and possibly become more 
immunogenic due to apoptosis induced modifications (Berden et al., 1999; Bruns et al., 2000 ).
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The role of nucleosome as an autoantigen in SLE is further strengthened by the presence of 
nucleosome specific T helper cells and the high prevalence of nucleosome specific antibodies 
in patients with SLE (Bruns et al., 2000 )
T cell autoimmunity to nucleosomes may be a latent property of the immune system, 
but the spontaneous expansion of nucleosome-reactive T cells is a lupus specific event (Lu et 
al., 1999; Bruns et al., 2000; Andreassen et al., 2002 ). A recent hypothesis by Datta et al, 
proposes that a sustained hyper-expression of CD40 ligand by lupus T cells, instigates 
tolerogenic dendritic cells or resting B cells to present nucleosomes in an immunogenic fashion 
(Kaliyaperumal et al., 2002). Only certain epitopes in nucleosomes have been found to be 
dominantly recognised by the autoimmune T and B cells of SLE patients. By testing 
overlapping synthetic peptides spanning the core histones in nucleosomes, autoepitopes for 
murine and human lupus were identified. Autoimmune T cells from lupus prone mice, as well 
as patients with SLE were shown to be spontaneously primed to these disease relevant epitopes 
(Lu et al., 1999). Anti-dsDNA and anti-ssDNA antibodies were found to be cross reactive 
with nucleosome antigens and conversely, antinucleosome antibodies with DNA. This cross 
reactivity of the antibodies is commonly explained by epitope spreading (Monneaux et al., 
2001).
The pathogenic impact of antinucleosome antibodies in human SLE is highlighted by a 
strong correlation with a more severe disease course, namely nephritis. Nucleosomes have 
been shown to bind to the glomerular basement membrane (GBM), via their histone proteins. 
Glomerulonephritis is then caused by the formation of nucleosome-anti-nucleosome antibody 
immune complexes (Van Bruggen et al., 1997).
Nucleosomes in vivo are generated by the process of apoptosis. There is growing 
evidence that in systemic lupus erythematosus, apoptosis is disturbed, leading to the release of 
nucleosomes. Moreover, the immunogenicity of these autoantigens might be enhanced by 
apoptosis induced modifications. Impaired clearance of apoptotic cells might be another factor 
contributing to the abundance of autoantigens (e.g., nucleosomes) in SLE (Bruns et al., 2000).
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1.7: Apoptosis
Apoptosis from the Greek meaning “falling o ff’ refers to the morphological 
appearance of cells dying by default (e.g. in embryogenesis) or following active initiation of a 
programmed pathway by a variety of soluble and surface signals. The importance of 
programmed (apoptotic) versus toxic (necrotic) cell death is that the former results in the 
ordered fragmentation of the cell. Cell fragments are degraded and phagocytosed by 
neighbouring cells or professional phagocytes, which are not activated and therefore do not 
cause inflammation.
Multiple signalling and effector pathways that mediate active responses to external 
growth, survival, or death factors control apoptosis. The defining characteristic of apoptosis is 
a complete change in cellular morphology. Cells undergo shrinkage, chromatin margination, 
membrane blebbing, nuclear condensation and then segmentation, and division into apoptotic 
bodies which may be phagocytosed, often within several hours (Cohen, 1993). Apoptosis or 
programmed cell death is distinct from accidental cell death (necrosis). Numerous 
morphological and biochemical differences that distinguish apoptotic from necrotic cell death 
are summarized in table 1.6.
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Apoptosis Necrosis
Morphologic criteria
Deletion of single cells
Membrane blebbing, but no loss of integrity
Cells shrink, ultimately forming apoptotic bodies
No inflammatory response
Phagocytosis by adjacent normal cells, 
macrophages
Lysosomes intact
Compaction of chromatin into 
dense masses
Biochemical Criteria
Induced by physiological stimuli disturbances
Tightly regulated process with synthetic 
steps
Requires energy
Requires macromolecular synthesis
De novo gene transcription
Non-random oligonucleosomal length 
DNA
Death of cell groups 
Loss of membrane integrity 
Cells swell and lyse 
Significant inflammatory response 
Phagocytosis by macrophages and some
Lysosome leakage
Clumpy, ill-defined aggregation uniformly 
of chromatin
Evoked by nonphysiological 
disturbances
Loss of regulation of and ion activation 
homeostasis
No energy requirements
No requirements for protein or
nucleic acid synthesis
No new gene transcription
Random digestion of fragmentation of 
DNA
Table 1.6: Morphological and biochemical differences between apoptotic and necrotic 
cell death. Table adapted from (Elkon, 1994; Seki et al., 1998).
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1.7.1: Regulation o f apoptosis
Over the past decade, our understanding of apoptosis, or programmed cell death, has 
increased greatly, with the identification of some of the major components of the apoptotic 
program and the processes regulating their activation. Although apoptosis is an intrinsic 
process present in all cells, it can be regulated by extrinsic factors, including growth factors, 
cell surface receptors, cellular stress and hormones.
Bcl-2 and related cytoplasmic proteins are key regulators of apoptosis, the cell suicide 
program critical for development, tissue homeostasis, and protection against pathogens. The 
bcl-2 gene was originally identified at the chromosomal breakpoint of t( 14; 18) -bearing B-cell 
lymphomas. The Bcl-2 family of proteins can somehow register diverse forms of intracellular 
damage, gauge whether other cells have provided a positive or negative stimulus, and integrate 
these competing signals to determine the cell’s fate. Members of the Bcl-2 protein family 
most similar to Bcl-2 promote cell survival by inhibiting adapters needed for the activation of 
proteases (caspases) that dismantle the cell. More distant relatives instead promote apoptosis, 
apparently through mechanisms that include diplacing adapters from the pro-survival proteins 
(Reed, 1997; Adams and Cory, 1998). Pro- and anti-apoptotic family members can 
heterodimerize and seemingly titrate one another’s functions, suggesting that their relative 
concentration may act as a rheostat for the suicide program (Oltvai et al., 1993). At least 15 
Bcl-2 family members have been identified in mammalian cells and several others in viruses.
A list of some of the better known members of the Bcl-2 family is given below in table 1.7.
Pro-apoptotic BC1-2 
family members
Anti-apoptotic Bcl2 
family members
Bax Bcl-2
Bak B c 1-x l
Bok Bcl-w
Bad Mcl-1
Bim
Bid
Table 1.7: The Bcl-2 family of pro- and anti- apoptotic proteins.
42
Elegant studies by Oltvai et al., have demonstrated that Bax counters the death 
repressor activity of Bcl-2 and proposed a model in which the inherent ratio of Bcl-2 to Bax 
determines the susceptibility to death following an apoptotic stimulus (Figure 1.2) (Oltvai et 
al., 1993).
SURVIVAL
BCL-2 BCL-2
BCL-2 BAX
BAX BAX
DEATH
Figure 1.2: Model of interrelationship of Bcl-2 andBax and the regulation of 
programmed cell death (Oltvai et a l ,  1993).
In 1993, Boise et al., reported the isolation of Bcl-x, a Bcl-2 related gene that could 
function as a Bcl-2-independent regulator of apoptosis. Alternative splicing of the Bcl-x 
mRNA was found to result in two distinct forms of the mRNA. The protein product of the 
larger mRNA, B c 1 -x l ,  was similar in size and predicted structure to Bcl-2. Surprisingly, the 
second mRNA species bcl-xs, encodes a protein that inhibits the ability of Bcl-2 to enhance 
the survival of growth factor-deprived cells. Thus, the authours concluded that Bcl-x plays an 
important role in both positive and negative regulation of apoptosis (Boise et a l ,  1993).
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1.7.2: Apoptosis Dysregulation in SLE
Recent research shows that the genes with a distinct expression pattern in 
autoimmunity are not necessarily “immune response” genes, but are genes that encode 
proteins involved in apoptosis, cell cycle progression, cell differentiation, and cell migration.
A large number of genes that encode proteins involved in multiple apoptosis pathways were 
found to be under expressed in PBMC’s of patients with SLE, when compared to healthy 
controls(Maas et al., 2002). These findings highlight the impact of defective apoptosis 
pathways on the pathogenesis of autoimmune disorders such as SLE.
Several molecules known to influence the induction of apoptosis have been studied in 
patients with SLE to evaluate their role in disease pathogenesis. The molecules studied in most 
detail are the Fas-FasL apoptotic pathway and the Bcl-2 family of genes.
The study of spontaneous and induced apoptosis in SLE lymphocytes has yielded 
conflicting results. Earlier studies indicated accelerated in vitro and in vivo apoptosis of 
lymphocytes from patients with SLE although, a more recent study reports lack of consistent 
abnormalities (Emlen W. et al., 1994; Lorenz et al., 1997; Pemiok et al., 1998; Caricchio and 
Cohen, 1999)
1.7.3: The Fas receptor in SLE
Fas/APO-1 (CD95) is a 48 kDa cell surface glycoprotein receptor belonging to the 
tumour necrosis factor(TNF)/ nerve growth factor (NGF) rceptor family(Nagata and Golstein, 
1995). Cross-linking of Fas by Fas ligand (FasL), a 40 kDa membrane glycoprotein, triggers 
apoptotic cell death in many cell types.
Increased Fas expression has been documented on peripheral blood mononuclear cells 
(PBMC) of patients with SLE when compared to healthy control individuals. The increased 
Fas expression was observed in both B and T cells although expression was higher on CD8+ve 
T cells (Mysler et al., 1994; Lorenz et al., 1997; Bijl et al., 2001). Conversely, other reports 
suggest that most patients with SLE do not appear to have a defect in Fas expression or 
function (Ohsako et al., 1994; Yang et al., 1997; Caricchio and Cohen, 1999). However, levels 
of soluble Fas (sFas), a secreted variant with the potential to block Fas-L has been detected in 
the serum of 10-60% of patients with SLE, although a similar rise was also observed in 
patients with RA (Rose et al., 1997; Jodo et al., 1997). Serum levels of sFas are also reported
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to correlate with percentages of activated B cells but not with that of activated T cells (Bijl et 
al., 1998).
1.7.4: Fas Ligand in SLE
Fas-L induces apoptosis upon binding to Fas/Apo-1 (CD95) bearing target cells and 
plays an important role in activation induced cell death in T cells upon crosslinking of the T 
cell receptor (TCR) (Nagata et al., 1995). Patients with active lupus showed increased Fas-L 
expression on PBMCs, especially in the activated T cell subset. The function and regulation of 
Fas-L in T cells from patients with SLE was found to be within normal parameters (Kovacs et 
al., 1997; McNally et al., 1997; Feng, 1997). The increased expression of Fas-L on activated 
T cells of patients with SLE could account for the observation of increased apoptotic rates in 
some patients (Kovacs et al., 1997).
1.8: bcl-2 fam ily o f  genes in SLE
Many genes are involved in survival, proliferation and programmed cell death or 
apoptosis. Among them are the bcl-2 gene family, p53, c-myc, the large families of TNF 
related receptors and ligands, as well as the caspase family.
bcl-2 the proto-oncogene contributing to cell survival has been studied extensively in 
the context of apoptosis in patients with SLE, often with conflicting findings. Expression of 
Bcl-2 protein on freshly isolated PBMC has been controversial, with some investigators 
showing increased Bcl-2 expression on T cells but not B cells and other groups showing 
unaltered or decreased Bcl-2 quantities in unfractioned PBMC from patients with SLE (Rose 
et al., 1995; Chan et al., 1997; Aringer et al., 1994; Ohsako et al., 1994; Graninger et al., 1992 
; Graninger, 1992; Falcini et al., 1999; Miret et al., 1999). A further study found no detectable 
differences in Bcl-2 protein expression immediately after isolation of the cells, but 
significantly up-regulated levels in T lymphocytes from patients with SLE after three days of 
culture, in complete medium. The up-regulated Bcl-2 levels were accompanied by an 
increased rate of in vitro apoptosis in the T cells (Lorenz et al., 1997). The same results were 
also observed with other autoimmune disease controls (Mixed connective tissue disease 
(MCTD), Wegner’s granulomatosis, Takayasu arteritis, polyarteritis nodosa) and the authors
45
concluded that the increased in vivo activation levels of PBMC from autoimmune patients 
might explain these phenomenon (Lorenz et al., 1997).
The study of other apoptosis related gene products such as Bcl-xL and Bax in patients 
with SLE, found no differences in levels of expression on PBMC when compared to healthy 
subjects (Lorenz et al., 1997; Graninger et al. , ). In bone marrow cells, however, decreased 
levels of Bax mRNA and protein have been reported both in patients with SLE and in lupus 
prone NZB/W mice. It has been suggested that this decreased expression of Bax in bone 
marrow might lead to decreased apoptosis in mature blood cells, resulting in autoreactive cells 
in the secondary lymphoid organs (Nazareth et al. , ; Alvarado-de et al., 1998).
1.9: Impact o f defective Apoptosis on SLE
It is now widely agreed that defective regulation of apoptosis ( increased apoptosis or 
impaired clearance of apoptotic cell material) plays a role in the development of autoimmune 
diseases including SLE. As the autoantibody production in SLE is antigen driven, and 
involves T and B cell contributions, defective regulation of apoptosis in patients with SLE 
might impact disease pathogenesis in the following ways-
• Cause impaired tolerance resulting in the survival of autoreactive T and B lymphocytes
•  Prolonged survival of activated autoreactive T and B lymphocytes
•  Increased levels of apoptosis and/or defective clearance of apoptotic cells - the source of 
autoantigens such as nucleosomes.
1.9.1: Impaired Tolerance
Defects in the apoptotic pathway may increase the likelihood that lymphocytes avoid 
the normal processes used by the immune system to eliminate unwanted lymphocytes. 
Normally, autoreactive lymphocytes that survive the process of thymic selection and circulate 
in the periphery can respond to self antigen if presented by the correct MHC. This process is 
held in check by the combined actions of apoptosis and anergy and results in the state of 
peripheral tolerance. However, in patients with SLE, genes required both for apoptosis and 
induction of tolerance have been found to be under-expressed (Maas et al., 2002 ). This may
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permit lymphocytes to escape tolerance and adopt a pro-survival agenda that results in the 
formation of autoantibodies. The isolation of autoreactive T cell clones from murine lupus 
models and patients with SLE that support polyclonal autoantibody production by autologous 
B cells is consistent with this theory (Chen et al., 1997; Takeno et al., 1997; Shivakumar et 
al., 1989).
1.9.2: Activation induced cell death in SLE
Activation of mature peripheral T cells through repeated cycles of antigen recognition 
and clonal proliferation leads to activation induced cell death by apoptosis (Nagata and 
Golstein, 1995). Activation induced cell death (AICD) plays an important role in the 
regulation of immune response by limiting the unwanted expansion of T cell clones reacting 
against foreign antigens beyond the course of infection, as well as the clones, which cross- 
react with self-antigens. Activated T cells from patients with SLE have been shown to be 
relatively resistant to a T cell receptor (TCR) mediated stimulus (Kovacs et al., 1996). This 
defective antigen-mediated cell death could contribute to increased numbers of activated 
autoreactive cells in SLE patients (Kovacs et al., 1996). Activated T cells from patients with 
SLE have also been shown to be resistant to apoptosis induced by human thymic stromal cells 
pointing to a defect in the apoptosis pathway (Budagyan et al., 1998).
1.9.3: Clearance o f Apoptotic cells in SLE
It has been speculated that autoantigens released from apoptozing cells may contribute 
to the aetiopathogenesis of SLE by both activation of autoreactive lymphocytes and the 
formation of immune complexes. This theory is supported by studies where modest transient 
antibody production has been documented in animals immunized with apoptotic cells 
(Mevorach, 1999). In other systems, T cell reactivity to transfected antigens contained within 
apoptotic cells in vivo and in vitro has been observed, and is enhanced when appropriate 
costimulatory molecules and cytokines are present (Rovere et al., 2000; Rovere et al., 1999). 
The autoantigens targeted in SLE have been found to be clustered in the surface blebs of 
apoptotic cells, where they are vulnerable to oxidative modifications. The revelation of 
previously cryptic antigens from apoptotic cells to the immune system, by these oxidative 
modifications may result in the autoimmune reaction of SLE (Casciola-Rosen et a l ,  1994).
Vast numbers of apoptotic cells are generated through cell senescence, maturation, and 
turnover. Multiple macrophage scavenger receptors serve the important function of
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recognising and promoting engulfment and removal of apoptotic cells (Fadok et al., 2001). 
Several recent reports have emphasised that defective macrophage clearance of apoptotic 
debris may lead to autoimmunity. Delayed apoptotic cell clearance in mice lacking the c-mer 
membrane tyrosine kinase, and in C lq  complement deficient mice have been shown to lead to 
lupus like autoimmunity (Cohen et al., 2002 ; Taylor et al., 2000 ). Recent studies have also 
shown that impaired uptake of apoptotic cells by macrophages can result in their association 
with immature dendritic cells (Baumann et al., 2002). The dendritic cells can then 
phagocytose the apoptotic cells and present apoptotic cell-derived antigens to T cells and B 
cells (Albert et al., 1998; Inaba et al., 1998; Rovere et al., 1998).
These results give weight to the notion that apoptotic cells provide an immunogenic 
stimulus for autoimmunity, and that impaired clearance is an important factor in the 
pathogenesis of systemic autoimmune disease such as SLE.
1.10 : Double Negative T cells
In a general context, human peripheral blood T cells are classified into T helper (Th) 
cells which express the surface glycoprotein CD4 and cytotoxic/suppressor cells expressing 
the surface glycoprotein CD8. Other minor T cell subsets that possess various distinct 
functional properties and disease associations are -
• “double positive”(DP) T cells expressing both CD4 and CD8 surface 
glycoproteins and
• “double negative”(DN) cells which express neither the CD4 nor CD8 
glycoprotein, but possess a functional T cell receptor (TCR) and the CD3 surface T cell 
marker.
These double negative T cells can express a T cell antigen receptor consisting of alpha- 
beta (ap) chains or gamma-delta (y5) chains (Bachmaier et al., 1996; Groh et al., 1989). 
Although the majority of double negative (DN) T cells express the y5TCR a small proportion 
of the peripheral CD4 CD8' T lymphocytes, express the classical ap  TCR heterodimer.
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1.10.1: apTCR+ double negative T cells
Double negative, ap  T cell antigen receptor (TCR) expressing cells have been detected 
in man and mouse and account for a small but variable proportion (1-10 %) of circulating T 
cells (Kusunoki et al., 1992). The emerging picture of these cells in normal tissue, 
autoimmune lesions and transgenic mice seems heterogenous, although some common themes 
related to questions of self-tolerance and self reactivity in the T cell compartment appear 
frequently, (table 1.7).
apTCR+ DN T cells can be unambiguously classified as mature T cells by their stable 
peripheral phenotype (CD2+, CD5+, CD7+) (Londei et al., 1989; Niehues et al., 1994). They 
lack the expression of CD4 or CD8 glycoproteins: these proteins are neither found on the cell 
surface nor are their transcripts detectable in these T cells (Rivas et al., 1990; Huang and 
Crispe, 1992). They are CD3+, CD2+ve and express the IL-2 receptor on their surface, as 
shown by studies on both stable cell lines and freshly isolated cells from peripheral blood 
(Brooks et al., 1993; Niehues et al., 1999). They were also found to show high constitutive 
expression of HLA-DR, a marker for recent T cell activation (Brooks et al., 1993; Niehues et 
al., 1999; Niehues et al., 1994). A study by Brooks et al, showed the presence of significantly 
more DN T cells expressing the CD45RO phenotype and low levels of CD45RA and lacking 
L-selectin, defined as a ‘memory’ T cell phenotype (Brooks et al., 1993; Niehues et al., 1994). 
Expression of CD28, a T cell marker up-regulated by activation and survival signals was 
earlier reported to be absent on a(3 DN T cell lines, though a more recent study shows normal 
expression levels (Niehues et al., 1999; Londei et al., 1989).
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Mouse Human
A. Normal tissue
thymus
bone marrow 
peripheral blood
spleen
lymph node
skin
(Fuss et al., 1997)
(Toribio et al., 1988) 
(Dejbakhsh-Jones et al., 1995) 
(Rivas et al., 1990),
(Londei et al., 1989),
(Murison etal., 1993), 
(Niehues et al., 1999) 
(Reimann, 1991), 
(PrudHomme eta l., 1991) 
(Fowlkes eta l., 1987),
(Huang and Crispe, 1992)
B. Autoimmune diseases
•  Human
Autoimmune lymphoproliferative syndrome (ALPS)
Insulin dependent diabetes mellitus (IDDM) 
Systemic sclerosis (SSc)
Autoimmune thyroid disease (AITD) 
Systemic lupus erythematosus (SLE)
(Rivas et al., 1990) 
(Groh etal., 1989)
(Fuss et al., 1997),
(Ilium et al., 1991) 
(Wilson et al., 1998) 
(Sakamoto et al., 1992) 
(Wu et al., 1994) 
(Shivakumar et al., 1989), 
(Devi et al., 1998),
(Liu et al., 1998)
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Mouse Human
• Murine
NZB mouse
lpr/lpr mouse
gld/gld mouse
transplanted nude
(Datta etal., 1987),
(Adams et a l ,  1990) 
(Benihoud etal., 1997), 
(Christianson et al., 1996), 
(Giese and Davidson, 1995), 
(Ravirajan etal., 1996) 
(Theofilopoulos etal., 1989) 
(Cohen and Eisenberg, 1992) 
(Sakaguchi etal., 1985)
mouse
Table 1.7: Double negative (CD3+CD4'CD8‘) TCR ap  expressing peripheral T cells : 
distribution in humans and mice. Table adapted from a review by Reimann. (Reimann, 1991).
1.10.2: Functional characteristics o f double negative T cells
The nature and function of double negative T cells have not been fully characterised, 
although they are being extensively studied in view of their associations with disease 
pathogenesis, a p  TCR+ DN T cells exhibit a functional T cell receptor (TCR) of limited 
heterogeneity and are biased towards the preferential usage of certain TCR-Vp genes both in 
normal subjects and some disease conditions such as SLE and Systemic Sclerosis (Brooks et 
al., 1993; Sakamoto et al., 1992; Shivakumar et al., 1989). Various immunological functions 
are induced in a p  TCR+ DN T cells by stimulation of CD3-dependent pathway. Unusual 
patterns of cytokine expression of normal DN T cell subset are not characterised. An 
unexpected characteristic of these cells was their response to IL-3, a growth factor previously 
shown to affect haemopoietic cells, chiefly progenitor cells and mast cells (Londei et al., 
1989).
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Recent reports in literature (reviewed below) have attributed three distinct 
immunological effector functions to apTC R + DN T cells. They are-
• Helper T cell function
• Cytotoxic T cell functions and
• Suppressor/regulatory T cell function.
1.10.3: apTCR f DN T cells: Helper T cell function.
ap  TCR+ DN T cell cell clones from healthy individuals have been demonstrated to 
possess the physiological potential to induce polyclonal immunoglobulin production by 
autologous B cells (Pelkonen et al., 1990). T helper cell function has also been demonstrated 
for DN T cells in the context of the autoimmune diseases Autoimmune lymphoproliferative 
syndrome (ALPS) and SLE (Fuss et al., 1997; Shivakumar et al., 1989). Shivakumar et al., 
have reported the presence of a a p + DN T cell line derived from the peripheral blood of a 
patient with active SLE that induced the production of pathogenic anti-DNA antibodies by 
autologous B cells (Shivakumar et al., 1989). Moreover, murine a p + DN T cells with helper 
function for B cells have been identified from the spleens of MRL lpr/lpr and (NZBxNZW)Fl 
and (NZBxSWR)Fl mice which are known to develop autoimmune manifestations(Datta et 
al., 1987; Seman etal., 1990; Pelkonen and Palacios, 1990). Various studies have also shown 
a p + DN T cell lines and clones from healthy subjects to have a higher proportion of IL-4 
producing clones. These findings have led to the suggestion that these cells may play a role in 
‘Th2 like’ responses, and provide help for antibody production (Katsikis et al., 1995; Niehues 
et al., 1999). The role of a p + DN T cell function as T helper cells is significant in view of 
their associations with a number of autoimmune diseases.
1.10.4: Cytotoxic activity o f a/3 TCR+ DN T cells.
Both spontaneous cytotoxicity and cytotoxicity induced by CD3 MoAb (monoclonal 
antibody) or lectin have been reported for a p  TCR+ DN T cells, although their target antigens 
and cell surface structures recognising target cells have remained obscure. Spontaneous and 
MHC unrestricted cytotoxity of a p + DN T cells from normal human skin, and the blood of a 
patient with combined immunodeficiency disease have been demonstrated, probably through 
specific recognition of the CD1 family of proteins (Groh et al., 1989; Brooks et al., 1990;
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Matsumoto et al., 1991; Porcelli et al., 1992). Other contradictory studies report the lack of 
spontaneous cytotoxic activity, which could be induced in the presence of lectin or anti-CD3 
MoAb (Londei et al., 1989). MHC-restricted alloantigen specific ap  TCR+ DN T cells from 
peripheral blood of healthy donors have been generated by Rivas et al., suggesting that this 
population of cells might be heterogeneous with respect to function and MHC restriction 
(Rivas et al., 1990). The characteristic of any particular clone probably varies with the tissue 
source and methods of selection/propagation.
1.10.5: Suppressor/ regulatory cell function o f aj3TCR+ DN T cells
Down regulation of immune responses by regulatory T cells is one of the major 
mechanisms involved in the induction of tolerance to self and alloantigens as demonstrated in 
a number of models of transplantation and autoimmunity, ap  TCR+ DN T cells may represent 
a novel suppressor/regulatory cell population whose function is to regulate immune responses 
negatively. Reports in the literature have demonstrated a regulatory role for a p  TCR+ DN T 
cells in murine models of transplantation tolerance (Young et al., 2002; Young and Zhang, 
2002; C arroll,; Ford et al., 2002 ). In these studies a p  TCR+ DN T cells have been shown to 
specifically eliminate syngeneic CD4+ and CD8+ T cells that share the same TCR specificity 
as the DN T cells (Zhang et al., 2001 ).
Mature CD4 CD8' a p + T cells (DN T cells) in the periphery of TCR transgenic mice 
have been found to be resistant to clonal deletion in cognate Ag-expressing (Ag+) mice 
(Reimann, 1991). Self-antigens appear to mediate the peripheral expansion and conversion of 
these cells into potent immunoregulatory cells in the TCR transgenic mice. These self-reactive 
regulatory cells could be uniquely poised to suppress immune responses and prevent 
autoimmunity.
In humans, ap  TCR+ DN T cells bearing the V a24JaQ + TCR have been found to be in 
lower frequencies in patients with atopic diseases (Oishi et al., 2000 ). This sub-population of 
cells has also been shown by others to be reduced or dysfunctional in patients with several 
autoimmune disorders such as SLE, systemic sclerosis (Sumida et al., 1995; Oishi et al., 2000; 
Wilson et al., 1998).
Taken together, these results strongly point to an immunoregulatory role for all or part 
of the a p  TCR+ DN T cell population.
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1.10.6: Developmental origin o f a p  TCR+ DN T cells
a p  TCR+ DN T cells may be the progeny of a unique developmental pathway which 
either originates from a separate lymphoid stem cell pool, or represents a side-line of one of 
the two main lineages (TCRaP+ and TCR y8+) of T cell differentiation. Thymic as well as an 
extrathymic developmental origin of a p  TCR+ DN T cells in normal, autoimmune and 
transgenic mice has been proposed. Different differentiation pathways may be involved, as 
these cells may represent a heterogeneous cell population.
Thymus dependent development on a p  TCR+ T cells has been suggested by some 
studies. Thymectomy eliminates the accumulation of a p  TCR+ DN T cells in lpr/lpr and 
gld/gld mice and DN T cells expressing transgenic TCR in transgenic mice are found to be 
thymus dependent (Steinberg et al., 1980; von Boehmer et al., 1991). In addition, self reactive 
a p  TCR+ DN T cells are not found in nu/nu mice (Reimann, 1991).
An extrathymic T cell developmental pathway is suggested by the appearance of TCR 
expressing CD3+ T cells in athymic nude mice (Reimann, 1991). Extrathymic maturation of 
a p  TCR+ DN T cells from haemopoietic stem cells has also been demonstrated in 
thymectomized and irradiated mice, reconstituted with haemopoietic stem cells from the bone 
marrow of normal mice (Dejbakhsh-Jones et al., 1995). A recent report on a unique 
population of a p  TCR+ DN T in the mouse female genital tract has indicated these cells are of 
extrathymic origin as they were found in nude mice as well as mice deficient for MHC class 
II, p2 microgobulin and CD1 (Johansson et al., 2003). Studies in mice have also shown that 
IL-3, a growth factor affecting haemopoietic cells could induce differentiation and/or 
proliferation of a p  TCR+ DN T cells in the bone marrow (Kubota et al., 1992). The 
appearance of DN T cells bearing self-reactive T cell receptors in the livers of mice injected 
with bacteria might indicate the liver as a potential site for a major extrathymic pathway for T 
cell differentiation (Abo et al., 1991).
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1.11: a/3TCR+ve D N  T cells: do they have a role in SLE?
DN T cells are notorious for their involvement in murine lupus of MRL/lpr and 
gld/gld mice, which have been used as a model of human systemic lupus erythematosus 
(SLE). Massive numbers of DN T cells accumulate in the secondary lymphoid organs 
including lymph nodes and spleen in lupus prone MRL/lpr and gld mice (Cohen and 
Eisenberg, 1992). Many of the autoreactive T cell clones isolated from the MRL/lpr mice 
were found to be lacking expression of CD4 and CD8 co-receptors. All these autoreactive T 
cells responded to syngeneic splenic cells and helped syngeneic B cells to produce anti-DNA 
antibodies, especially of the IgG class (Chen et al., 1997). Similar autoreactive helper DN T 
cells have also been isolated from the (SWRxNZB) FI (SNF1) murine model of lupus (Adams 
et al., 1990; Datta et al., 1987). These observations have highlighted a possible role for DN T 
cells in SLE.
In human SLE, Shivakumar et al (1989) first reported that the markedly expanded a p  
TCR+, CD3+ T cells, among the CD7CD8" population from active lupus contained the double­
negative subset of T helper cells (Th) responsible for augmenting the production of pathogenic 
autoantibodies. Two later studies reported an expanded population of ap  TCR+ DN T cells in 
patients with active SLE, but the increased numbers were not always statistically significant 
(Devi et al., 1998; Liu et al., 1998). Increased levels of total DN T cells (expressing a p  or y8 
TCR) have also been reported in patients with SLE, with numbers decreasing after six months 
of cyclophosphamide treatment and better clinical prognosis (Lacki et al., 1997). A recent 
study by Sieling et al., suggested that CD1 restricted DN T cells from patients with SLE can 
provide help to CD1+ B cells for IgG antibody production and could therefore promote 
pathogenic autoantibody responses in SLE (Sieling et al., 2000 ). Thus, although there is 
evidence of DN T cells playing a role in the pathogenesis of SLE, the mechanisms of their 
contribution remain unclear and merit detailed study.
Preliminary work on DN T cells using two-colour immunofluorescence staining in our 
laboratory indicated an increased expression of the Bcl-2 anti-apoptotic protein in the DN T 
cell population of patients with SLE compared to the same population in healthy subjects. In 
addition, other investigators have shown that DN T cells from patients with SLE provide T 
cell help to autologous B cells augmenting the production of pathogenic autoantibodies.
Based on these observations, we hypothesised that DN T cells in patients with SLE could, 
perhaps survive for unusually long periods of time (resisting activation induced cell death) due
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to an overexpression of Bcl-2 protein, resulting in expanded populations that contributed to the 
disease pathogenesis by providing prolonged T cell help to autoreactive B cells. Therefore, we 
undertook to study activation status, Th2 associated cytokine (IL-4) levels and apoptosis 
susceptibility in DN T cells from patients with SLE and healthy individuals to establish their 
role in the disease pathogenesis of SLE.
1.12: M ajor Aims o f  this Thesis:
1. To determine the levels of DN T cells in patients with SLE.
2. To determine the activation status of DN T cells in patients with SLE.
3. To determine the production of the Th2 associated cytokine IL-4 by DN T cells in 
patients with SLE.
4. To investigate the susceptibility of SLE DN T cells to apoptosis.
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Chapter 2.
Materials and Methods.
57
2.1: Materials.
2.1.1 .Reagents.
Heparin BP
RPMI 1640 
Ficoll hypaque
Hank’s Balanced salt solution (HBSS) 
Foetal calf serum
Penicillin and Streptomycin (Pen/Strep) 
Glutamine 
Acridine Orange 
Ethydium bromide
Dynabeads M-450 (sheep anti-mouse IgG 
Bovine serum albumin 
Sodium azide
Rabbit anti-mouse immunoglobulin 
(fluorescein isothiocyanate comjugate) 
Rabbit anti-mouse immunoglobulin 
(phycoerythrin conjugate) 
Paraformaldehyde 
Normal mouse serum 
Human Immunoglobulin G 
(Cohn fraction II)
Permeafix™
Apoptosis Detection Kit 
Lysine coated slides 
Mounting fluid 
Caltag Fix and Perm 
Phytohaemagglutinin (PHA)
Monensin
Monoparin: CP Pharmaceutical, Clwyd,
UK.
Life Technologies, Renfrewshire, UK. 
Nycomed, Birmingham, UK.
Life Technologies,Renfrewshire, UK.
Life Technologies, Renfrewshire, UK.
Life Technologies, Renfrewshire, UK.
Life Technologies, Renfrewshire, UK. 
Raymond A. Lamb. Wembley, London, UK. 
Sigma chemical Co. Dorset, UK.
Dynal, Norway.
Sigma chemical Co. Dorset, UK.
Sigma chemical Co. Dorset, UK.
DAKO Ltd. Buckinghamshire, UK.
DAKO Ltd. Buckinghamshire, UK.
Merck Ltd, Leicestershire, UK.
DAKO Ltd. Buckinghamshire, UK.
Sigma chemical Co. Dorset, UK.
Ortho, New Jersey, USA.
R&D systems, Minneapolis, USA.
Sigma chemical Co. Dorset, UK.
Vecta laboratories, Burlingame, USA. 
Caltag laboratories, Burlingame, USA 
Sigma chemical Co. Dorset, UK.
Sigma chemical Co. Dorset, UK.
58
Phosphate buffered saline (PBS) tablets Sigma chemical Co. Dorset, UK.
2.7.2: Monoclonal Antibodies.
2.1.2.1: Hybridomas.
UCHT-8 anti-human CD4
UCHT-4 anti-human CD8
BU -12 anti-human CD 19
MY-23 anti-human CD 14
UCLH-1 anti-human CD45R0
2.7.2.2: Directly conjugated antibodies.
Anti-CD3 FITC 
Anti-CD4 CyChrome 
Anti-CD8 CyChrome 
Anti-aPTCR FITC 
Anti-y8 TCR FITC 
Anti-CD69 FITC 
Anti-HLA-DR FITC 
Anti-CD28 FITC 
Anti-Fas FITC 
Anti-IL-4 PE 
Anti-Bcl-2 FITC
2.1.2.3: Un-conjugated antibodies.
Anti-CTLA-4 
Anti-Bcl-x 
Anti-bax 
CD45 RA
a kind gift from Prof. P. Beverly, 
a kind gift from Prof. P. Beverly, 
a kind gift from Prof. J. Gordon, 
a kind gift from Prof. M. Fanger. 
a kind gift from Prof. B.M. Chain
Pharmingen, SD, U.S.A. 
Pharmingen, SD, U.S.A. 
Pharmingen, SD, U.S.A. 
Pharmingen, SD, U.S.A.
T cell Diagnostics, Cambridge. 
Pharmingen, SD, U.S.A.
DAKO Ltd. Buckinghamshire, UK. 
a kind gift from Dr. Y. Latchmann. 
DAKO Ltd. Buckinghamshire, UK. 
R&D systems, Minneapolis, USA. 
DAKO Ltd. Buckinghamshire, UK.
a kind gift from Dr. B. Broker. 
Santa Cruz biotechnology, U.S.A. 
Santa Cruz biotechnology, U.S.A. 
a kind gift from Prof. B.M. Chain.+
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2.1.2.4: Isotype controls.
IgGl FITC DAKO Ltd. Buckinghamshire, UK.
IgGl PE Pharmingen, SD, U.S.A.
IgGl CyChrome Pharmingen, SD, U.S.A.
IgG2b FITC Pharmingen, SD, U.S.A.
2.1.3: Plastics.
All plastics were supplied by Life Technologies, Renfrewshire, UK.
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2.2: Methods.
2.2.1: Cell source.
2.2.1.1: Patients and Controls.
Peripheral blood was obtained from patients with Systemic Lupus Erythematosus 
attending the Middlesex Hospital Rheumatology clinic with informed consent. Each met four 
or more of the revised criteria of the American college of Rheumatology for the classification 
of rheumatic disease (Tan et al., 1982). Disease activity was assessed using the British Isles 
Lupus Assessment Group (BILAG) computerised index (Hay et al., 1993). The index is based 
on the ‘physician’s intention to treat’ principle and divides lupus activity into eight organs or 
systems which are scored from A (most active) to E (never previously active). A global score 
determined using A=9, B=3, C =l, D=0, E=0 has been successfully compared with other 
methods of calculating global scores (Gladman et al., 1994), and in this study patients scoring 
>6 were deemed active and <6 inactive. Patients with SLE were predominantly female (lm ale 
patient studied), with an average age of 35 and ranging from 17 to 50 years of age. Levels of 
circulating anti-dsDNA antibodies and C3 levels were measured during routine patient 
assessment. Serum levels of anti-dsDNA antibodies in excess of 50 IU/ml( ELISA test-Shield 
diagnostics, Dundee) and levels of C3 less than 0.9 IU/ml(by laser nephelometry) are regarded 
as abnormal. For statistical analysis in this study, anti-dsDNA antibody levels of >100 IU/ml 
were considered to be high. Patients with Rheumatoid Arthritis (RA) who fulfilled four or 
more of the ARA criteria for Rheumatoid Arthritis and age and sex matched healthy controls 
were also studied (Arnett et al., 1988). Details of relevant patient groups are given in the 
appropriate results chapters. Control blood was taken from healthy laboratory staff and 
medical students (with no history of autoimmune disease).
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2.2.1.2: Preparation o f human peripheral blood mononuclear cells using density 
gradient separation.
Peripheral blood samples (50mls) were collected in heparinised (100 Units) Universals 
by venesection. Blood samples from patients and age and sex matched healthy control 
volunteers were collected with informed consent. Peripheral blood was diluted 1:1 in RPMI 
1640 and 25ml carefully layered over 25ml of Ficoll-Hypaque Lymphopaque 1077. The 
density gradient and diluted blood were spun at 2000rpm(750g) for 30 minutes at room 
temperature. After spinning, the interface of cells between the diluted blood and Ficoll- 
Hypaque was aspirated using a sterile Pasteur pipette and washed twice in Hank’s Balanced 
Salt Solution (HBSS) at 1500rpm, 4°C for 10’. The resulting cell pellet was suspended in a 
known volume of medium and 20pl stained with an equal volume of Ethidium Bromide 
Acridine Orange solution . Twenty microlitres (pi) of this mixture was introduced under the 
coverslip of an Neubauer haemocytometer and the number of cells and viability assessed using 
a fluorescence microscope. The viable cells stained green and the non-viable cells orange.
Cell viability was calculated by dividing the number of viable cells (green) by the total 
number cells in the field (green +orange cells ). A greater than 95% viability was obtained in 
most of the samples after density gradient separation.
2.2.2: Enrichment o f Double Negative T cells.
The double negative T cells in the PBMC’s were enriched by negative depletion using 
Dynabeads. Separated Mononuclear cells were incubated with monoclonal antibodies raised 
against CD4, CD8, CD 19, and CD 14. The monoclonal antibodies were in the form of 
supernatants from Hybridoma cultures, anti-CD4 from the hybridoma UCHT8, anti-CD8 from 
UCHT4, anti-CD19 from BU12 and anti-CD14 from MY23. Each of the four supernatants 
from the hybridomas were added to the cells at super-saturation levels (1.5 ml each) and 
incubated on ice for 30’ with gentle mixing. The unbound antibodies were then washed off 
with an excess of RPMI 1640 at 1500 rpm, 4°C for 10’. Dynabeads (sheep anti-mouse IgG) 
were washed twice, by placing the required amount in a polypropylene tube (15ml) on the 
magnet and removing the unattached liquid and reconstituting the Dynabeads bound to the 
magnet with an equal volume of RPMI 1640 as was removed. The washed Dynabeads were 
added to the cells with previously bound surface antibody to a final concentration of 1-2 x
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107/ml and with at least 4 Dynabeads for each cell. The mixture was incubated for 30’ on a 
roller at 4°C. The rosetted cells (bound to beads) were removed by placing the tube on the 
magnet and aspirating the supernatant containing unbound cells. The aspirated cells were 
washed in excess volumes of complete medium (RPMI 1640+10% Fetal calf serum) at 
1500rpm and 4°C for 10’. The cell pellet was suspended in an appropriate volume of complete 
medium for cell culture or staining. The enrichment was checked by immunofluoresence 
staining and flow cytometric analysis (described in detail in chapter 3) and was always greater 
than 95% pure.
2.2.3: Immunofluorescence staining and flow  cytometry.
Separated mononuclear cells or enriched double negative cells were re-suspended in 
phosphate buffered saline (PBS) containing 1% bovine serum albumin and 0.05% sodium 
azide (NaN3), at lxlO6 cells/ml. Two hundred pi of this cell suspension was added to each 
well of a 96 well U bottomed tissue culture plate and spun at 1500 rpm for 5’. The supernatant 
was aspirated, the cell pellet re-suspended by agitating the plate and 20pl of appropriate 
monoclonal antibody added to each well at the required dilution. The cells were incubated 
with the antibody for 40' on ice. The cells were washed 3 times with PBS/BSA, by adding 
200pl to each well and centrifuging the plate as before and aspirating the supernatant. A 1:20 
dilution of the second antibody, a rabbit-anti mouse immunoglobulin conjugated to a relevant 
fluorochrome, was made up in PBS/BSA and 20pl added to the resuspended cell pellet. The 
cells were incubated for 40' on ice and again washed 3 times with PBS/BSA. After the final 
wash, the cells were re-suspended in 200pl of 1% paraformaldehyde in PBS. The cells were 
left for at least one hour before analysis on a FACScan flow cytometer (Becton Dickinson). If 
the cells were to be left overnight the plate was wrapped in aluminium foil to exclude light and 
kept at 4°C until analysed.
2.2.3.1: Double Immunofluorescence staining o f cells fo r  flow  cytometric analysis.
The mononuclear cells were treated for the first part as above and stained with a first, 
and fluorochrome conjugated second antibody. After washing 3 times to remove any unbound 
second antibody, the cell pellet was re-suspended and 20pl of a 2% normal mouse serum 
(NMS) was added and the cells incubated on ice for 40'. The mouse serum was added to
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prevent any free binding sites in the secondary antibody to bind non-specifically to final 
antibody. The cells were again washed 3 times in PBS/BSA and 20pl of final antibody directly 
conjugated to a complementary fluorochrome, was added to the re-suspended cells and 
incubated on ice for 40’. After a final 3 washes the cells were fixed with 2% paraformaldehyde 
and analysed on a flow cytometer as described above.
2.23.2: Three colour immunofluorescense staining.
Cells were stained with CyChrome™ (Pharmingen) and PE conjugated monoclonal 
antibodies with the third colour being FITC. Cells were incubated with 20pl of a cocktail of 
antibodies containing CD3-PE (FL2 channel), CD4-CyChrome, and CD8-CyChrome (FL3 
channel) in the ratio 1:2:2, as previously titrated for optimum staining. A third antibody 
conjugated to FITC and fluorescing in the FL1 channel was also added to the cells at 
concentrations for optimum staining.
2.2.3.3: Intracellular staining fo r  Bcl-2 family o f proteins.
The Bcl-2 (Bcl-2, Bax, Bcl-x) family of proteins are localised in the cytoplasm of the 
cells. Hence it is necessary to permeabilise the cells to enable the antibodies to enter the cells 
and bind to the antigen. To enable this, cells were incubated with 50pl of 1:1 dilution in PBS 
of ORTHO Permeafix™, a one step permeabilising and fixative reagent and incubated for 40’ 
on ice. The cells were then washed 3 times in PBS/BSA and stained with anti-Bcl-2, anti-Bax 
or anti- Bcl-x antibodies as described above.
2.2.4: Measurement o f apoptosis.
An AnnexinV-FITC/Propidium Iodide kit was used to quantitate levels of apoptosis in 
cell samples. The cells were washed in lOOpl annexin binding buffer (supplied with the kit) at 
1500 rpm for 5’. Twenty pi of annexin binding buffer was added to the cells in each well along 
with 5pi of AnnexinV-FITC and 5pi of Propidium iodide . The cells were then incubated in 
the dark at room temperature for 15 minutes before being analysed on the FACScan (Becton 
Dickinson). Representative dotplot of AnnexinV-FITC/Propidium Iodide staining are shown 
below.
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2.2.5: Flow cytometric analysis o f  mononuclear cells.
The stained cell preparations were analysed on a Becton Dickinson FACScan flow 
cytometer using Win FCM research software. Essentially, the mononuclear cells were gated 
on forward light scatter (FSC) and right angle light scatter (SSC) to discount any debris or 
polynuclear cells. The cells were analysed for fluorescence staining on channels FL1 (FITC), 
FL2 (PE) and FL3 (Cy chrome). Whenever possible, a minimum of 10,000 events was 
analysed. Data analysis was performed using WinMDI version 2.8 software.
2.2.6: Confocal Microscopy o f stained cells.
The cells were stained as described above and fixed in 1 % paraformaldehyde. The 
cells were then placed on a Lysine coated slide and incubated for 10 minutes. The non­
adherent cells were removed and the slide coated with mounting fluid and covered with a 
cover slip. The slides were then analysed under a confocal microscope (MRC 1024 [Bio-Rad] 
equipped with a krypton-argon laser). The confocal-assistant software was used to analyse 
data and generate images.
2.2.7 : T cell activation assays.
Enriched double negative T cells or CD4+/CD8+ T cells were cultured in sterile NUNC 
24 well plates in complete medium (RPMI 1640 + 10% fetal calf serum) supplemented with
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L-glutamine (lOOU/ml), penicillin (lOOU/ml) and streptomycin (lOOpg/ml) at 37°C, 5% CO2. 
Cells were stimulated by adding a 20% stock solution of PHA in complete medium to each 
well, such that the final concentration was 1%. Cells were harvested at appropriate time 
points, washed and immunofluoresence staining for activation markers was carried out as 
described above.
2.2.8: Intracellular staining fo r  IL-4.
2.2.8.1: Constitutive levels o f  IL-4.
PBMCs from patients with SLE and healthy controls were fixed and permeabilized 
using Caltag Fix and Perm in accordance with the manufacturer's instructions prior to 
intracellular staining for IL-4. Background staining was determined using mouse isotype and 
conjugate-matched irrelevant antibodies. Representative dotplot of intracellular IL-4 staining 
of enriched DN T cells is shown below.
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2.2.8.2: IL-4 levels after PHA stimulation.
PBMCs from patients and controls were incubated overnight at 37° C, 4.5% CO2 in the 
presence of 10 pg/ml PHA. Monensin (0.05M) was added for the final 6 hours to facilitate 
accumulation of cytokine in the Golgi and the cells were stained for surface markers and 
intracellular IL-4 as described above.
DN ce lls  1 .1%  IL4+
1023
Forward Scatter
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2.2.9: Statistical analysis.
Data were analysed using the non-parametric Mann-Whitney test and the Wilcoxon’s test for 
paired samples. The two-tailed non-parametric (Spearman) test with 95° confidence limits was 
used to determine correlations.
67
C hapter 3.
D N  T  cells in patien ts with SLE.
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3.1: Introduction and aims.
ap  TCR+ve Double negative T cells have been shown to be associated with the 
pathogenesis of systemic lupus erythematosus in previous studies. This chapter aims to study 
the presence and frequency of double negative T cells in the peripheral blood of patients with 
SLE compared to patients with RA and healthy individuals.
3.1.1: Introduction.
The exact role of double negative (DN) T cells in the pathogenesis of systemic 
autoimmune diseases such as SLE has not been established. However, studies in recent years 
have indicated a firm link between the dysregulation of the frequency and function of this T 
cell population with a number of autoimmune diseases including SLE.
The DN T cell subset in man was identified in the late 1980’s, although the exact 
nature and role of this enigmatic T cell subset is not yet fully understood (de la Hera et al., 
1985). Double negative T cells have been shown to express either the ap  or y5 TCR 
(Shivakumar et al., 1989; Rajagopalan et al., 1990). Double negative T cells by definition, 
lack the CD4 and CD8 adhesion receptors of the immunoglobulin superfamily which 
participate in specific antigen recognition of T lymphocytes by acting as co-receptors for 
MHC class I and II molecules (Pames, 1989; Springer, 1990). CD4 and CD8 molecules also 
mediate signal transduction in the course of T cell activation (Barber et al., 1989). The 
prominent role of the CD4 and CD8 co-receptors in T cell function makes it surprising to find 
DN T cells in peripheral tissues of mouse and man. Hence, it has been suggested that these 
cells may not be restricted by the major histocompatability complex molecules (MHC) 
(Sieling, 2000). Investigators have also suggested a role for non-classical MHC -like 
molecules, the CD1 family of antigen presenting proteins.
Association of DN T cells with various autoimmune diseases such as systemic 
sclerosis, autoimmune lymphoproliferative disease (ALPS) and SLE argues for their role in 
the pathogenic process of autoimmune diseases (Sakamoto et al., 1992; Furukawa, 1997;
Ilium etal., 1991; Rajagopalan et al., 1990; Shivakumar et al., 1989). Double negative T cells 
(expressing a p  or y5 TCR) are thought to be a separate lineage of T cells and their apparent 
autoreactive nature may be as a result of avoidance of the process of thymic selection that
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would delete the autoreactive T cells. Their lack of CD4 or CD8 co-receptors might aid escape 
from negative selection in the thymus leading to potentially autoreactive cells in the periphery. 
In addition, their proposed use of the CD1 antigen presenting molecules to recognize unusual 
antigens such as hydrophobic lipids and peptides furthers the argument for autoreactivity due 
to ‘antigenic mimicry’. This theory for the activation of self-reactive T cells is that the 
immune response spreads from first targeting exogenous antigens to targeting highly related 
self-antigens secondarily (Hayday and Geng, 1997; Bamaba and Sinigaglia, 1997; Schaible 
and Kaufmann, 2000). DN T cells have been found to be present in all healthy individuals and 
account for a small but variable proportion (1-10 %) of circulating T cells.
In contrast to human DN T cells, murine DN T cells have been the subject of a number 
of investigations, most of which have been performed in the lpr/gld mice which develop an 
SLE/arthritis like autoimmune condition. These studies have revealed a number of unique 
characteristics of these cells. They are oligoclonal and express normally deleted (forbidden) 
Vp regions implying that they have bypassed negative selection in the thymus(Kubota et al., 
1992). Furthermore, they bear reduced levels of the CD3: TCR complex and respond to 
haematopoietic stem cell growth factor IL-3 (Okuyama et al., 1992; Abo et al., 1991; Kubota 
etal., 1992).
Similarly, one of the characteristic features of human ap  TCR+ve DN T cells from 
healthy individuals and disease conditions ( SLE and adult T cell leukaemia) that has been 
reported previously, is the lower levels of CD3:TCR complex expressed by these cells in-vivo 
(Shivakumar et al., 1989) (Suzushima et al., 1993; Londei et al., 1989). In contrast, y5 TCR+ 
DN T cells from the same individuals expressed CD3: TCR levels similar to those of CD4+or 
CD8+, indicating that the reduced levels observed in the ap  TCR+ DN T cell population are 
not related to the absence of the CD4 or CD8 markers (Murison et al., 1993). Studies on ap  
TCR+ DN T cells in lymph nodes of normal mice have also revealed that the TCR density on 
the surface of these cells was lower than that of CD4+ and CD8+ T cells (Huang and Crispe, 
1992). Although the CD3: TCR complex on a p  TCR+ DN T cells has been shown to be 
functionally competent, the significance of lower cell surface densities of the CD3:TCR 
complex is not known (Groh et a l ,  1989; Rivas et al., 1990; Matsumoto et al., 1991).
Systemic lupus erythematosus (SLE) is characterised by antibody production against 
non-protein self-antigens, including nucleic acids and phospholipids. Autoantibody responses
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in SLE are T cell dependent, as shown by studies demonstrating a decrease in the incidence of 
SLE in T cell depleted lupus prone mice and HIV infected individuals (Wofsy and Seaman, 
1987; Molina et al., 1995). Insight into the nature of T and B cell interactions in SLE has 
come in part, from the study of CD4~CD8~ (double-negative (DN)) T cells. The involvement 
of expanded populations of DN T cells in murine lupus of MRL/lpr mice, which have been 
used as a model of human SLE has led to an interest in their role in this autoimmune disease. 
Massive numbers of DN T cells accumulate in the secondary lymphoid organs including 
lymph nodes and spleen in lupus prone MRL/lpr mice when proteinuria due to nephritis 
ensues (Sobel et al., 1993) The frequency of both total DN (ap  and y8 TCR+) T cells and the 
ap  TCR expressing sub-population of DN T cells have been shown to be increased in patients 
with SLE (Shivakumar et al., 1989; Devi et al., 1998; Lacki et al., 1997). The increased 
numbers have been observed particularly in patients with active disease, suggesting that these 
T cells are involved in the pathogenesis of the disease. A study of Chinese patients with SLE 
showed increased levels of a p  TCR+ DN T cells within the total lymphocyte population, 
although the differences did not reach statistically significant levels when compared to healthy 
individuals (Liu etal., 1998).
T cells expressing the y8 TCR are attractive candidates for mediators of autoimmunity 
and have been linked to a number of autoimmune conditions including SLE, Sjogren’s 
syndrome and RA (Brennan et al., 1989; Gerli et al., 1991). Studies on y8 TCR*T cells 
(including both CD4+or CD8+ T cells and DN T cells) have reported both decreased and 
increased numbers of these cells in the peripheral blood of patients with SLE (Gerli et al., 
1991; Riccieri et al., 2000 ; Robak et al., 2001 ; Robak et al., 1999).
Interestingly, in one study reporting decreased numbers of yb+ T cells in the peripheral 
blood, increased numbers of y8 TCR+ T cells were detected in clinically normal skin from 
patients, compared to healthy controls. The accumulation of y8 TCR+ T cells in the skin of 
patients with SLE was also found to have a positive correlation with their disease activity 
(Robak et al., 2001 ). The role of the expanded y8 TCR+ T cell population in the skin of SLE 
patients and their relation to disease pathogenesis remains unclear. Pathogenic anti-DNA 
autoantibody- inducing y8 TCR+DN T cells have also been isolated from patients with SLE 
although expansion in their numbers in the peripheral blood has not been reported consistently 
(Rajagopalan etal., 1990).
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3.1.2: Aims.
In order to understand the role of DN T cells in the pathogenesis of SLE, the frequency 
of double negative (DN) T cells (CD3+ CD4 CD8 ) expressing ot(3 TCR and y8 TCR, have 
been examined in patients with SLE. Patients with rheumatoid arthritis (RA) as autoimmune 
disease controls, and healthy individuals were also included in the study. Since ap  TCR+ve 
DN T cells have been previously reported to express significantly lower levels of CD3: TCR 
complex, the density of CD3 molecules on the surface of DN T cells has also been studied in 
patients and control subjects.
3.2: Results.
3.2.1: Patients used in this study.
The data in this chapter is based on peripheral blood samples taken from 18 patients 
diagnosed with SLE and 15 patients diagnosed with rheumatoid arthritis at the Bloomsbury 
Rheumatology Clinic, UCL. Control blood was taken from 15 healthy laboratory staff and 
medical students (with no history of autoimmune disease) in the department of Immunology 
UCL.
The SLE patients all met four or more criteria of the American College of 
Rheumatology for the classification of the disease (Tan et al., 1982). The mean age of SLE 
patients was 42 years and the range 17-67 years. Fourteen of the patients were female and one 
male. Table 3.1 below lists the disease activities of the patients included in this study.
Fifteen patients with rheumatoid arthritis, all of whom met the criteria for the disease 
as determined by Arnett et al, were studied as autoimmune disease controls (Arnett et al., 
1988). The mean age of the cohort of RA patients studied was 59 years, the range 35-82 years 
and included 11 females and 3 males.
The normal healthy controls (HC) consisted of laboratory staff and students. The mean 
age was 31 years and the range 18-45 years. Fourteen females and one male were studied.
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Patient Global Score Drug treatment
1 7 No major drugs
2 4 No major drugs
3 10 Anti- hypertensive only
4 13 Anti- hypertensive only
5 3 200 mg Plaquenil
6 9 400 mg Plaquenil
7 4 400 mg Plaquenil
8 6 15 mg Prednisolone
9 6 15 mg Predisolone
10 5 100 mg Azathioprine
11 4 5 mg Prednisolone
15 mg weekly Methotrexate
12 6 3 mg Predisolone 
100 mg Azathioprine
13 3 20 mg Prednisolone 
150 mg Azathioprine
14 3 3 mg Prednisolone 
100 mg Azathioprine
15 4 5 mg Prednisolone
15 mg weekly Methotrexate
16 6 15 mg Prednisolone 
125 mgAzathioprine
17 8 400 mg Plaquenil 
8 mg Prednisolone
18 5 400 mg Plaquenil 
5 mg Prednisolone 
150 mg Azathioprine
Table 3.7: Disease activity (global score) and treatments of patients with SLE studied 
in this chapter.
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3.2.2: Enrichment o f Double negative T cells from  PBMC.
Mononuclear cells were isolated by density gradient separation from peripheral blood 
and an enriched population of DN T cells obtained by depletion of CD4+, CD8+ T cells, B 
cells and monocytes as described in chapter 2. Three-colour
immununofluoresence staining with CD3-PE, CD4-Cy Chrome and CD8-Cy Chrome 
identified the DN (CD3+ CD4' C D 8 ') T cell compartment. A representative FACScan profile 
of the cell populations studied is shown in Figure 3.1. The enriched DN T cell population was 
tested for purity and was consistently more than 95% pure.
Non-depleted PBMC Enriched DN T cells
4 31%
' - 96*
fc;
10°
85 38%
<— CD8 
T cells
e - CD4 
T cells
7. •
■J f c  ->-x
• V:
■
<— DN 
T cells
4 .35%
101 io2 
CD3-PE—»
103 10*
2 .65%
.
• • •
•, ,  *
: ..*£•••
• /  .• #•■%
a% •
3 ; <- d n
r * T cells
<
............1---—'--- " ........ i— ....................io° io1 io2 
CD3-PE->
102 10 *
Figure 3.1: Representative fluorescence profiles of lymphoid cells stained for CD3 
(horizontal axis), CD4 and CD8 markers (vertical axis), before and after enrichment of double 
negative (DN) T cells.
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3.2.3: Confocal microscopy images o f DN T cells.
Enriched populations of DN T cells were stained with antibodies to CD3 (conjugated 
to the fluorochrome phycoerythrin (PE)) marker and the CD4 and CD8 co-receptors 
(conjugated to the fluorochrome CyChrome (Cy)) to visualize DN T cells using two colour 
confocal microscopy as described in chapter 2. This method was used to confirm the correct 
identification of single positive (SP) and DN T cells using the combination of CD3 and 
CD4/CD8 set of markers.
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Enriched DN T cells stained with anti- 
CD3 PE antibody (red)
Enriched DN T cells stained with anti-CD4 
and anti-CD8 CyChrome antibodies (blue)
SP T cell
Confocal image with DN T cells 
(red-CD3+CD4/8-) and single 
positive(SP) T cells 
(purple-CD3+ CD4 or CD8 +).
DN T cell
Figure 3.2: Confocal Images of enriched DN T cell populations stained with anti-CD4 
and anti-CD8-CyChrome (blue), and anti CD3-PE (red) antibodies. Stained cells were 
observed by confocal microscopy and images generated using confocal assistant software.
76
3.2.4: The total T cell population is not expanded in patients with SLE when compared 
to patients with RA or healthy controls.
The percentage of total T (CD3+) lymphocytes was determined in patients with SLE 
using flow cytometric staining with an anti-CD3-PE antibody. Using Win MDI software an 
electronic gate (R l) was placed around the lymphocyte population in a forward scatter (FSC) 
vs side scatter (SSC) dotplot. Percentage of cells gated on Rl and positive for PE staining 
(FL2 channel) were quantitated. The results of the investigation are shown in Figure 3.3. As 
shown in the figure the percentage of total T cells showed no differences between patients 
with SLE, RA and healthy controls (HC: p=0.4). Overall, SLE patients had lower numbers of 
lymphocytes compared with healthy controls (SLE: 1.05±0.36x 106cells/ ml, HC: 
6.45±2.45xl06cells/ml).
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Figure 3.3: Percentage total T cells in SLE (n=15), RA (n= 9) and healthy controls 
(HC, n=12) showed no significant difference (p= 0.4). Total blood PBMCs were stained with 
an anti-CD3-PE antibody and analyzed by flow cytometry.
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3.2.5: Quantitation o f double negative T cells in patients with SLE, RA and healthy 
controls.
As a start to understanding the contribution of DN T cells to SLE disease pathogenesis, 
the presence and frequency of DN T cells in the blood of patients with SLE was determined 
and compared to levels in patients with RA (autoimmune disease controls) and healthy 
individuals. The proportion of DN T cells in the PBMC’s of patients with SLE, RA and HC 
was measured by two-colour flow cytometry using antibodies to CD3 and CD4 and CD8 as 
described in section 3.2.2. The percentage of DN T cells in the PBMCs of SLE patients did 
not differ from autoimmune control patients with RA or healthy controls as shown in Figure 
3.4 (SLE:7.7±10.4, RA:4.87±7.12, HC:7.12±4.05) (p=0.3). There was also no correlation 
between the percentage of DN T cells and the disease activity (as defined by their global 
score) in patients with SLE ( r= - 0.404 and p= 0.89).
33
SLE RA HC
Figure 3.4: The percentages of blood DN T cells in patients with SLE (n=18), RA 
(n=9) and HC (n=13) did not show statistically significant differences (p=0.3). Total blood 
PBMCs were stained with anti-CD3-PE (FL2), anti-CD4 and anti-CD8 CyChrome(FL3) 
conjugated antibodies and analyzed by flow cytometry. DN T cells were defined as CD3+ 
CD4 CD8\
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3.2.6: Expanded population o f circulating a(3 TCR expressing DN T cells in patients 
with SLE.
The proportions of a p  and y8 T cell receptor-expressing cells in the DN T cell compartment 
were studied to evaluate further the relative contributions of these sub-populations. The T cell 
receptor expression of the enriched DN T cell population from patients with SLE, RA and 
healthy controls was examined using three-colour flow cytometry as described in chapter 2, 
using FITC conjugated antibodies to a p  and y8 TCR. Both ap  TCR+ and y8 TCR+ T cells 
were present in the enriched DN T cell population. Representative histogram profiles showing 
a p  and y8 TCR expression is shown in figure 3.5.
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Figure 3.5: Representative histograms showing ap  and y8 TCR expression on DN T 
cells. Enriched DN T were stained with anti-CD3-PE (FL2), anti-CD4 and anti-CD8 
CyChrome (FL3) conjugated and defined as CD3+CD4' CD8\ TCR was studied using anti-ap 
TCR-FITC or anti-y8 TCR-FITC antibodies and analyzed by flow cytometry. Measurements 
were made on gated enriched DN T cells identified by two-colour immunofluorescence 
staining as shown in Figure 1.
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The percentages ap  TCR+ve DN T cells in SLE patients within the total DN 
population (59.81±10.39) were significantly increased (p=0.04) compared with RA (53.08+ 
21.91) and HC (48.24± 15.23). The results are shown on figure 3.6. Detailed examination of 
the treatment regimes at the time of sampling showed that while many of the patients were on 
steroid therapy, either alone or in combination with other drugs, seven were receiving no 
major drug therapy.
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Figure 3.6: The percentages of a p  TCR+ DN T cells are increased in SLE patients 
(n=18) compared with RA (n=14) and HC (n=15). p=0.02 for increase in a p + DN T compared 
with both RA and HC. Enriched DN T cells were triple stained for CD4/CD8 (CyChrome), 
CD3 (PE) and aP  TCR (FITC). Cells gated on an electronic DN T cell gate (CD3+CD4'CD8 ) 
were analyzed for ap  TCR (FITC) expression.
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3.2.7: Density o f CD3.TCR expression in DN T cells.
To define the distinct characteristics of DN T cells further, the density of expression of 
CD3: TCR complex on the surface of these cells was examined. The simultaneous staining of 
PBMC’s and enriched DN T cells for CD3 (PE), CD4 (CyChrome), CD8 (CyChrome) and 
TCR (FITC) permitted qualitative observation of the levels of expression of these markers in 
different subpopulations. The mean fluorescence intensity (MFI) of CD3 staining on the 
surface of ap  and yb TCR expressing DN T cells and CD4/CD8 single positive T cells was 
evaluated. The results are shown in figure 3.7. As can be seen, a p  TCR+ DN T cells from 
patients with SLE, expressed consistently lower levels of CD3 compared to yb TCR+ve DN T 
cells (p=0.03) and single positive CD4+/CD8+ subpopulations (p=0.001). P values were 
calculated using the Wilcoxon signed rank test. The lower levels of CD3: TCR expression 
were found to be an intrinsic characteristic of all a p  TCR+ DN T cells, whether from patients 
with SLE , RA or healthy individuals(data not shown).
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Figure 3.7: Mean Fluorescence Intensity (MFI) of CD3 expression on a p  TCR+ DN T 
cells (n=l 1) from patients with SLE was lower than values for yb TCR+ DN T cells (p=0.03) 
and CD4+/CD8+ T cells (p=0.001). Enriched DN T cells were triple stained for
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CD4/CD8(CyChrome), CD3(PE) and a p  TCR or y8 TCR (FITC). Cells gated on an electronic 
DN T cell gate (CD3+CD4’CD8 ) were analyzed for a p  TCR or y8 TCR (FITC) expression.
3.2.8: Levels o f y& TCR+ T  cells remain unchanged patients with SLE when compared 
to patients with RA and healthy controls but numbers o f y& TCR+ DN T cells are decreased in 
patients with SLE .
The percentages of T cells expressing y5 TCR were studied in patients with SLE, RA 
and healthy controls using three-colour immunofluoresence staining as described in chapter 2. 
The cell population studied included both DN T cells and T cells expressing CD4 or CD8 
surface co-receptors. The results are shown in Figure 3.8. There was no difference in the 
percentages of y8 T cells in patients with SLE compared to healthy controls (p = 0.12) and 
patients with RA (p = 0.9).
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Figure 3.8: Percentages of y8 TCR+ T cells are similar in patients with SLE (n=8), 
RA (n=6)(p = 0.9) and HC (n=7) (p = 0.12). Blood PBMCs were triple stained for 
CD4/CD8(CyChrome), CD3(PE) and y8 TCR (FITC). Cells gated on an electronic 
Lymphocyte gate were analyzed y8 TCR (FITC) expression.
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When the percentage of yb TCR+ DN T cells were examined in enriched DN T cell 
populations, both patients with SLE (p=0.0054)and RA (p=0.016) showed significantly 
reduced percentages compared with healthy controls (SLE: 44.16±12.72; RA: 40.71±20.81; 
HC: 58±13.34). These results are shown in Figure 3.9.
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Figure 3.9: Percentages of y8 TCR+ DN T cells are reduced in patients with SLE 
(n=17) (p=0.0054), and RA (n=15) (p = 0.0161) when compared to HC (n=15). Enriched DN 
T cell populations were triple stained for CD4/CD8 (CyChrome), CD3 (PE) and y5 TCR 
(FITC).Cells gated on an electronic DN T cell (CD3+ CD4' CD8‘) gate were analyzed for yb 
TCR (FITC) expression.
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3.2.9: Summary o f results from  chapter 3.
The data from this chapter can be summarized as follows:
i. The percentages of CD3+ T cells in patients with SLE were unchanged when compared 
to patients with RA or healthy controls (p = 0.4)
ii. The percentages of total double negative (ap  and y5 TCR +) T cells was not significantly 
increased in patients with SLE when compared to RA patients (p = 0.3) and healthy 
controls (p = 0.3). The percentages of DN T cells also showed no correlation with the 
disease activity (global score) in patients with SLE (p = 0.8).
iii. There was a significant increase in the a p  TCR expressing sub-population of DN T cells 
in patients with SLE compared to RA patients and healthy controls (p = 0.02).
iv. The a p  TCR+ DN T cells from both patients with SLE and healthy controls displayed 
significantly lower levels of expression of the CD3: TCR complex on their cell surface 
than their y8 TCR+(p = 0.03) counterparts and single positive (CD4+/8+) T cells (p = 
0.001).
v. The percentage of total yd TCR expressing T cells was unchanged between SLE patients, 
RA patients (p = 0.9) and healthy controls (p = 0.12). The percentages of y5 TCR 
expressing DN T cells however was reduced in patients with SLE (p=0.0054) and RA 
(p=0.016) compared to healthy controls.
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3.3: Discussion.
3.3.1: T cells and DN T cells in SLE.
As discussed in the introduction, the pathogenesis of SLE has been established as a T 
cell dependent process prompting a detailed study of the numbers and functions of this group 
of cells, in patients with SLE (Cohen, 1993). In this study, we did not find increased 
percentages of T cells in patients with SLE, compared to RA patients and healthy controls.
An increased percentage of CD3+T cells, in patients with SLE, was reported by 
Erkeller-Yiiksel et al, in 1993 (Erkeller-Yusel et al., 1993). In contrast, other studies have 
found a decrease in T cell percentages in SLE patients when compared to healthy controls 
(Glinski et al., 1976; Smolen et al., 1982). We examined the percentages of CD3+ T cells in 
patients with SLE and found them unchanged, when compared to both autoimmune disease 
controls (RA patients) and healthy individuals. The variable results reported in the numbers of 
T cells in SLE patients might be because of the larger cohort of patients (71 patients) in some 
of the studies (Erkeller-Yusel et al., 1993) and the heterogeneous nature of patients included in 
each of the studies.
I also failed to find an increase in the total DN T cell population (ap  or y8 TCR 
expressing DN T cells) in SLE patients we studied compared with autoimmune controls (RA 
patients) and healthy subjects. This is in contrast to some previous reports on the total DN T 
cell population in SLE. These studies have indicated the presence of increased percentages of 
this population in patients with SLE (Lacki et al., 1997; Devi et al., 1998). These reports also 
indicated that in patients with SLE who have consistently elevated levels of DN T cells, 
treatment with corticosteroids and cyclophosphamide reduced the percentages of these cells. 
Interestingly, although my data does not suggest a statistically significant expansion in the 
total DN T cell population in SLE patients compared to RA patients and healthy controls, a 
few patients in the study showed a large increase in their DN T cell population though this was 
not related to their disease activity. We studied this population in patients with variable 
disease activity (as indicated by their disease activity global score) and could find no 
correlation between the percentages of total DN T cells and disease activity. The patient 
population studied, consisted of both patients receiving immunosuppressive therapy and those 
receiving no drug treatment.
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3.3.2: a p  TCR+ DN T cells in SLE.
On further analysis of the DN T cell populations expressing either the a p  or y8 TCRs, 
the percentages of a p  TCR+ DN T cells in patients with SLE, within the total DN population 
were significantly increased compared with RA and HC. It is unlikely that the observed 
increase was a result of therapy because, although many of the patients were receiving 
steroids, either alone or in combination with other drugs, eight patients were not receiving any 
major drugs. There was no significant increase in the numbers of a p  TCR+ DN T cells in 
patients with RA compared with HC demonstrating that this expanded population is specific to 
SLE. These data are consistant with other reports of expanded populations of a p  TCR+ DN T 
cells in patients with autoimmune diseases such as SLE and systemic sclerosis (Shivakumar et 
al., 1989; Sakamoto et al., 1992; Liu et al., 1998; Sieling et al., 2000). On the other hand, 
long term clonal proliferation of ap TCR+ DN T cells was not found to be associated with any 
history of severe illness in two apparently healthy subjects (Kusunoki et al., 1992).
3.3.3: CD3. TCR complex on a p  TCR+ve DN T cells.
One of the distinctive characteristics of ap TCR+ DN T cells previously reported, is 
the expression of lower levels of the CD3: TCR complex on the cell surface. My data show 
that the density of expression of both CD3 and the ap TCR (as indicated by the MFI of anti- 
CD3 or TCR ap surface staining) was found to be reduced significantly in SLE DN T cells, 
when compared to CD4+ or CD8+ T cells. Interestingly this decreased expression of CD3 was 
not peculiar to SLE since it was found in patients with RA, healthy individuals and has been 
previously reported in, patients with adult T cell leukemia (ATL), systemic sclerosis and in 
murine DN T cells (Murison et al., 1993; Sakamoto et al., 1992; Suzushima et al., 1993;
Huang and Crispe, 1992). My data also suggests a significant reduction in CD3 expression on 
all ap TCR+ DN T cells compared with y8 TCR+ DN T cells. This characteristic was also 
common to DN T cells from patients with SLE, RA and healthy individuals. Surprisingly, the 
CD3: TCR complex has been shown to be functionally competent in ap TCR+ DN T cells, so 
the functional significance of the paucity of CD3: TCR expression is unclear and requires 
further study (Groh et a l,  1989; Rivas et al., 1990; Matsumoto et al., 1991).
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3.3.4: yS T  cells in SLE.
No change in the percentage of total TCR y8 expressing T cells (both DN and CD8+) in 
patients with SLE compared to RA or HC was seen in this study. This observation, however 
does not rule out a role for this population as the y5 T cells in the particular patients included 
in our study might have been ‘trafficked away’ to the sites of local inflammation in various 
organ systems. The role of y5 T cells in patients with SLE is the subject of many contradicting 
reports in literature. Although some investigators suggest an expansion of this population in 
the peripheral blood of patients with SLE, others report unchanged or decreased numbers in 
the peripheral blood (Gerli et al., 1991;Riccieri et al., 2000 ; Robak et al., 2001 ; Robak et al., 
1999).
3.4: Concluding remarks.
An expanded population of a p  TCR+ DN T cells relative to other T cells in SLE 
patients was found although this was not directly related to their disease activity. The next 
question is related to whether DN T cells in SLE patients are ‘activated’ suggesting that they 
could be functionally important in the disease.
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C hapter  4.
Activation status o f  D N  T cells  in patients with SLE.
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4.1: Introduction and aims.
4.1.1: Introduction.
4.1.1.1: Expression o f activation markers by T cells in SLE patients.
For conventional T cells, activation is initiated by interaction of the CD3: TCR 
complex with a processed antigenic peptide bound to class I or class IIM HC molecule on the 
surface of antigen-presenting cell. This interaction and the resulting activating signals also 
involve a variety of accessory molecules on the T cell and antigen-presenting cell (APC).
Following the interaction of T cell with antigen, numerous genes are activated. The 
gene-products can be grouped into categories depending on how early they can be detected 
following activation:
Early genes: expressed within 1-2 hours of antigen recognition; encode IL-2, IL-2R, 
IL-3, IFN-y, IL-6, CD69 and numerous other proteins.
Late genes: expressed more than 2 days after antigen recognition; encode various 
adhesion molecules, HLA-DR etc (Kuby, 1997).
Thus characterising the activation phenotype of T cells can provide clues to their 
participation in on-going immune reactions. The activation of DN T cells is thought to be 
through unconventional antigen presenting molecules like CD1, but is still believed to be 
accompanied by the expression of activation molecules expressed by conventional T cells. 
Therefore, in order to understand their potential role in the pathogenesis of SLE, we have 
evaluated the expression of a number of these activation molecules in the DN T cell 
population of patients with SLE.
A number of studies on the expression of early and late activation markers on SLE 
lymphocytes have been reported to date. The most commonly studied activation markers are 
CD69, HLA-DR, CD45 and the CD28/CTLA-4 co-stimulatory molecules.
89
4.1 .12: CD69.
CD69 is a phosphorylated disulfide-linked homodimer that appears on the surface of 
human T, B cells and thymocytes in the early steps of activation; its molecular mass is 28 to 
34 kDa under reducing conditions. This molecule is able to mediate positive signals to the 
lymphocytes as the anti-CD69 mAb (MLR3, AIM, Leu 23) in synergism with phorbol esters, 
induce IL-2 production and proliferation of lymphocytes. The relevance of CD69 in the 
activation process is also suggested by the broad range of signals able to modulate CD69 on T 
cells. In fact, not only the mitogens or the CD3-promoted activation, but also the alternative 
pathways mediated by CD2 or CD28 are accompanied by CD69 expression; moreover a very 
rapid and transient appearance of CD69 on the cell surface is observed also in response to a 
stimulus not specifically involved in T cell activation such as heat shock (Barclay, 1997). 
Crosslinking of CD69 generates intracellular signals in all cell lineages studied, both mouse 
and human, and results in a variety of cellular end responses such as cell proliferation and 
cytokine secretion. Since a specific ligand has not yet been identified, a definite functional 
identity for CD69 is still missing. However, the broad expression of CD69 and its conserved 
ability to generate intracellular signals suggests a general role for the CD69 receptor in the 
biology of hematopoietic cells (Marzio et al., 1999).
Some studies have reported increased constitutive CD69 expression on T cells in 
murine models of lupus and human SLE (Sobel et al., 1999; Ishikawa et al., 1998; Portales- 
Perez et al., 1997) (Crispin et al., 1998). Other studies on larger numbers (n=30) of patients do 
not, however, confirm these results (Femandez-Gutierrez et al., 1998; Afeltra et al., 1993). 
Abnormalities in CD69 expression after activation of T cells from patients with SLE with anti- 
CD3, anti-CD2 monoclonal antibodies or mitogens such as phytohaemagglutinin (PHA), 
phorbol myristate acetate (PMA) have been reported by several investigators (Femandez- 
Gutierrez et al., 1998; Portales-Perez et al., 1997; Crispin et al., 1998). Increased numbers of 
CD69 bearing cells and their hypo-responsiveness to stimulation in culture have also been 
reported in synovial fluid but not peripheral blood T cells of patients with RA (Afeltra et al., 
1993; Hemandez-Garcia et al., 1996).
Su et al, report a high correlation between CD69/CD3 ratios and SLEDAI scores of 
disease activity in patients with SLE, and suggest it could be used as an estimation of disease 
activity when levels of anti-dsDNA, C3 and C4 fail to show good correlation (Su et al., 1997).
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4.1.1.3: HLA-DR.
HLA-DR, a MHC class II molecule is expressed on dendritic cells, B cells, monocytes, 
macrophages, myeloid and erythroid precursors and some epithelial cells. MHC-class II is also 
expressed on activated T cells in humans and rats, where expression is regulated by cytokines 
including interferon-y (Seddon and Mason, 1996). MHC class II molecules present 
exogenously derived antigen to CD4+ T lymphocytes, which are usually helper T cells 
(Rudensky, 1995).
Previous studies had reported a higher proportion of HLA-DR+ T cells in both the 
CD4+ and CD8+ T cells in patients with SLE which correlated with disease activity.(Tokano et 
al., 1997; Spronk et al., 1996) (Hashimoto et al., 1994; Bijl et al., 2001).
4.1.1.4: CD28/B7 system o fT  cell costimulation.
T cell costimulatory interactions are necessary for effective lymphocyte activation and 
and also serve to enhance the immune response. It is now accepted that a major costimulatory 
pathway involves the CD28 molecule. CD28 interactions with the B7 family of costimulatory 
ligands are essential for initiating antigen-specific T cell responses, up-regulating cytokine 
expression and promoting T cell expansion and differentiation (June et al., 1994). The CD28 
glycoprotein is expressed constitutively on the surface of 80% of human T cells. CD28 
expression is not static because the levels of CD28 increase on T cells following activation, 
but ligation of CD28 leads to transient downregulation. Cytotoxic T lymphocyte antigen- 4 
(CTLA-4), the other component of the CD28/B7 T cell costimulatory system is not 
constitutively expressed on T cells. Instead, it is upregulated following T cell activation due to 
positive regulatory elements(Lenschow et al., 1996). In both human and murine systems, 
CTLA-4 expression peaks during period of transient downregulation and less responsiveness 
of CD28, suggesting that CTLA-4 might be functionally active at a time when CD28 function 
is impaired (Allison and Krummel, 1995). The function of CTLA-4 remains controversial and 
it is suggested that during T cell activation, CTLA-4 is upregulated and through interactions 
with its ligands (B7) may facilitate or promote downregulation of the immune response 
(Allison and Krummel, 1995; Lenschow et al., 1996). It has been reported that patients with
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SLE have a preferential decrease of CD28+ T cells, especially in the CD8+ T cell compartment 
(Kaneko et al., 1996; Garcia-Cozar et al., 1996; Horwitz et al., 1997; Kaneko et al., 1996).
It has been suggested that the absence of costimulators on normal tissue cells could 
serve to induce self-tolerance and that inappropriate expression of costimulators on antigen- 
presenting cells (APC) could activate self-reactive T cells, resulting in autoimmunity (Kaneko 
eta l., 1997).
Based on function and experimental data, the gene encoding cytotoxic T lymphocyte- 
associated antigen 4 (CTLA4) has been suggested as a candidate gene for conferring 
susceptibility to autoimmunity including SLE (Kristiansen et al., 2000; Pullmann et al., 1999; 
Heward and Gough, 1997). Patients with SLE have been shown to have increased numbers of 
CTLA-4+ T cells compared to controls. In addition, induction of CTLA-4 expression after 
stimulation with PMA in vitro was found to be weaker in T cells from patients with SLE 
compared to HC (Liu et al., 1998). Further evidence of CD28/CTLA-4-B7 involvement in 
SLE disease pathogenesis comes from studies where, treatment with soluble CTLA-4 IgG 
resulted in blocked autoantibody production and prolonged life in murine models of lupus 
(Finck et al., 1994; Takiguchi et al., 2000 ).
4.1.1.5: CD45.
CD45 proteins are found on all cells of haematopoietic origin, except erythrocytes and 
are necessary for signalling through the T cell receptor (Thomas, 1989). Various isoforms of 
CD45 (CD45 RA, CD45RB, CD45RC and CD45R0) are generated by alternative splicing and 
are expressed differentially on leucocytes. This differential expression has been of use in 
defining subsets of T cells, in which naive T cells express CD45RA whereas most memory 
cells express CD45R0 (Barclay N, 1997). The associations between expression of various 
CD45 isoforms on the peripheral blood T (CD4+/CD8+) lymphocytes, with autoimmune 
processes and haematological manifestations in SLE have been studied by several 
investigators. In SLE patients the pattern of CD45 isoform expression (from CD45RA to 
CD45R0) was found to vary directly with time since the onset of disease symptoms with 
higher numbers of CD45R0 cells in patients with active disease (Neidhart et al., 1996; Gordon 
etal., 1996; Hemandez-Fuentes etal., 1999).
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4.1.1.6: In vitro T cell activation in SLE.
Previous studies have demonstrated that various T and B cell functions, including 
immunoglobulin and IL-2 secretion, IL-2R expression, and proliferation of T and B cells in 
response to antigenic or mitogenic stimulation, are all moderately to severely impaired in SLE 
(Cohen, 1993). I wished to understand if this hyporesponsiveness was also true of the DN T 
cell population in patients with SLE or was restricted to the conventional T cell subsets 
reported in previous studies (Alcocer-Varela et al., 1991; Crispin et al., 1998) (Portales-Perez 
et al., 1997) (Horwitz etal., 1997; Hemandez-Fuentes etal., 1999).
4.1.2: Aims.
This part of my work aimed to characterize and compare the activation status of DN T 
cells in patients with SLE, RA and healthy individuals. I have evaluated the expression of 
early (CD69) and late (HLA-DR) activation markers, the proportion of naive and memory 
cells and the status of the CD28/CTLA-4-B7 costimulatory system. Activation of DN T cells 
from patients with SLE and HC has also been studied in cell cultures stimulated with a 
mitogen (PHA) for 24 hours.
4.2: Results.
4.2.1: Patients used in this study.
Twenty two patients with SLE (21 females and 1 male aged 17 to 67 years, mean 42 
years) were studied with informed consent. Each met four or more of the revised criteria of 
the American College of Rheumatology for the classification of the disease (Tan et al., 1982). 
Disease activity was assessed using the British Isles Lupus Assessment Group (BILAG) 
computerised index (Hay et al., 1993). In this study patients with a global scoring >6 were 
deemed active <6 as inactive. Levels of circulating anti-dsDNA antibodies and C3 were 
measured during routine patient assessment. Serum levels of anti ds-DNA antibodies in excess 
of 50 I.U. m l'1 (Shield Diagnostics, Dundee) and levels of C3 less than 0.9 I.U. m l'1 (by laser 
nephelometry) are regarded as abnormal. For statistical analysis in this study, anti-dsDNA 
antibody levels of >100 I.U. m l'1 or more were considered to be high. Detailed examination of
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the treatment regimes at the time of sampling showed that while many of the patients were on 
steroid therapy, either alone or in combination with other drugs, eight were receiving no major 
drug therapy (Table 4.1).
Seventeen patients with rheumatoid arthritis (RA: 15 female, 3 male, aged 35 to 82 
years, mean 59 years) who fulfilled four or more of the ARA criteria for rheumatoid arthritis 
and 18 healthy controls (HC: 17 females, 1 male aged 18 to 45 years, mean 31 years) were 
also studied (Amett et al., 1988).
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Patient No Global Score Drug Treatment
19 10 No major drugs
5 3 No major drugs
20 3 No major drugs
8 4 No major drugs
16 5 No major drugs
10 6 No major drugs
21 6 No major drugs
1 4 No major drugs
22 11 No major drugs
18 9 5 mg Prednisolone
9 10 400 mg Hydroxychloroquine
13 0 200mg Plaquanil
6 2 2 mg Prednisolone 
200mg Hydroxychloroquine
17 1 2.5 mg Prednisolone 
400 mg Plaquanil
4 2 5 mg Prednisolone
400 mg Hydroxychloroquine
7 4 8 mg Prednisolone
400 mg Hydroxychloroquine
750 mg quarterly Cyclophosphamide
10 mg Prednisolone
2 8 400 mg Hydroxychloroquine 
7.5 mg prednisolone
12 7 25 mg Azathioprine 
7.5 mg prednisolone
15 4 150 mg Azathioprine 
400 mg Hydroxychloroquine
11 3 125 mg monthly Deltastab pulse 
50 mg Azathioprine
3 9 125 mg monthly Deltastab pulse
Table 4.1: Disease activity (global score) and treatments of patients with SLE 
studied in this chapter.
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4.2.2: Expression o f surface markers on DN T cells o f patients with SLE.
The expression of cell surface markers HLA-DR, CD69, CD28, CTLA-4 and 
CD45RA/R0 in the CD4+/CD8+ and DN T cell populations of patients with SLE, RA and 
healthy individuals were examined.
HLA-DR: The percentages of HLA-DR+ DN T cells were increased in patients with 
SLE compared to both RA patients (p=0.016) and HC (p=0.01:Fig 4.1a). In addition, there 
were significantly more HLA-DR+ DN T cells than CD4/8+ T cells in patients with SLE 
(p=0.006: Fig 4.1b). However, there was neither any significant difference in percentages of 
HLA-DR+ DN T cells nor of CD4/8+ T cells in patients with active disease compared with 
inactive disease (BILAG Global Disease Activity Index). There was no correlation between 
the global score and percentage of HLA-DR+ CD4/8+ T cells (r=0.21, p=0.48) or HLA-DR+ 
DN T cells (r=-0.08, p=0.78). With regard to anti dsDNA antibody levels, there were no 
significant differences in percentages of HLA-DR+ CD4/8+ T cells or HLA-DR+ DN T cells 
between patients with high versus low levels and no correlation between levels of anti dsDNA 
antibody and percentage of HLA-DR+CD4/8+ T cells (r=0.35, p=0.25) or HLA-DR+ DN T 
cells (r=-0.38, p=0.19). However, when high and low levels of circulating C3 were related to 
HLA-DR expression, HLA-DR expression was significantly higher in DN T cells from 
patients with high C3 (p=0.03). There was a positive correlation between C3 level and HLA- 
DR expression in both CD4/8+ T cells and DN T cells (r=0.57, p=0.04 and r=0.58, p=0.04 
respectively). These results are summarised in table 4.2.
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Figure 4.1:
a) Increased percentages of HLA-DR+DN T cells in patients with SLE (n=17), 
compared to RA (n=14)(p=0.02) and HC (n=14) (p=0.01).
b) DN T cells in patients with SLE (n=17) show a higher percentage of HLA-DR+ 
cells compared to the conventional (CD4/8+) population (p=0.006).
Enriched DN T cells were stained with fluorochrome conjugated antibodies to CD3 (PE) 
(FL2), CD4/CD8 (CyChrome) (FL3) and HLA-DR (FITC) (FL1) and analyzed by flow 
cytometry. An electronic gate was placed around DN T cells (CD3+ CD4' CD8 ) or single 
positive (SP) T cells (CD3+, CD4+ or CD8+) and gated cells analyzed for HLA-DR (FL1) 
expression.
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HLA-DR+ DN T cells HLA-DR+CD4+/CD8+ 
T cells
r value p value r value p value
Global disease 
activity index
-0.08 0.78 0.21 0.48
Anti ds DNA 
antibody levels
0.38 0.19 0.35 0.25
Serum C3 levels 0.58 0.04 0.57 0.04
Table 4.2: Correlation between HLA-DR expression in DN T cells and SLE patient
criteria.
CD69: Although patients with SLE showed an increased percentage of DN T cells 
expressing CD69 compared to HC, this was not significant (p = 0.08: Fig 4.2a). However, 
there was a significant increase in CD69+ DN T cells in SLE compared with RA patients 
(p=0.005). In addition, in the case of RA there was a significantly lower percentage of CD69+ 
DN T cells compared with the CD69+ CD4/8+ T cell population (p=0.004, data not shown). In 
patients with SLE, the percentages of DN CD69+ cells were not significantly different from 
the percentages of CD4/8+CD69+ T cells (Fig 4.2b).
There was no significant difference in CD69+ DN T cells or CD69+ CD4/8+ T cells in 
those patients with active disease compared with inactive disease. In addition there was no 
correlation between either CD69+ DN or CD69+ CD4/8+ expression and BILAG Global 
Disease Activity Index (r=0.21, p=0.54 and r=-0.55-0.52, p=0.95 respectively). No significant 
differences in percentages of CD69+ DN or CD69+ CD4/8+ were seen between high and low 
levels of serum anti dsDNA and no correlation was found between percentage of CD69+ 
CD4/8+ T cells (r=0.05, p=0.87) or CD69+ DN T cells (r=0.33, p=0.31) and level of anti 
dsDNA antibody. In addition, no significant differences were seen between low and high 
levels of serum C3 and percentage of CD69+ DN or CD69+ CD4/8+ and no correlation 
between percentage of either CD69+ DN (r=0.49, p=0.12) or CD69+ CD4/8+ (r=-0.38, p=0.25) 
and level of anti dsDNA antibody. These results are summarised in table 4.3.
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Figure 4.2:
a) CD69 expression is significantly increased in DN T cells from patients with SLE 
(n=l l )  compared to patients with RA (n=l l)(p=0.005). In HC (n=9), expression of CD69 is 
lower but the difference is not significant.
b) There is no significant difference in expression of CD69 between CD4/8+ T cells 
and DN T cells(n=l 1) in patients with SLE.
Enriched DN T cells were stained with fluorochrome conjugated antibodies to CD3 (PE) 
(FL2), CD4/CD8 (CyChrome) (FL3) and CD69 (FITC) (FL1) and analyzed by flow 
cytometry. An electronic gate was placed around DN T cells (CD3+ CD4' CD8 ) or single 
positive (SP) T cells (CD3+, CD4+ or CD8+) and gated cells analyzed for CD69 (FL1) 
expression.
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SLE
RA
HC
CD69+ DN T cells CD69+CD4+/CD8+ 
T cells
r value p value r value p value
Global disease 
activity index
0.21 0.54 0.55 0.95
Anti ds DNA 
antibody levels
0.33 0.31 0.05 0.87
Serum C3 levels 0.49 0.12 -0.38 0.25
Table 4.3: Correlation between CD69 expression in DN T cells and SLE patient
criteria.
CD28: There were more DN T cells expressing the costimulatory molecule CD28 in 
SLE patients than in either RA (p= <0.0001) or HC (p=0.002: Fig 4.3a): Higher levels of 
CD28+ DN T cells were seen compared with CD28+CD4+/CD8+ T cells populations in SLE 
(p=0.05: Fig 4.3b).
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Figure 4.3: a) Increased percentages of CD28+ DN T cells in patients with SLE 
(n=17) compared to RA (n=15)(p<0.0001) and HC (n=12)(p=0.002).
b) DN T cells in patients with SLE (n=17) show a higher percentage of CD28+ cells 
compared to the conventional (CD4/8+) population (p=0.05).
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Enriched DN T cells were stained with fluorochrome conjugated antibodies to CD3 (PE) 
(FL2), CD4/CD8 (CyChrome) (FL3) and unconjugated anti-CD28 antibody, followed by 
FITC-conjugated secondary antibody (FL1) and analyzed by flow cytometry. An electronic 
gate was placed around DN T cells (CD3+ CD4" CD8") or single positive (SP) T cells (CD3+, 
CD4+ or CD8+) and gated cells analyzed for CD28 (FL1) expression.
CTLA-4: Although few CTLA-4+ cells were detected (Fig 4.4a), there were
significantly more in the DN T cell population of the patients with SLE compared with both 
the RA patients (p= 0.002) and HC (p= 0.004). Numbers of CTLA-4+ CD4/8+ T cells also 
appeared to be increased compared to control groups but the increase was not statistically 
significant. The percentages of CTLA-4+ DN T cells were significantly higher than the 
CTLA-4+CD4+/CD8+ cells in both the SLE patients (p=0.03: Fig 4.4b) and HC (p=0.001:data 
not shown).
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Figure 4.4: a) Increased percentages of CTLA-4+ DN T cells in patients with SLE 
(n=14) compared to RA (n=10)(p=0.002) and HC (n=8)(p=0.004).
b) DN T cells in patients with SLE (n=14) show a higher percentage of CTLA-4+ cells 
compared to the conventional (CD4/8+) population (p=0.003).
Enriched DN T cells were stained with fluorochrome conjugated antibodies to CD3 (PE) 
(FL2), CD4/CD8 (CyChrome) (FL3) and CTLA-4 (FITC) (FL1) and analyzed by flow 
cytometry. An electronic gate was placed around DN T cells (CD3+ CD4~ CD8 ) or single
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positive (SP) T cells (CD3+, CD4+ or CD8+) and gated cells analyzed for CTLA-4 (FL1) 
expression.
CD45RA/RO: DN T cells from patients with SLE showed significantly increased 
percentages of CD45RA+ compared with HC (p = 0.007) but not with RA controls (Fig 4.5a). 
Conversely, SLE patients had significantly lower percentages of CD45RO+ T cells in 
comparison with HC (p=0.03) but not with RA controls (Fig 4.5b). In patients with SLE, the 
DN population was significantly increased in CD45RA+ compartment compared with the 
CD4/CD8+ population (p=0.048: Fig 4. 6a) while it was significantly decreased in CD45R0 
(p=0.03: Fig 4.6b).
There were insufficient data to determine accurately whether there was any correlation 
between disease activity, anti dsDNA or C3 and the levels of expression of CD28, CTLA4, 
CD45RA or CD45RO.
CD45RA CD45RO
% positive % positive
Figure 4.5: DN T cells from patients with SLE (n=15) showed significantly increased 
percentages of CD45RA+ cells (p=0.007) and decreased percentages of CD45R0+(p=0.03) 
cells compared to patients with HC (n=9). There were no significant differences in the 
percentages of CD45RA+ or CD45R0+ DN T cells between patients with SLE and RA(n=12). 
Fluorochrome (FITC) conjugated CD45RA and CD45R0 antibodies were used to stain 
enriched DN T cells alongwith anti-CD3 (PE) and anti-CD4/CD8 (CyChrome) antibodies
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before flow cytometric analysis. Cells gated on an electronic DN T cell gate (CD3+ CD4+ 
CD8+) were analyzed for CD45 RA and RO expression.
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Figure 4.6: DN T cells in patients with SLE showed significantly higher CD45RA 
(n=8)(p=0.05) and significantly lower CD45R0 (n=7)(p=0.03) expression compared to single 
positive (CD4/CD8+) T cells. Fluorochrome (FITC) conjugated CD45RA and CD45R0 
antibodies were used to stain enriched DN T cells and T cells alongwith anti-CD3 (PE) and 
anti-CD4/CD8 (CyChrome) antibodies before flow cytometric analysis. Cells gated on an 
electronic DN (CD3+ CD4+ CD8+) or a single positive (SP: CD4+/CD8+) T cell gate were 
analyzed for CD45 RA and RO expression.
4.2.3: DN T cells from patients with SLE are hypo-responsive to stimulation with 
Phytohaemaglutinin (PHA) in in-vitro cultures.
To study the effect of mitogen stimulation on DN T cells from patients and healthy 
controls, we evaluated the expression of HLA-DR on enriched DN T cell cultures, 24 hours 
after addition of PHA. PHA as a stimulant was chosen because it is a potent and specific T cell
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activator. HLA-DR was chosen as an activation marker in these studies as it is a late activation 
marker appearing 24-48 hours after activation.
The number of DN T cells from patients with SLE expressing HLA-DR after PHA 
stimulation was significantly lower as shown in figure 4.7.
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Figure 4.7: Percentages of HLA-DR+ DN T cells from patients with SLE (n=12) and 
HC (n=8) 24 hours after stimulation with PHA. Enriched DN T cells were stimulated with 
PHA for 24 hrs in in vitro cultures and HLA-DR (FITC) expression analysed by flow 
cytometric staining. Antibodies to CD3 (PE), CD4 and CD8 (CyChrome) were used to 
identify and place electronic gates on the DN T cell compartment.
The percentage increase in the number of activated (HLA-DR+) DN T cells over 24 
hours after PHA stimulation was also calculated. DN T cells from patients with SLE were 
hyporesponsive to PHA stimulation, and showed a significantly lower percentage increase in 
numbers of activated cells compared to healthy controls (P<0.0001)(Mann-Whitney U-test). 
These results are shown in figure 4.8.
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Figure 4.8: Percentage increase in HLA-DR+ DN T cells from patients with SLE 
(grey) and HC (black) in culture, 24 hours after PHA stimulation. Data shows Mean± standard 
deviation. Percentage increase was calculated using the equation:
(%HLA-DR+DN T cells at t = 24hrs)- (%HLA-DR+DN T cells at t = Ohrs) x 100
(%HLA-DR+DN T cells at t = 24hrs)
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4.2.4: Summary o f results from  chapter 4.
The data from this chapter can be summarized as follows:
i. Increased numbers of freshly isolated DN T cells from patients with SLE were HLA-DR+ 
when compared to RA(p=0.016) and HC (p=0.01). The numbers of HLA-DR+ DN T 
cells was significantly greater than the number of HLA-DR+ CD4+/CD8+ T cells, in the 
peripheral blood of patients with SLE (p=0.006).
ii. There was a slight but non-significant, increase in the number of DN T cells from 
patients expressing CD69, in the peripheral blood of SLE patients compared to patients 
with RA and HC (p=0.08).
iii. The numbers of CD28+ DN T cells in the peripheral blood of SLE patients was 
significantly higher than in patients with RA (p=<0.0001) or HC (p=0.002). In addition, 
the numbers of CD28+ DN T cells was significantly greater than CD28+ CD4+/CD8+ T 
cells in the peripheral blood of patients with SLE(p=0.05).
iv. The numbers of CTLA-4+ DN T cells in the peripheral blood of SLE patients were 
significantly higher than in patients with RA (p=0.002) or HC (p=0.004). In freshly 
isolated lymphocytes, the numbers of CTLA-4+ DN T cells were significantly greater 
than CTLA-4+ CD4+/CD8+ T cells, in patients with SLE (p=0.03).
v. Patients with SLE, showed a higher proportion of “naive”(CD45RA+) to “memory” 
(CD45R0+) DN T cells, compared both to their conventional T cell compartment 
(CD4+/CD8+) (CD45RA- p=0.05, CD45R0-p=0.03) and the DN T cells of control 
subjects (HC) (CD45RA-p=0.007, CD45R0-p=0.03).
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4.3: Discussion.
4.3.1: Activation status o f SLE DN T cells.
The data in this chapter indicates that DN T cells in patients with SLE have an 
activated phenotype. The expression of activation markers by the DN Tcells of patients could 
indicate that they are functionally important in the disease.
4.3.1.1: HLA-DR.
Increased percentages of DN T cells expressing HLA-DR in patients with SLE 
compared with the two control groups (RA and HC) were found. HLA-DR is mainly found 
expressed by T cells. However, there was a high level of HLA-DR+ cells in the DN T cell 
compartment compared with the CD4+/ CD8+ T cells in SLE. This finding suggested that the 
DN T cells are more activated and is further evidence that they could be playing a role in SLE 
disease pathogenesis. No significant differences in HLA-DR expression between patients with 
SLE and the control groups (RA and HC) in the conventional CD4+/CD8+ population were 
found. Several studies have reported increased numbers of HLA-DR+ T lymphocytes in 
peripheral blood and tissues of SLE patients with active disease (Groen et al., 1993; 
Hashimoto et al., 1994; Heiligenhaus et al., 1996; Tokano et al., 1997). Surprisingly, patients 
with inactive or clinically quiescent disease also showed large numbers of HLA-DR+ 
lymphocytes (Spronk et al., 1996; Spronk et al., 1993). The persistent presence of a high 
proportion of activated T cells in both patients with active or quiescent disease is of interest 
with respect to our understanding of the possible pathogenesis of this condition. Although 
many factors, including viral agents have been proposed, the factors that sustain 
immunoactivation even during quiescent lupus are unknown (Blomberg et al., 1994; 
Fredriksen et al., 1993; Hardgrave et a l ,  1993). It is unclear why there were no differences in 
expression of the overall CD4+/CD8+ cells and unlikely that these findings were due to the 
disease activity of our patient cohort, as there does not appear to be any correlation between 
BILAG Global Disease Activity Index and HLA-DR expression.
However, there was a positive correlation between C3 levels and HLA-DR expression 
in both CD4+/CD8+ T cells and DN T cells. Higher levels of circulating C3 are indicative of 
less active disease and this finding might indicate that highly activated DN T cells could have
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a protective effect. Studies have reported no relationship between deficient PKA-I activity and 
the proportion of HLA-DR T cells in patients with SLE (Kammer, 1999).
4.3.1.2: CD69.
This study is the first to investigate CD69 expression by DN T cells in patients with 
SLE. The differences between the percentages of CD69+ DN T cell populations between SLE 
patients and controls, were much more significant than the differences seen comparing the 
CD4/CD8+ populations, suggesting that the level of expression of CD69, although increased 
on the overall T cell populations was highest for the DN T cells in patients with SLE.
Other investigators have however, shown that numbers of CD69+ cells are marginally 
increased in freshly isolated CD4+ or CD8+ T cells from patients with SLE, especially in the 
CD8+ T cell compartment (Crispin et al., 1998) (Femandez-Gutierrez et al., 1998; Sakata et 
al., 1998; Portales-Perez et al., 1997). In patients with RA, the percentage of CD69+ and 
HLA-DR+ T cells was found to be increased in the synovial fluid but not peripheral blood 
illustrating the restriction of activated T cells to the site of inflammation (Afeltra et al., 1993; 
Bodman-Smith et al., 2000 ). It has also been reported that CD69/CD3 ratio, which detects T 
cell activation, is correlated with disease activity in patients with SLE (Su et al., 1997).
4.3.1.3: CD28.
More DN T cells expressed CD28 in patients with SLE compared to RA or HC. 
Ananlysis of the CD4+ and CD8+ cells together showed that there were significantly more 
CD28+ cells in the DN compartment than in the CD4/8+ population in patients with SLE.
CD28 has been shown to be present on the majority of CD4+ T cells with fewer CD8+ T cells 
expressing this molecule (June et al., 1994). Phenotype analysis studies of peripheral blood 
lymphocytes from patients with SLE revealed a decrease in the absolute number of CD28+ T 
cells in both the CD4+ and CD8+ T cell compartments, while that of CD28’ T cells was 
maintained ( Garcia-Cozar et al., 1996; Horwitz et al., 1997; Kaneko et al., 1996). The 
CD28+ T cells from patients and healthy controls maintained a normal proliferative response 
to both CD28 dependent and independent stimulation, but the CD28' T cells were found to be 
hypo-responsive to anti-CD3 stimulation (Kaneko et al., 1996). Decreased T cell response to 
anti-CD2 and its reversal by anti-CD28 antibody, observed in patients with SLE may be due to 
decreased CD28 mediated costimulatory activity following interactions of T cells with
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conventional accessory cells (Horwitz et al., 1997; Garcia-Cozar et al., 1996). These results 
might explain in part the functional T cell defects observed in SLE. Conversely, other reports 
in the literature attribute T cell activation abnormalities in patients with SLE to irregularities in 
B7 expression on antigen presenting cells (Garcia-Cozar et al., 1996; Denfeld et al., 1997).
The significance of increased numbers of CD28+ DN T cells in patients with SLE is 
currently unclear, but engagement of CD28 on T cells by its counter-receptors B7-1 (CD80) 
and B7-2 (CD86) on accessory cells is pivotal for T cell activation and in the absence of this 
costimulation T cells are anergised (Schwartz, 2003; Wells et al., 2001). Recent studies in 
CD28T mice have also indicated an essential role for CD28 in Th2 differentiation and the 
initiation of T cell expansion in response to immunogenic antigen (Rulifson et al., 1997; 
Howland et al., 2000). Interestingly, a defective CD28/B7 costimulatory pathway has also 
been described in SLE T cells which could contribute to the disease pathogenesis (Horwitz et 
al., 1997; Garcia-Cozar etal., 1996).
4.3.1.4: CTLA-4.
Following activation via CD28, CD4+ and CD8+ T cells express CTLA-4, which has a 
higher affinity for the same ligands as CD28 (CD80/CD86). This expression is thought to 
deliver a negative signal to the T cells (Allison and Krummel, 1995; Waterhouse et al., 1995; 
Tivol et al., 1995). In these studies on CTLA-4 expression by CD4/CD8+ T cells in patients 
with SLE increased percentages of CTLA-4+ T cells were found compared to normal controls, 
consistent with that reported by others (Liu et al., 1998). In addition, our patients with SLE 
also showed a low but significantly increased percentage of DN T cells expressing CTLA-4. 
This concomitant increase in the number of cells expressing both CD28 and CTLA-4 confirms 
the highly activated status of some DN T cells in patients with SLE.
CTLA-4 is often detected intracellularly. However, in this study I did not stain for 
intracellular CTLA-4 routinely because, in three patients studied I found no significant 
differences in the results for surface or intracellular staining (data not shown).(Garcia-Cozar et 
al., 1996; Kaneko etal., 1996)
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43.1 .5: CD45RA and CD45R0.
Expression of CD45R0 usually means that the cells are ’antigen experienced’ whereas 
those that are CD45RA are 'antigen naive'. I found that a significantly higher percentage of 
DN T cells expressed CD45RA in patients with SLE compared with HC. The opposite was 
found for the CD45R0 status, with significantly decreased percentages of CD45R0+ DN T 
cells seen in patients with SLE compared to HC. The patients also showed a significantly 
higher proportion of CD45RA+ cells to CD45RO+ cells in the DN T cell compartment 
compared to the CD4+/CD8+ T cell population. One explanation for this could be the 
recruitment of naive/resting DN T cells to the ongoing immune reaction in patients with SLE 
rather than the reactivation of existing memory clones. This finding is in agreement with the 
results of studies following the course of disease from the onset of symptoms in patients with 
SLE (Gordon et al., 1996).
There was no significant increase in the percentages of CD45RA+ DN T cells in 
patients with RA compared to HC. This is a surprising observation considering both patients 
with SLE and RA have ongoing inflammatory autoimmune reactions. This finding implies that 
the recruitment of DN T cells to autoimmune reactions differs in patients with varying 
autoimmune diseases. On the other hand, as RA is a relatively organ specific disease and 
newly recruited CD45RA+ DN T cells could be present at the sites of inflammation (joints) 
and therefore the increased numbers not detected in the peripheral blood of patients.
4.3.2: DN T cells from patients with SLE are hypo-responsive to PHA stimulation.
In stimulation assays with a strong stimulant such as PHA, DN T cells from patients 
with SLE showed a lower response compared to cells from HC. Previous work monitoring 
activation of SLE lymphocytes in culture, after different stimuli has demonstrated that they 
show suboptimal proliferation and activation responses ( (Alcocer-Varela et al., 1991; Crispin 
et al., 1998) (Portales-Perez et al., 1997) (Horwitz et al., 1997; Hemandez-Fuentes et al.,
1999). These studies on DN T cells agreed with these results, with the percentage increase in 
HLA-DR expression over 24 hours being significantly lower in DN T cells from patients with 
SLE compared to HC. This hypo responsiveness might be due to their already being highly 
activated when isolated from the peripheral blood of patients with SLE. Previous studies have 
demonstrated that the decreased proliferation response of SLE T cells can be restored by the 
addition of anti-CD28 MoAb suggesting the absence of an intrinsic defect in the activation and
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proliferation pathways of these cells (Garcia-Cozar et al., 1996). Interestingly, cell cycle 
analysis of activated (HLA-DR+) T cells from patients with SLE by Takano et al., showed the 
majority to be present in the G1A phase with very few cells in the S, G2 or M phase (Tokano 
et al., 1997). The authors concluded that there were at least two types of activated T cells in 
patients with SLE which differed in their cell cycle distribution (activated T cells in G1A 
phase or those in Gl-M phase) and suggest that this variation may be related, perhaps 
indirectly to SLE pathogenesis.
4.4: Concluding remarks.
The data in this chapter suggests an activated phenotype for DN T cells from patients 
with SLE, indicating their participation in the ongoing immune reaction. The response of DN 
T cells from these patients to in vitro activation was lower than cells from HC, perhaps due to 
their already highly activated state in the peripheral blood of patients. The hyporesponsivenes 
of the DN T cells measured in these studies was consistent with similar observation by other 
groups looking generally at T cells.
ill
C hapter 5.
Cytokine secretion by SLE D N  T cells.
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5 .7: Introduction and aims.
5.1.1: Introduction.
5.1.1.1: Double negative T cells in SLE: Cytokine profile.
My studies on DN T cells have shown the presence of expanded populations of ap  
TCR+ DN T cell, and activated phenotypes in patients with SLE. The functional significance 
of these cells in the autoimmune reaction can be further understood by studying their cytokine 
production. The cytokine profile of these cells could indicate their role as Thl (inflammatory), 
Th2 (humoral immune response), Th3 (regulatory function) or ThO as described in detail in the 
general introduction.
Studies in the literature have shown that a p  TCR+ DN T cell lines and clones from 
healthy subjects to have a higher proportion of IL-4 producing cells indicating that they may 
play a role in host ‘Th2 like’ responses, and provide help for antibody production (Katsikis et 
al., 1995; Niehues et al., 1999). a p  TCR+ DN T cells from healthy subjects have also been 
shown to produce IFN-y and IL-10 indicating a ThO phenotype (Katsikis et al., 1995). The 
production of both IL-4 and IL-10 by these cells could indicate an immunosuppressive and 
anti-inflammatory role for these cells in the autoimmune disease pathogenesis. In mice, a 
novel cell population called NK1.1+ cells within the CD4+ and DN T cell compartments 
associated with initial IL-4 production and Th2 differentiation has been reported, although 
equivalent cells in humans have not been clearly defined (Yoshimoto et al., 1995). Recent 
studies on PBMC’s from patients with SLE have reported higher frequencies of IL-4+ T cells 
in both the CD4+ and DN T cell compartment of active SLE patients compared to 
corresponding cells in healthy control subjects (Funauchi et al., 1999).
5.1.1.2: Intracellular cytokines.
To determine cytokine production on the single-cell level, intracellular cytokine (IL-4) 
was determined by FACS. Cytokine synthesis was maximised by stimulating the cells with 
PHA and monensin which is a secretion inhibitor and allows the accumulation of cytokines in 
the Golgi bodies (Pala et al., 2000). In general, measuring cytokines from plasma and serum
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samples or culture supernatants (using techniques such as ELISA) does not reflect real in vivo 
conditions. Cytokines do not effectively regulate immune function systematically, but rather in 
low concentrations near the effector site. In addition, in vitro analyses of cytokine levels in 
supernatants from cultured cells are tempered by consuming cells within bulk cultures. All 
these factors can affect levels measured in the supernatant and hence the intracellular cytokine 
staining method was used in our studies (Jacob et al., 2001).
5.1.2: Aims.
At the start of this project, nothing was known about the constitutive production of 
cytokines by DN T cells in patients with SLE. The aim of this study was to determine the 
percentages of IL-4 producing a p +DN T cells ex vivo, and following activation with PHA, 
from patients with SLE and controls and to compare these levels of cytokine production with 
those from the CD4+ and CD8+ ap  TCR+T cell subpopulations.
5.2: Results.
5.2.1: Patients used in this study.
Fifty patients with SLE (49 females and 1 male aged 17 to 66 years, mean 37.2 years) 
were studied with informed consent. Each met four or more of the revised criteria of the 
American College of Rheumatology for the classification of the disease (Tan et al., 1982). 
Disease activity was assessed using the British Isles Lupus Assessment Group (BILAG) 
computerised index (Hay et a l ,  1993). In this study patients with a global scoring >6 were 
deemed active <6 as inactive. Levels of circulating anti ds-DNA antibodies and C3 were 
measured during routine patient assessment. Serum levels of anti dsDNA antibodies in excess 
of 50 I.U. m l'1 (Shield Diagnostics, Dundee) and levels of C3 less than 0.9 I.U. m l'1 (by laser 
nephelometry) are regarded as abnormal. For statistical analysis in this study, anti-dsDNA 
antibody levels of >100 I.U. m l'1 or more were considered to be high. Detailed examination of 
the treatment regimes at the time of sampling showed that while many of the patients were on 
steroid therapy, either alone or in combination with other drugs, ten were receiving no major 
drug therapy.
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Fifteen patients with rheumatoid arthritis (RA: 7 female, 8 male, aged 26 to 77 years, 
mean 50.7 years) who fulfilled four or more of the ARA criteria for rheumatoid arthritis and 
16 healthy controls (HC: 13 females, 3 males aged 21 to 57 years, mean 36.1 years) were also 
studied (Amett et al., 1988).
Patient No Global Score Drug Treatment
1 2 5 mg Predisolone
2 5 4 mg Predisolone
3 2 5 mg Predisolone
4 4 5 mg Predisolone
5 3 5 mg Predisolone
6 4 2 mg Prednisolone
7 7 3 mg Predisolone
8 1 5 mg Predisolone
9 4 15 mg Predisolone 
Cell Sept 1500
10 4 10 mg Prednisolone 
150 mg Azathioprine
11 4 5 mg Predisolone
15 mg weekly Methotrexate
12 3 3 mg mg Predisolone
13 1 5 mg mg Predisolone
14 15 7.5 mg mg Predisolone
15 4 5 mg mg Predisolone
16 7 10 mg Predisolone
400 mg Hydroxychloroquine
17 1 7.5 mg Predisolone
400 mg Hydroxychloroquine
18 7 10 mg Predisolone
400 mg Hydroxychloroquine
19 5 10 mg Predisolone
400 mg Hydroxychloroquine
20 9 8.5 mg Predisolone
400 mg Hydroxychloroquine
21 2 2.5 mg Predisolone
400 mg Hydroxychloroquine
22 2 400 mg Hydroxychloroquine
23 4 400 mg Hydroxychloroquine
24 2 400 mg Hydroxychloroquine
25 2 400 mg Hydroxychloroquine
26 5 400 mg Hydroxychloroquine
27 9 400 mg Hydroxychloroquine
28 2 400 mg Hydroxychloroquine
29 4 400 mg Hydroxychloroquine
30 1 200 mg Hydroxychloroquine
31 9 200 mg Hydroxychloroquine
32 2 400 mg Hydroxychloroquine
33 4 400 mg Hydroxychloroquine
34 10 5 mg Predisolone 
100 mg Azathioprine
35 8 5 mg Predisolone 
100 mg Azathioprine
36 1 5 mg Predisolone 
100 mg Azathioprine
37 3 5 mg Predisolone 
100 mg Azathioprine
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38 7 5 mg Predisolone 
100 mg Azathioprine
39 2 5 mg Predisolone 
75 mg Azathioprine
40 2 5 mg Predisolone 
100 mg Azathioprine
41 2 6 mg Predisolone 
150 mg Azathioprine
42 2 6 mg Predisolone 
150 mg Azathioprine
43 6 5 mg Predisolone 
125 mg Azathioprine
44 6 7.5 mg Predisolone 
100 mg Azathioprine
45 5 15 mg Predisolone
150 mg Azathioprine
400 mg Hydroxychloroquine
46 5 9 mg Predisolone
400 mg Hydroxychloroquine
47 4 50 mg Azathioprine
200 mg Hydroxychloroquine
48 5 10 mg Azathioprine 
400 mg Hydroxychloroquine 
5 mg weekly Methotrexate
49 7 100 mg Azathioprine
50 2 12.5 mg Predisolone 
400 mg Hydroxychloroquine 
10 mg weekly Methotrexate
Table 5.1: Disease activity (Global scores) and treatments of patients with SLE studied 
in this chapter.
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5.2.2: Production o f IL-4 by a ffD N , CD4+ and CD8+ T cells.
a) Constitutive levels o f IL-4. 
ap  TCR+DN T cells isolated from patients with SLE, constitutively had significantly 
higher percentages of IL-4 containing cells than patients with RA (p = 0.003, Fig.5.1). The 
difference between patients with SLE and HC was not significant (p = 0.066). However, 12 of 
the patients with SLE were shown to have a percentage of ap  TCR+DN T cells containing IL- 
4 of more than twice the standard error of the mean of HC (Fig. 5.1). The number of patients 
with SLE who showed high percentages of IL-4 containing cells was significantly different 
from HC by Fischer’s exact test (p = 0.025). In addition, it was observed that the percentages 
of IL-4 positive cells were significantly higher in the a p  TCR+ DN T cell subset than in either 
the CD4+ or the CD8+ T cell subsets of patients with SLE both in whole population analyses 
(p = <0.0001 in each case) and in the 12 patients with IL-4 positive cells greater than twice the 
standard error of the mean of HC (p = 0.006 for CD8+ and p = 0.019 for CD4+). It was 
difficult to determine whether increased numbers of IL-4+ ap  TCR+ DN T cells in patients 
compared with controls also showed these individual cells to be producing more IL-4 (by 
measuring the mean fluorescence intensity: MFI of IL-4 staining) owing to variations in 
binding of isotype controls and anti-IL-4 antibody between patients.
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Figure 5.1: IL-4 production by a p  TCR+ DN T cells in patients with SLE (n=50), RA 
(n=15) and HC (n=15). The mean is indicated by solid line and the dotted line represents +2 x 
SEM of patients with SLE. Enriched DN T cells were identified by immunofluorescence 
staining with antibodies to a p  TCR (FITC) (FL1) and CD4 and CD8 (CyChrome) (FL3). Cells 
were further stained with fluorochrome (PE) conjugated antibodies to intracellular IL-4 and 
analyzed by flow cytometry as described in materials and methods. An electronic gate was 
placed around ap  TCR+ DN T cells and their intracellular IL-4 expression analyzed.
b) IL-4 production after PHA stimulation.
When cells from these experimental groups were stimulated by overnight incubation 
with PHA, the differences in frequency of IL-4 positive cells between the groups were no 
longer observable (Fig 5.2). Analysis of paired data from constitutive and PHA stimulated 
cells showed a significant increase in the percentage of IL-4 positive a p  TCR+DN T cells on 
stimulation for SLE (p=0.03), RA (p=0.006) and HC (p=0.004). There was no significant 
difference in the percentage IL-4 positive cells either between SLE and RA (p=0.8) or 
between SLE and HC (p=0.9). It was noted that, while most individuals tested showed an
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increase in IL-4 positive cells following PHA stimulation, six of the patients with SLE 
decreased their percentages of IL-4 positive a p  TCR+ DN T cells after stimulation.
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Figure 5.2: ap  TCR+ DN T cells from patients with SLE (n=19), RA (n=10) and 
healthy controls (n=9) expressing IL-4 before and after stimulation with PHA in vitro. The 
mean in each set of data points is indicated by the horizontal solid line. Enriched DN T cells 
were identified by immunofluoresence staining with antibodies to ap  TCR (FITC) (FL1) and 
CD4 and CD8 (CyChrome) (FL3). Cells were further stained with flurochrome (PE) 
conjugated antibodies to intracellular IL-4 before and after stimulation with PHA, and
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analyzed by flow cytometry as described in the materials and methods. An electronic gate was 
placed around oc(3 TCR+ DN T cells and their intracellular IL-4 expression analyzed.
5.2.3: Quantitation o f a/3 TCR+ double-negative T cells.
Previous studies (described in chapter 3) indicated that the ap  TCR+DN T cell 
subpopulation was expanded within the total DN population in patients with SLE. While the 
total lymphocyte population comprised of approximately 1%-12% DN T cells in all 
experimental groups, an average of 60% of these cells were ap  TCR+ in patients with SLE 
compared with an average of 48% in healthy people (p=0.0216) (Fig 3.6). Comparison of 
percentages of ap  TCR+DN T cells as a proportion of total ap  TCR+ T cells for those 15 
patients who had the highest frequency of IL-4 positive a p  TCR+DN T cells with percentage 
of a p +DN T cells for those patients with low frequency of IL-4 positive cells, showed that 
those patients with high percentages of IL-4 positive cells had significantly fewer a p  TCR+ T 
cells in the DN compartment than did the group with low frequency of IL-4 positive cells 
(p=0.02) (Figure. 5.3). However, further analysis showed that there was no overall correlation 
between percentages of IL-4 positive a p +DN T cells and total aP +DN T cells (r=-0.15, 
p=0.36).
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Figure 5.3: Percentages of a p  TCR+ DN T cells in patients with high (n=14) and low 
(n=25) numbers of IL-4 producing cells. The mean is indicated by the horizontal solid line. 
Enriched DN T cells were identified by immunofluoresence staining with antibodies to ap  
TCR (FITC) (FL1) and CD4 and CD8 (CyChrome) (FL3). Cells were further stained with 
fluorochrome (PE)(FL 2) conjugated antibodies to intracellular IL-4 and analyzed by flow 
cytometry as described in materials and methods. An electronic gate was placed around a p  
TCR+ DN T cells and their intracellular IL-4 expression analyzed.
5.2.4: No correlation o f IL-4 production with cell surface markers
Levels of the surface activation markers CD69 and HLA-DR were measured on ap  
TCR+DN T cells from 21 patients with SLE, 17 of whom had low frequencies of IL-4 positive 
cells and four had high frequencies of IL-4 positive ap  TCR+DN T cells. There was no
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significant difference in activation marker expression between high and low producers of IL-4 
(p= 0.51 for HLA-DR and p=0.58 for CD69) (Fig.5.4). In addition, there was no significant 
correlation between expression of activation markers and high or low frequency of IL-4 
positive a p +DN T cells (r=-0.12, p=0.33 for HLA-DR and r=0.78, p=0.39 for CD69) (Fig5.4). 
In the above experiments, DN T cells were independently evaluated for activation markers 
and IL-4 expression. It was not possible to determine whether the IL-4 containing cells 
themselves expressed HLA-DR or CD69 in this study owing to the technical limitations of 
three colour staining.
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Figure 5.4: Relationship between activation marker expression and numbers of high 
(n=4) and low IL-4 (n=17) expressing a p  TCR+ DN T cells in patients with SLE. Enriched 
DN T cells were identified by immunofluorescence staining with antibodies to a p  TCR 
(FITC) (FL1) and CD4 and CD8 (CyChrome) (FL3). Cells were further stained with 
flurochrome (PE) conjugated antibodies to intracellular IL-4 or surface HLA-DR or CD69 and 
analyzed by flow cytometry as described in materials and methods. An electronic gate was 
placed around ap  TCR+ DN T cells and their intracellular IL-4 or HLA-DR or CD69 
expression analyzed.
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5.2.5: IL-4 production and disease activity.
There was no correlation between the BILAG Global Disease Activity Index and IL-4 
production (r=0.07, p=0.6). Similarly, when the patients with SLE were divided into groups 
depending on the specific organs or systems affected, there was no connection between IL-4 
production and the organ or system involved. It was not possible to calculate correlation 
coefficients for each of the specific organs or systems owing to the small sample size.
The 12 patients in the high constitutive EL-4 group had a mean disease duration of 10.67 years 
± 2.64 years. The low IL-4 group consisted of 29 patients of mean disease duration 12.64 
years ± 1.56 years. There was no significant difference in disease duration between the two 
groups (p= 0.6).
5.2.6: No association o f constitutive IL-4 production with drug treatment.
All but one of the patients with SLE who showed high levels of IL-4 positive ap  
TCR+DN T cells was receiving prednisolone therapy (dosage varying from 3-10mg). Five of 
these patients were also being treated with azathioprine (dosage varying from 50 -lOOmg). 
The remaining patient was being treated with antimalarial drugs (Hydroxychloroquine, 
400mg). Twenty four of the low IL-4 group were also being treated with prednisolone, eleven 
of these in combination with azathioprine and one in combination with antimalarials. One 
patient was receiving azathioprine alone, seven antimalarials alone, and one patient was being 
treated with a combination of antimalarials and azathioprine. There was no association 
between drug treatment and levels of constitutive production of IL-4. When the patients 
treated with prednisolone were divided arbitrarily on the basis of steroid dosage into high and 
low dose groups (> lOmg and <10mg respectively) no significant differences in percentages 
of IL-4 positive ap  TCR+DN T cells or percentages of ap  TCR+DN T between the two 
groups were found (p= 0.77 and p=0.84 respectively).
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5.2.7: IL-4 production did not correlate with levels o f plasma C3 or circulating anti 
dsDNA antibodies in patients with SLE.
Circulating anti dsDNA antibodies are a characteristic of patients with SLE and rising 
levels of antibody are often a predictor of severe disease. In the 47 patients for whom data 
were available, there was no correlation between levels of circulating anti dsDNA antibodies 
and the percentages of IL-4 positive a p +DN T cells (r=0.07 p=0.66).
Plasma C3 is measured routinely in all patients attending the Lupus clinic. Low levels 
of C3 often correlate with active disease. However, in 47 patients for whom data were 
available, percentages of a p +DN T cells constitutively expressing IL-4 did not correlate with 
plasma C3 (r=0.21, p=0.44)
However, there was a statistically significant negative correlation between C3 and anti 
dsDNA for the patient samples considered in this study (r=-0.45 p=0.01) confirming the 
known relationship between high anti dsDNA antibodies and low C3.
5.2.8: No association o f IL-4 production with HLA phenotype.
Tissue-typing data were not available for all of the patients but were obtained for nine 
of the high frequency IL-4 positive group and for 24 of the low frequency group. There was a 
wide variation in HLA expression but it was noted that several phenotypes occurred multiple 
times. Five of the 24 patients in the low frequency group expressed HLA A1 and HLA B8 
while another five expressed HLA DQ5. In the high frequency group, four of the nine patients 
expressed each of these phenotypes. Fischer’s exact test indicated that the differences in 
expression between the two groups were not significantly different (p= >0.5)_as might be 
expected, given the relatively small sample number.
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5.2.9: Summary o f results from  chapter 5.
The data from this chapter can be summarized as follows:
i. The number of constitutively IL-4 expressing ap  TCR+ DN T cells was significantly 
greater in patients with SLE than patients with RA(p=0.003). The difference between 
patients with SLE and HC was not significant (p=0.066).
ii. The percentage of IL-4 positive cells was significantly higher in the ap  TCR+ DN T cell 
subset than in either the CD4+ or the CD8+ T cell subsets of patients with SLE 
(p=<0.0001 in each case).
iii. Twelve patients with SLE showed a percentage of IL-4+ a p  TCR+ DN T cells of more 
than twice the standard error of mean of this population of cells in HC.
iv. On stimulation of ap  TCR+ DN T cells with PHA, no difference in the numbers of IL-4 
positive cells was found either between patients with SLE and RA (p=0.8) or between 
those with SLE and HC (p=0.9). All the groups (SLE, RA and HC) showed increased 
numbers of IL-4 positive cells after PHA stimulation compared to freshly isolated ap  
TCR+ DN T cells (SLE p=0.03, RA p=0.006 and HC p=0.004).
v. Patients with SLE who had high percentages of IL-4 positive cells had significantly 
fewer ap  TCR+ T cells in the DN compartment than did the group with a low frequency 
of IL-4 positive cells (p=0.02).
vi. There was no relationship between expression of activation markers (CD69 and HLA- 
DR) and high and low IL-4 expression by ap  TCR+ DN T cells in patients with SLE (p= 
0.51 for HLA-DR and p=0.58 for CD69).
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vii. Levels of constitutive IL-4 expression by ap  TCR+ DN T cells of patients with SLE 
showed no association with disease activity, drug treatment, levels of plasma C3 or 
circulating anti-dsDNA antibodies.
5.3: Discussion
In this chapter I have shown that the a p  TCR+DN T cell compartment of patients with 
SLE contains more cells positive for intracellular IL-4 than the equivalent cells of RA 
autoimmune controls or healthy controls. These results are consistent with the results of 
Sieling et al., who have also reported increased numbers of IL-4 producing a p  TCR+ DN T 
cells in patients with SLE (Sieling et al., 2000). Other groups have also reported increased 
production of IL-4 by T cells from patients with autoimmune and atopic diseases(Nagy et al., 
2000 ; Funauchi et al., 1998; Richaud-Patin et al., 1995). Since these studies only looked at 
IL-4 and not IFN-y production, I was unable to determine whether the IL-4 producers were 
also IFN-y+. Intracellular staining with a number of anti-IFN-y antibodies failed to give 
consistent staining patterns on enriched DN T cell populations making the data difficult to 
interpret and was therefore abandoned.
Funauchi et al, have demonstrated that the frequency of IL-4 positive cells is increased 
in SLE compared with IFN-y producers and it has been shown that IL-4 enhances the 
differentiation of both B cells and T cells, particularly Th2 helper T cells (Funauchi et al., 
1998). Recent studies in murine lupus, have advocated a protective role for IL-4 producing 
cells in down regulating the production of Thl mediated IgG3 subclass of autoantibodies, 
which have been shown to be more nephritogenic (Santiago et a l,  1997).
A higher frequency of NK T cells (a subpopulation of a p +DN T cells) producing IL-4 
in patients with SLE than controls, following stimulation with PMA and ionomycin has been 
described (Funauchi et al., 1999). This NK T population mainly utilizes Va24JaQV(311+ T 
cell receptor in healthy subjects and these cells have been shown to produce both IL-4 and 
IFN-y on activation. In insulin dependent diabetes mellitus (IDDM) it has been reported that 
Thl cell-mediated tissue damage is initially regulated by V a24JaQ V pi 1+ T cells producing 
both IFN-y and IL-4 cytokines, and loss of their capacity to produce IL-4 is correlated with 
IDDM (Wilson et al., 1998). This population of V a24JaQ V pl 1+ DN T cells has been shown
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by others to be reduced in patients with active SLE is dysfunctional in about 50% of patients 
although DN V a24+ T cells are expanded overall (Oishi et al., 2001 ; Kojo et al., 2001). When 
these patients become inactive with the help of prednisolone therapy, patients on therapy 
regain their V a24JaQ V pi 1+ DN T cells but it is unclear as to whether their function is 
restored. This finding would implicate V a24JaQ V pi 1+ DN T cells in control of the 
pathogenesis of SLE possibly through the production of IL-4 (Kojo et al., 2001). In general, it 
has been suggested that IL-4 producing NK T cells might function as regulatory cells, and the 
selective reduction of this population may be essential for the generation of autoimmune 
diseases.
It is unclear at present why only a minority of patients had an increased frequency of 
intracellular IL-4 in the ap  TCR+DN subpopulation, suggesting that these patients are in some 
way different from others within the group. In addition, a high frequency of intracellular IL-4 
appeared to be specific to the a p  TCR+DN T cell population and was not found in the CD4+ 
and CD8+ T cell populations. Attempts to correlate the increased expression of IL-4 by the ap  
TCR+DN T cell population with a variety of other criteria failed to yield any relationships. 
These patients were not from a common ethnic background, did not share a common HLA 
phenotype and there was no relationship between the severity of their disease at the time of 
sampling and the percentage of IL-4 positive cells. This last observation is in contrast to the 
work of another group who found that disease activity was lowest in those patients who 
produced the highest levels of IL-4 (Funauchi et al., 1999). Indeed, the highest levels of IL-4 
in their patient cohort were produced by patients with a SLEDAI global score of one.
However, their data was only generated from the subpopulation of DN cells expressing CD57 
(NK T cells) and not from the whole a p +DN T cell population and so may not be comparable 
with our findings^ There appeared to be no relationship between levels of plasma C3 and anti 
dsDNA antibodies and IL-4 produced suggesting that the high levels of intracellular IL-4 in 
some patients are not simply related to disease activity using these criteria. In addition, there 
appeared to be no obvious relationship between drug therapy and production of IL-4. 
Interestingly, almost all of our patients were being treated with prednisolone.
Further analysis of the data showed that the percentages of ap  TCR+DN T cells present 
in the 15 patients with the highest frequency of IL-4 containing cells was significantly lower 
than that in the other patients with SLE. Although the significance of this observation is not
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yet clear, it may lend weight to the theory that high levels of IL-4 within the DN T cell 
population are seen in those patients who lack a regulatory population of cells that would 
otherwise control cytokine production. Recent reports have also suggested a role for IL-4 
producing cells in containing T hl (IFN-y) mediated production of nephritogenic subclass of 
IgG autoantibodies (Kirou and Crow, 1999; Theofilopoulos et al., 2001). Alternatively, it is 
possible that when the apTC R +DN T cells are present in lower numbers, they receive more 
help to produce cytokines. Such a possibility would suggest that the IL-4 producing cells 
would be more activated and measurement of activation markers on the whole subpopulation 
of ap  TCR+DN T cells appeared to confirm this theory though the difference was not 
significant and numbers were too low to draw firm conclusions. However, It was not possible 
to determine whether those cells positive for intracellular IL-4 were also activated within the 
constraints of three-colour staining and further work would be needed to clarify this point. 
Since IL-4 is under genetic control and polymorphisms have been shown to be related to its 
production, it would be valuable in future studies to determine any differences in the genotype 
in relation to IL-4 production (Kanemitsu et al., 1999). The increased receptor function seen 
in some patients with SLE may play a role in the development of disease through induction of 
Th2 subset development.
The observation that stimulation with PHA masked the differences observed between 
the experimental groups may be explained by the fact that cells in patients with SLE are 
already in an activated state and have been shown not to react strongly to mitogenic 
stimulation (Hemandez-Fuentes et al., 1999). Stimulation with PHA caused most of the 
individuals tested to have a higher percentage of IL-4 positive a p  TCR+ DN T cells although 
there appeared to be a lower level of stimulation in the patients with SLE. Indeed, six of these 
patients could be seen to have a lower percentage of IL-4 positive DN T cells than they 
expressed constitutively. It is unclear as to why these six patients had reduced levels of IL-4 
containing cells since there was no apparent correlation following PHA stimulation with 
disease activity, disease duration, or percentage of ap  TCR+ DN T cells. In addition, these six 
patients were not concordant for drug treatment and did not appear to be concordant for HLA 
phenotype.
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5.4: Concluding remarks
In conclusion, the data in this chapter indicates that in about one third of patients with 
SLE, there is a higher frequency of a p  TCR+DN T cells that constitutively express IL-4 than 
in control individuals. This increase in IL-4 was more accentuated in the a p  TCR+DN T cells 
then in the CD4+ and CD8+ T cell populations, suggesting that the DN T cell compartment 
could be functionally more important than the conventional a p + T cells in these patients with 
SLE. Recent studies in mice and patients with SLE have indicated a regulatory 
/immunosupressive role for IL-4+ V a24JaQ V pl 1+ DN T cells and conventional IL-4 
producing T cells in containing Thl mediated pathogenic autoantibody response.
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C hapter 6. 
A poptosis  in SLE D N  T cells.
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6.1: Introduction and aims.
The process of programmed cell death (PCD) or apoptosis is thought to play a central 
role in the pathogenesis of SLE by providing an immunogenic stimulus for autoimmunity. 
Defects in the apoptotic process can also lead to impaired activation induced cell death 
(AICD) and impaired tolerance to self-antigens, also contributing to the pathogenesis of 
autoimmune diseases such as SLE.
Double negative T cells have been implicated, as contributing to the disease 
pathogenesis of SLE, in a number of studies. The main roles proposed for their involvement is 
as helper T cells or regulatory/suppressor cells. Many investigators have studied apoptosis and 
apoptosis related molecules in conventional (CD4+ or CD8+ ) T and B cells of SLE patients. 
The DN T cell population has largely been ignored in these studies. In view of their potential 
contribution to the disease pathogenesis in SLE, the process of apoptosis in these cells merits 
study.
6.1.1: Introduction.
6.1.1.1: Apoptosis in SLE.
The immunological pathogenesis of SLE is multifactorial but the precise details remain 
elusive. Several clues from animal models of autoimmunity suggest that dysregulation of 
apoptosis can lead to clinically overt autoimmune phenomena. Until recently, the importance 
of these mechanisms in the development of human autoimmune diseases remained uncertain. 
Recent advances in the field of apoptosis have suggested new paradigms for the development 
of lupus autoimmunity.
Apoptosis plays an important role in the homeostasis of the immune response (Cohen, 
1993). It can be induced by the interaction of the Fas receptor, a member of the TNF receptor 
family and regulated by the Bcl-2 family of genes. Apoptosis is defective in MRL lpr/lpr mice 
(which do not express a functional Fas receptor) and gld/gld mice (which have defective 
expression of the Fas ligand). Both murine strains develop autoimmune syndromes that have
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similarities to human SLE (Cohen and Eisenberg, 1992). However, characteristic mutations 
similar to those reported in the MRL lpr/lpr or gld/gld mice have not been identified in 
patients with SLE. On the other hand, defects in the apoptotic pathway involving Fas-Fas-L 
interactions and the bcl-2 family of genes, have been identified in some patients with SLE.
Early reports indicating increased numbers of circulating apoptotic cells in the 
peripheral blood of SLE patients, have not been substantiated by later studies as being specific 
to SLE (Emlen et al., 1994; Pemiok et al., 1998) (Lorenz et al., 1997; Courtney et al., 1999). 
Reports indicating impaired phagocytosis of apoptotic cells might provide a clue to the 
persistence of apoptotic cells in circulation, in SLE patients (Herrmann et al., 1998; Baumann 
et al., 2002).
Links between Bcl-2 expression and autoimmunity were established by observations in 
mice with bcl-2 transgenes over expressed in their B cells. These mice which developed an 
autoimmune syndrome, with many features of human SLE, had an excess of mature B-cells 
which showed extended survival (McDonnell et al., 1989; Strasser et al., 1991). Bcl-2 is an 
intracellular, apoptosis-inhibitory protein thought to block apoptosis due to its function in an 
antioxidant pathway and an oxygen independent pathway (Hockenbery et al., 1990). Bcl-2 
and the Fas/APO-1 system seem to be at least in part, functionally linked, since it has been 
shown that Bcl-2 signals are able to inhibit Fas induced apoptosis (Itoh et al., 1993). The 
phenotype of B c1-x l  transgenic mice is essentially indistinguishable from that of a Bcl-2 
transgenic animal (Chao et al., 1995).
As discussed in the general introduction, expression of the bcl-2 proto-oncogene has 
been extensively studied in the lymphocyte population of patients with SLE, with 
contradicting results. Increased expression of the Bcl-2 m-RNA and protein in SLE 
lymphocytes and sera has been observed in patients with SLE although, this would directly 
contradict reports of increased apoptosis (Liu et al., 1998; Gatenby and Irvine, 1994) (Miret et 
al., 1999; Falcini et al., 1999) (Aringer et al., 1994). Other investigators report unchanged or 
decreased levels of Bcl-2 expression in SLE lymphocytes in-vivo (Chan et al., 1997) (Rose et 
al., 1995; Lorenz et al., 1997). There have been no conclusive reports on the other pro and 
anti- apoptotic members of the Bcl-2 family such as Bax, Bcl-x, bak etc.
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6.1.2: Aims.
SLE has been associated with a dysregulation of the apoptotic machinery. In view of 
previous studies and these studies, which have shown a possible association of DN T cells 
with the pathogenesis of SLE, I decided to study the regulation of apoptosis in the DN T cell 
population of patients with SLE and healthy controls.
The questions I set out to answer were:
•  Do constitutive levels of apoptosis in the DN T cell population of patients with SLE, 
differ from conventional T cells?
• Do constitutive levels of apoptosis differ betwwen the DN T cell populations of 
patients with SLE and healthy controls?
• Are the rates of apoptosis different between the DN T cell populations of patients with 
SLE and healthy controls, when cells are cultured in-vitro?
• Is the expression of Bcl-2 and Fas molecules changed between the DN T cell 
populations of patients with SLE and healthy controls?
• Is the rate of apoptosis in the DN T cells associated with the Bcl-2/Bax ratio, in 
patients with SLE patients and healthy controls?
• Is there an association between the expression levels of Bcl-x in the DN T cells of 
patients with SLE and healthy controls, and the rate of apoptosis?
6.2: Results.
6.2.1: Patients used in this study.
Fifteen patients with SLE were used in this study. All the patients were female. The 
mean age was 39 years and the range 20 to 65 years. Disease activity was assessed using 
BILAG index. A global score was determined as described in the Introduction and patients 
scoring >6 were deemed active and < 6 inactive. Fifteen patients with rheumatoid arthritis (12 
female, 3 male aged 27 to 75 years, mean 51 years) who fulfilled four or more of the ARA 
criteria for rheumatoid arthritis were also studied (Arnett et al., 1988).
The 15 healthy controls studied were laboratory staff and female. The mean age was 
31 years and the range 20 to 45 years.
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6.2.2: Apoptosis in conventional (CD4+/CD8+) T cells o f patients with SLE and 
healthy controls.
Apoptosis in cells was analyzed by annexin V- FITC staining as described in chapter 2 
(Pepper et al., 1998). Annexin V identifies cells at an early stage of apoptosis by binding to 
membrane phosphatidyl serine.
The CD4+/CD8+ T cell population of SLE patients and healthy individuals showed no 
differences in the levels of apoptosis in cells, freshly isolated from peripheral blood (p=0.91). 
The rate of apoptosis of the cells in culture, over 48 hours, did not differ significantly between 
SLE CD4+/CD8+ T cells and those of healthy controls ( 0-24 hrs p=0.3, 24-48 hrs p=0.47). 
The results are shown in figure 6.1.
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Fiure 6.1: Percentage apoptotic (CD4+/CD8+) T cells in patients with SLE (solid bars) 
(n=10) and healthy controls (hatched bars) (n=7) at times 0, 24 and 48 hours in culture. The 
bars represent the mean ± standard deviation. PBMCs in in-vitro cultures were stained with 
CD3 (PE) and Annexin V (FITC) at times 0, 24 and 48 hours. An electronic gate was placed 
around T cells (CD3+) and gated cells analyzed for annexin V binding.
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6.2.3: Apoptosis in DN T cells o f patients with SLE and healthy controls.
Enriched double negative T cells were isolated from patients with SLE and healthy 
controls as described in chapter 2. DN T cells were cultured for different periods of time (0, 24 
and 48 hrs). At each time point cells were harvested and apoptotic cells quantitated.
Both the constitutive levels of apoptosis, and rate of apoptosis in culture of DN T cells 
in both SLE patients and healthy controls was significantly lower than in CD4+/ CD8+ T cells 
as shown in table 6.1.
SLE n=10 HC n=7
Time DN T cells CD4+/CD8+ 
T cells
DN T cells CD4+/CD8+ 
T cells
0 hrs
Mean sd Mean sd Mean sd Mean sd
3.05 2.49 20.4 10.9 11.01 8.2 20.9 10.07
24 hrs 6.35 4.07 25.22 12.7 21.9 12.8 30.9 15.1
48 hrs 7.65 4.65 21.28 12.07 10.7 5.12 25.28 12.9
Table 6.1: Percentages of apoptotic cells in culture at times 0, 24 and 48 hours (sd: 
standard deviation).
When analyzed by Wilcoxon paired non-parametric statistical test, p values of less 
than 0.05 indicated significantly lower rates of apoptosis in the DN T cell population from 
both patients with SLE and HC. The p values are shown in table 6.2.
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DN T cells < CD4+/CD8+ T cells 
p values
SLE HC
Day 0 0.0039 0.015
Day 1 0.002 0.04
Day 2 0.002 0.0156
Table 6.2: P-values for the lower cell death in DN T cell population from both SLE 
patients and healthy controls.
In addition, freshly isolated SLE DN T cells showed lower levels of apoptosis 
compared to DN T cells from healthy controls, although, the difference did not reach statistical 
significance (p=0.0639).
After 24 hrs in cell culture, DN T cells from patients with SLE still showed 
significantly lower levels of apoptosis (6.35±4.07 % annexinV+ cells) compared to cells from 
healthy controls (21.95± 12.8 % annexin V+ cells) ( p=0.0068).
Harvested after 48 hrs in culture, DN T cells from both SLE patients and HC exhibited 
similar levels of apoptosis (p=0.26). These results are shown in figure 6.2.
HC SLE
o
H
Z
O
o
OuO
8*
45
40
35
30
25
20
15
10
5
0
0 hrs 24 hrs 48 hrs
45
40
35
30
25
20
0 hrs 24 hrs 48 hrs
Figure 6.2: Programmed cell death in DN T cells on culture over 48 hours in patients 
with SLE (n=8) and healthy controls (HC: n=7). Enriched DN T cells were were cultured and
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identified by flow cytometric staining with antibodies to CD3 (PE) (FL2), CD4 and CD8 
(CyChrome) (FL3). Apoptosis at 0, 24 and 48 hours was measured by annexin V (FITC)
(FL1) staining. Cells gated on a DN (CD3+ CD4' CD8 ) T cell gate were analyzed for 
annexinV binding.
6.2.4: There was no difference in the expression o f surface Fas molecules between 
patients with SLE, RA and HC.
To understand if differential expression of Fas could play a role in the decreased levels 
of apoptosis seen in the DN T cells of patients with SLE, we studied Fas expression on the 
surface of these cells. As shown in figure 6.3, DN T cells from SLE patients showed no 
increase in spontaneous Fas expression compared to cells from RA patients or healthy controls 
(p=0.9). The density of surface expression of Fas, as indicated by the mean fluorescence 
intensity of Fas staining, also showed no difference between patients with SLE and RA and 
HC DN T cells.
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Figure 6.3: Fas+ DN T cells in patients with SLE (n=12), RA (n=9) and healthy 
controls (n=12) (p= 0.9). Enriched double negative cells identified by staining with antibodies 
to CD3 (PE), CD4 and CD8 (CyChrome), were examined for surface Fas expression by 
staining with an anti-Fas (FITC) antibody.
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6.2.5: Bcl-2 fam ily o f proteins: expression in double negative T cells.
I analyzed the expression of apoptosis related gene products at the protein level in DN 
T cells from patients with SLE and HC. The gene products studied were: Bcl-2, Bax, and Bcl- 
x. Enriched DN T cells from SLE patients and HC were cultured in-vitro in complete medium, 
over a 48-hour period. Cells were harvested at each time point (0, 24 and 48 hrs) and 
intracellular staining with Bcl-2, Bax or Bcl-x antibody was performed as described in Chapter
2. Representative histograms are shown in figure 6.4.
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Figure 6.4: Representative histograms of DN T cells from a patient with SLE stained 
for Bax, Bcl-x and Bcl-2 proteins using intracellular staining techniques described in chapter 2 
(materials and methods).
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6.2.6: Bcl-2 expression.
The studies on the levels of constitutive apoptosis in DN T cells showed significantly 
decreased apoptosis in DN T cells of patients with SLE. Since the Bcl-2 protein is anti- 
apoptotic in nature, I examined the expression of this protein in both the total T lymphocyte 
and the DN T cell populations of patients with SLE, RA and HC.
The numbers of Bcl-2+T cells remained unchanged between patients with SLE, RA and HC 
(p= 0.12). Also, there were no significant differences in the numbers of Bcl-2+ DN T cells 
between patients with SLE, RA and HC (p=0.367). These results are shown in figure 6.5. We 
also examined the mean fluorescence intensity (MFI) of Bcl-2 staining in DN T cells from 
patients with SLE, RA and HC and found no differences in the MFI values (p= 0.24), as seen 
in figure 6.6.
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Figure 6.5: Percentages of Bcl-2+ cells in Patients with SLE (n=14), RA (n= 12) and 
HC (n=14) as determined by intracellular immunofluorescence staining. PBMCs or enriched 
double negative cells identified by staining with antibodies to CD3 (PE), CD4 and CD8 
(CyChrome), were examined for intracellular Bcl-2 expression by staining with an anti-Bcl-2 
(FITC) antibody.
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Figure 6.6: Mean Fluorescence intensity (MFI) of Bcl-2 expression determined by 
flow cytometry, in SLE (n=15), RA (n=13) and HC (n=14) (P> .05) DN T cells. Enriched 
double negative cells identified by staining with antibodies to CD3 (PE), CD4 and CD8 
(CyChrome), were examined for intracellular Bcl-2 expression by staining with an anti-Bcl-2 
(FITC) antibody.
6.2.7: Bcl-2/Bax ratio.
One of the apoptotic pathways involves the proteins Bax (pro-apoptotic) and Bcl-2 
(anti-apoptotic). In many cell systems, the ratio of Bcl-2 to Bax has been found to regulate 
apoptosis (Vitali et al., 1992). A higher Bcl-2/Bax ratio indicates cell survival, while a lower 
ratio is responsible for increased cell death (Aggarwal et al., 1997). Therefore, I examined the 
expression of Bax and Bcl-2 in DN T cells in culture, over 48 hrs and calculated the ratio of 
Bcl-2 to Bax expression at time points 0, 24 and 48 hours. DN T cells in culture were 
harvested at 0, 24 and 48 hrs and intracellular staining for Bcl-2 and Bax proteins were carried 
out as described in chapter 2. The MFI of expression of each protein was determined by flow 
cytometry analysis. The ratio of Bcl-2 to Bax MFI was calculated for each population.
The Bcl-2/Bax ratio in the DN T cell population of patients with SLE (2.29±1.32) was 
significantly higher than that of DN T cells from HC (1.22±0.27)(p=0.02) in freshly isolated
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cells (t=0 hrs) as seen in figure 6.7. The CD4+/CD8+ T cell populations from SLE patients and 
HC showed no difference in their Bcl-2/Bax ratios (p=0.36).
When DN T cells in culture were harvested at 24 and 48 hours, and the Bcl-2/Bax ratio 
examined, we could detect no significant differences in ratios between patients with SLE and 
HC. These results are shown in figure 6.7. As before, the CD4+/CD8+ T cell population from 
patients with SLE and HC showed no difference in their Bcl-2/Bax ratio at time points 24 and 
48 hours (p>0.05).
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Figure 6.7: Bcl-2/Bax MFI ratios of DN T cells from SLE patients (n=9) and HC 
(n=7) at time points 0, 24 and 48 hours in culture. Enriched double negative cells identified by 
staining with antibodies to CD3 (PE), CD4 and CD8 (CYChrome), were examined for 
intracellular Bcl-2 or Bax expression by staining with anti-Bcl-2 (FITC) or anti-Bax (+ anti­
mouse FITC) antibodies.
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6.2.8: Bcl-x expression.
The alternatively spliced form of a Bcl-2 homologue, Bc1-xl, is involved in prolonging 
survival of cells undergoing apoptosis following various stimuli (Boise et al., 1993). We used 
an anti-Bcl-x antibody for intracellular staining and FACS analysis of DN T cell cultures at 0, 
24 and 48 hours. Immunoblotting studies after anti-Bcl-x immunoprecipitation by Dibbert et 
al., showed that the Bcl-x expression observed by flow cytometry after immunoflurescence 
staining was caused solely by B c1-xl expression, because no protein from the Bcl-xs splice 
form was detected (Dibbert et al., 1998). Therefore, it is possible to conclude that the 
immunofluoresence staining with the anti-Bcl-x antibody detects the levels of the B c1-Xl 
protein.
The intensity (MFI) of Bcl-x expression by freshly isolated (t=0 hrs) DN T cells of 
patients with SLE (89.6±53.1) was significantly higher than that of HC (45.96±32.23) (p =
0.03). On examining Bcl-x levels after 24 hours in culture, DN T cells from patients with SLE 
(56.4±43.5) showed lower levels of expression than HC (95.01±40.1), though the difference 
did not reach statistically significant levels (p = 0.05). When DN T cells in culture, were 
harvested at 48 hours and the Bcl-x intensity studied, cells from patients with SLE (68.2±53.1) 
again showed higher levels of Bcl-x expression compared to HC(39.2±15.7) (p = 0.04). These 
results are shown in figure 6.8. The CD4+/CD8+ T cell population from patients with SLE and 
healthy controls showed no difference in Bcl-x expression at 0, 24 or 48 hours (p > 0.05) (data 
not shown).
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Figure 6.8: Bcl-x expression (MFI) by DN T cells from patients with SLE (n=9) and 
HC (n=7) at time points 0, 24 and 48 hours in culture. Enriched double negative cells 
identified by staining with antibodies to CD3 (PE), CD4 and CD8 (CYChrome), were 
examined for intracellular Bcl-x expression by staining with an anti-Bcl-x antibody, followed 
by an anti-mouse FITC conjugated secondary antibody.
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6.2.9: Summary o f results from  chapter 6.
The data from this chapter can be summarized as follows:
i. DN T cells showed lower constitutive levels of cell death compared to conventional T 
cells.
ii. DN T cells from patients with SLE showed even lower levels of spontaneous apoptosis 
compared to DN T cells of healthy controls. DN T cells from patients with SLE also 
appeared to be resistant to apoptosis in the first 24 hours in in vitro culture.
iii. The expression of Bcl-2 and Fas proteins of the apoptotic pathway was unchanged in DN 
T cells of patients with SLE compared to healthy controls and patients with RA.
iv. Bcl-2/Bax ratios were significantly higher in DN T cells of patients with SLE when 
compared to healthy controls in freshly isolated cells.
v. The constitutive expression of Bcl-x anti-apoptotic protein was also significantly higher 
in DN T cells from patients with SLE when compared to cells from healthy controls.
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6.3: Discussion.
A number of studies in both murine models of lupus and human SLE have established 
an association between the DN T cell population and the disease pathogenesis. Studies have 
also indicated defective regulation of apoptosis as playing a role in the development of 
autoimmune diseases such as SLE (Elkon, 1994; McHugh, 2002). Therefore, it was important 
to study the mechanisms governing cell survival and cell death in the DN T cell population, to 
understand their contribution to the disease pathogenesis.
6.3.1: Apoptosis in DN T cells.
These studies on the constitutive levels of apoptosis in the DN T cell population have 
shown significantly lower levels of cell death in these cells compared to conventional 
(CD4+/CD8+) T cells. Decreased numbers of apoptotic cells were observed in freshly isolated 
cells from both patients with SLE and HC. Patients with SLE however, showed fewer 
numbers of apoptotic DN T cells compared to HC. There were no detectable differences in 
the numbers of apoptotic cells between patients with SLE and healthy controls in the 
conventional T cell compartment.
Studies on apoptosis of lymphocytes in SLE reported in literature have revealed 
contradictory results. Although several studies report abnormalities in the apoptotic process in 
patients with SLE, other investigators have found normal apoptotic pathways (Aringer et al., 
1994; Emlen et al., 1994; Kovacs et al., 1997; McNally et al., 1997; Rose et al., 1997). A 
more recent study by Caricchio et al., failed to find consistent abnormalities in spontaneous 
and induced apoptosis in lymphocytes from patients with SLE (Caricchio and Cohen, 1999). 
The methods used to detect apoptotic cells in the studies mentioned above, were different and 
might account for the discrepancies between them. Apoptosis was measured in this thesis by 
annexin-V binding, which reflects phosphatidyl serine exposure and is considered a very early 
marker of programmed cell death (Pepper et al., 1998). Carrichio et al., also used annexin-V 
binding as one of the methods of detecting apoptotic cells and the percentages of constitutively 
apoptotic lymphocytes detected is similar to our results (Caricchio and Cohen, 1999).
The rate of apoptosis in DN T cells of patients with SLE was significantly lower than 
that of HC in the first 24 hours in culture. By 48 hours, the rates of apoptosis in DN T cells
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from both patients and controls reached similar levels. This difference in the rate of apoptosis 
was unique to the DN T cell population, as conventional T cells from SLE patients and HC 
showed similar levels of cell death at all time points studied.
Thus, the DN T cells in patients with SLE displayed both lower levels of spontaneous 
apoptosis and resistance to apoptosis in culture in the first 24 hours.
This resistance to apoptosis of DN T cells in general and those of patients with SLE in 
particular might provide interesting clues to their role in the immune reaction. One of the roles 
proposed for DN T cells in the immune system is as suppressor/regulatory cells. Experiments 
in mice have shown that mature a p  TCR+ DN T cells possess antigen specific 
immunoregulatory/ suppressive function and can prevent graft-versus-host disease and 
autoimmunity (Palathumpat et al., 1992; Abraham et a l,  1992; Strober et a l,  1996; Priatel et 
al., 2001 ). The DN T cells in these studies have been shown to be more resistant to AICD 
(activation induced cell death) and TCR-cross-linking induced cell death than conventional T 
cells and are uniquely poised to suppress immune responses and prevent autoimmunity (Yang 
et al., 1998; Priatel et al., 2001 ).
6.3.2: Regulation o f apoptosis in DN T cells.
In order to explain the resistance of DN T cells from patients with SLE to apoptosis, I 
studied the expression of pro-and anti- apoptotic proteins Bcl-2, Bax and Bcl-x.
The study results showed no differences in the number of cells expressing Bcl-2 or in 
the density of expression, in either CD4+/CD8+ T cells or DN T cells of patients with SLE. 
These results are consistent with reports by Rose et al., studying lymphocytes in a large cohort 
of patients with SLE (Rose et al., 1995). Expression of Fas was also found unaltered in the 
DN T cell compartment of patients with SLE when compared to HC, in these studies. These 
results correlate with investigators reporting that regulation of apoptosis in mature DN T cells 
in mice do not appear to be influenced by the Fas/FasL or TNF-a/TNFR pathways (Khan et 
a l,  1999). These results however, did not explain the lower constitutive levels of apoptosis 
and subsequent resistance to cell death in culture, observed in SLE DN T cells.
The pathway of Fas mediated apoptosis has been found to be functionally intact in 
SLE patients, although increased Fas expression on the surface of B and T cells has been 
reported, especially in activated lymphocytes (Mysler et al., 1994; Bijl et al., 2001; Bijl et a l ,  
2001 ). Conversely, studies indicating unchanged Fas expression on SLE lymphocytes have
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also been reported (Kovacs et a l ,  1996). Increased levels of Fas-L and a serum soluble form 
of Fas (sFas) have also been cited as probable causes for the seemingly increased levels of 
circulating apoptotic cells in patients with SLE (Kovacs et al., 1997; Rose et al., 1997; Jodo et 
al., 1997; Bijl et al., 1998).
On examining the Bcl-2/Bax ratio in DN T cells of patients with SLE and controls, I 
found significantly higher values in SLE DN T cells in freshly isolated cells, consistent with 
the lower numbers of apoptotic cells observed. After 24 hours incubation in medium, many 
patients with SLE still showed higher Bcl-2/Bax ratio in their DN T cells compared to HC 
although, the results were not statistically significant. By 48 hours in culture there were no 
differences in the Bcl-2/Bax ratios of DN T cells from patients or healthy controls. In these 
studies, the Bcl-2/Bax ratios in the DN T cells of patients were consistent with the resistance 
to apoptosis observed in the first 24 hours in culture. Alterations of Bcl-2/Bax ratios are 
known to regulate apoptosis, thereby determining the survival or death of the cells in which 
these apoptotic proteins are found (Oltvai et al., 1993). Studies on apoptosis of eosinophils 
and cord blood lymphocytes have shown that, a high Bcl-2/Bax ratio coupled with high levels 
of Bc1-xl promoted cell survival and resistance to apoptosis on activation with mitogens 
(Aggarwal et al., 1997; Dibbert et al., 1998).
Changes in Bcl-x, expression in DN T cells from patients with SLE over 48 hours in 
culture were examined. The anti-Bcl-x antibody used in these experiments has been 
previously shown to mainly detect B c1-xl protein expression, because no protein from the Bcl- 
xs form could be detected by immunoblotting after immunoprecipitation (Dibbert et al., 1998). 
Therefore, the Bcl-x protein levels detected in this study were representative mainly of B c1-xl 
protein levels, which protects cells from apoptosis (Boise et al., 1993).
Bcl-x levels in the DN T cells of patients with SLE were significantly greater than HC 
in freshly isolated cells, although the CD4/ CD8 T cell populations showed no differences in 
expression. Studies on the regulation of apoptosis in mature DN T cells in mice have shown 
that these cells constitutively express a higher level of B c1-xl, but not Bcl-2, which may 
contribute to resistance to apoptosis in these cells (Khan et a l,  1999). Recent studies by Low 
et al., have shown that a decrease in levels of Bcl-x and Bcl-2 are required for membrane 
association of Bax and the subsequent cascade of events leading to apoptosis in cytokine 
dependent cells (Low et a l ,  2001). This requirement seems particularly true for apoptosis 
induced by cytokine withdrawal such as IL-3 removal, whereas cytotoxic drug induced
147
apoptosis pathways are not affected (Low et a l ,  2001). These studies contribute towards 
explaining my observations of an increase in Bax expression accompanied by decreased Bcl-2 
and Bcl-x expression after 24 hours in culture, of DN T cells from patients with SLE. An 
increased level of cell death at 48 hours post-culture followed these changes in the expression 
levels of proteins of the apoptotic pathway. The absence of cytokines required to support the 
survival of the patient DN T cells in the culture medium may account for the initiation of 
apoptosis. The cytokine- IL-3 is a good candidate for this role, as previous studies on both 
murine and human DN T cells, have reported their unique proliferative response to direct 
administration of IL-3 (Albert et a l ,  1998) (Kubota et a l ,  1992).
6.4: Concluding remarks.
The data in this chapter highlights the low levels of spontaneous apoptosis in DN T 
cells of patients with SLE and their resistance to apoptosis in culture. The high Bcl-2/Bax ratio 
and higher levels of Bcl-x observed in the DN T cells from patients contribute to explaining 
their resistance to apoptosis compared to conventional T cells. This resistance to apoptosis 
might explain the expanded populations of ocp TCR+ DN T cells found in patients with SLE.
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C h a p te r  7 .
G eneral D iscussion .
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The work presented in this thesis investigated the involvement of double negative 
(CD3+ CD4' CD8 ) T cells in the pathogenesis of SLE. The main conclusions of these studies 
are outlined below and the questions arising from those results are discussed. A tentative 
hypothesis is proposed, but, as always, more questions come to light. SLE is a complex 
disease and many avenues of investigation are in progress to understand the factors involved 
in initiating and maintaining the disease.
My studies on the DN T cell population in patients with SLE, RA and healthy subjects 
revealed several distinct features in this population of cells in patients with SLE that suggest 
their participation in the ongoing inflammatory reaction. The results in this thesis show that 
the a p  TCR+ DN T cell population is significantly expanded in patients with SLE compared to 
RA autoimmune controls and healthy subjects. The DN T cell population in patients with SLE 
was also found to be activated and greater numbers of cells expressed IL-4 compared to the 
same population of cells in healthy individuals. In addition, the DN T cell population in SLE 
patients showed a greater resistance to apoptosis both ex -vivo and in-vitro. A higher Bcl-2/Bax 
ratio and increased expression of Bcl-x anti-apoptotic protein was also observed in the DN T 
cells of patients with SLE compared to cells from healthy individuals.
7.1: T cells in SLE.
In this study no increase in the numbers of the conventional CD3+ T population in 
patients with SLE compared to patients with RA and HC were found. Although autoantibody 
production in SLE has been firmly established as a T cell dependent process, studies on the 
numbers of CD3+ T cell in patients with SLE have been inconclusive with some groups 
reporting an increase and others a decrease compared to healthy controls (Erkeller-Yusel et 
al., 1993) (Glinski et al., 1976; Smolen et al., 1982)). The differences in the patient cohorts 
studied by the various groups might account for the difference in results.
These studies also did not show an increase in the numbers of y5 TCR expressing T 
cells either in the conventional (CD8+), or DN T cell compartments. T cells expressing the y8 
TCR and belonging to either the CD8+or DN T cell compartment have been previously 
implicated in the disease pathogenesis of SLE and a variety of other autoimmune disorders
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(Brennan et al., 1989; Gerli et al., 1991). Their exact role in SLE however, has not been 
clearly established, with contradictory reports of expanded populations or unchanged or 
decreased numbers reported in the peripheral blood of patients (Gerli et al., 1991; Spinozzi et 
al., 1995; Robak et al., 1999; Robak et al., 2001 ; Riccieri et al., 2000). Reports of increased 
numbers of y5 TCR+ T lymphocytes in the skin of patients with SLE and displaying a positive 
correlation with disease activity, could indicate a role for this population at local sites of 
inflammation and explain the contradictory results reagrding their numbers in peripheral blood 
(Robak et al. ,2001 ).
7.2: DN T cells in SLE.
Examination of the total DN (ap  and y8 TCR+) in the peripheral blood of patients with 
SLE showed no significant differences between patients with SLE and autoimmune (RA) or 
healthy controls. A few studies have previously reported expanded populations of DN T cells 
in patients with SLE where, treatment with corticosteroids and cyclophosphamide reduced the 
numbers to normal levels (Lacki et al., 1997; Devi et al., 1998). A few of the patients in our 
study did show highly expanded (20-35%) populations of DN T cells although there was no 
correlation with disease activity. Differences in the cohort of patients recruited into the various 
studies might account for the differences in the numbers of DN T cell populations measured.
In murine models of lupus (Ipr, gld) DN T cells have been firmly associated with the disease 
process with massive accumulation of cells in the lymphoid organs accompanied by nephritis 
(Reimann, 1991). The role of DN T cells in the pathogenesis of human SLE is however, less 
defined.
In these studies, the relative numbers of the a p  TCR and ySTCR expressing 
subpopulations of DN T cell in SLE were examined. Here, significantly expanded populations 
of a p  TCR+ DN T cells compared with conventional T cells, in patients with SLE were found 
which suggested their involvement in the ongoing autoimmune reaction. These results are 
consistent with studies by other groups describing expanded populations of ap  TCR+ DN T 
cells in patients with SLE (Shivakumar et al., 1989; Devi et al., 1998; Sieling et al., 2000).
The significance and exact role of a p  TCR+DN T cells in SLE is yet to be defined. Studies 
showing expanded populations of a p  TCR+DN T cells in a number of autoimmune conditions
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including, autoimmune lymphoproliferative disorder (ALPS) and systemic sclerosis implicate 
their participation in autoimmune reactions (Shivakumar et a l ,  1989; Furukawa, 1997; Ilium 
et al., 1991; Sakamoto et al., 1992; Sieling et al., 2000; Liu et al., 1998). Isolation of ap  TCR+ 
and y5 TCR+ DN T cells with helper function which augment the production of pathogenic 
anti-DNA autoantibodies in an MHC-unrestricted manner have further suggested a role for 
these cells in the pathogenesis of SLE (Shivakumar et al., 1989; Rajagopalan et al., 1990). 
Recent studies also show that SLE DN T cells provide help for IgG production in a CD1 
(CDlc) restricted manner(Sieling et al., 2000).
In addition, the numbers of natural killer T cells (NKT), a subset of the DN T cell 
population and described as TCR V a24+ V pi 1+ have been found to be selectively reduced in a 
number of autoimmune diseases including systemic sclerosis (SSc), rheumatoid arthritis (RA), 
insulin-dependent diabetes mellitus (IDDM) and SLE (Dellabona et al., 1994; Sumida et a l ,  
1995; Sumida et al., 1998; Maeda et al., 1999; Wilson et al., 1998).
The role of a p  TCR+DN T cells in the pathogenesis of SLE can be understood in part 
by studying the role of this population in the normal immune system. In healthy subjects a p  
TCR+ DN T cells have been described as having a ThO cytokine profile, both cytotoxic and 
helper T cell activity, and responding to the hematopoietic stem cell growth factor IL-3 
(Kubota et al., 1992) (Groh et al., 1989; Brooks et al., 1990) (Matsumoto et al., 1991)
(Porcelli et al., 1992) (Katsikis et al., 1995; Niehues et a l,  1999). Based on studies in murine 
models of transplantation tolerance, experimental autoimmune encephalomyelitis and 
lymphoproliferative (lpr) mice, a regulatory role has also been advanced for the a p  TCR+ DN 
T cells by specifically eliminating syngeneic CD4+ and CD8+ T cells that share the same TCR 
specificity (Young et al., 2002 ; Young and Zhang, 2002; Carroll, 2001; Ford et al., 2002; 
Zhang et al., 2001 ). A regulatory role for IL-4 producing NKT cells (a sub population of ap  
TCR+DN T cells), is further supported by studies showing that the selective reduction of this 
population is essential for the generation of some autoimmune diseases (Kojo et al., 2001).
Thus, recent reports in the literature suggest that a p  TCR +DN T cells in addition to 
their potential role as T helper cells contributing to autoantibody production in lupus, could 
have the contradictory role of regulatory /suppressor T cells involved in containing the 
disease. The precise role of ap  TCR+ DN T cell population in the pathogenesis of autoimmune 
diseases is as yet difficult to define, as long term clonal proliferation of this population of cells
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has also been observed in apparently healthy subjects without any associated history of severe 
illness (Kusunoki et a l ,  1992).
7.3: Activation status and cytokine profile o f  SLE DN T cells.
Cell populations taking part in (auto) immune responses would be expected to be 
‘activated’. The data in this thesis indicates an activated phenotype for DN T cells from 
patients with SLE, with greater numbers of cells expressing the activation markers HLA-DR, 
CTLA-4 and CD28. The DN T cells from patients with SLE were also more resistant to in 
vitro stimulation by PHA, perhaps due to their being already activated in vivo. The activation 
status of these SLE DN T cells points to their participation in the ongoing autoimmune 
reaction.
It has become evident that cell activation events are involved in the deletion of auto­
reactive lymphocytes (through induction of apoptosis), and in differentiation of 
immunoregulatory cells, phenomena that clearly participate in the pathogenesis of 
autoimmunity. It is therefore feasible that abnormalities in cell activation events could 
significantly contribute to the immunoregulatory aberrations observed in SLE.
Studies by Siefken et al, have shown that at least in vitro, CD28-mediated activation of 
human T cells without costimulation of the CD3/TCR complex is possible, resulting in 
antigen-independent activation and expansion of T cells (Siefken et al., 1997). This pathway 
could contribute to the expansion and activation of increased numbers of CD28+ DN T cells in 
patients with SLE, which lack the CD4 and CD8 coreceptor for antigen binding through the T 
cell receptor. Recent studies by Tang et al., have shown that ligation of CD28 molecule 
partially protected T cell death, likely through the upregulation of the anti-apoptotic protein 
B c1-xl (Tang et al., 2003). As discussed in section 7.4, the studies on SLE DN T cells showed 
greater numbers of cells were resistant to apoptosis, accompanied by increased expression of 
Bcl-x. Thus, it might be hypothesised that expression of CD28 by greater numbers of DN T 
cells from patients with SLE might contribute to the observed resistance in cell death in these 
cells. In addition, participation of the DN T cells in a cognate interaction with APCs via CD28 
might be expected to contribute increased resistance to apoptosis.
The negatively signalling molecule CTLA-4 is involved in establishing and 
maintaining peripheral T cell tolerance, which controls T cell activation and reactivity. Its 
attenuating action helps prevent inappropriate initiation of T cell responses to self-antigens
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and to terminate ongoing T cell responses. Studies in patients with autoimmune diseases such 
as SLE, Hashimoto’s thyroditis, Grave’s diseaseand Insulin dependent diabetes (IDDM), have 
shown that the CTLA-4 gene could confer disease susceptibilty (Pullmann et al., 1999). In 
addition, studies in autoimmune (SLE) disease prone mice have shown that treatment with 
CTLA-4Ig can suppress the pathogenesis of disease and increase longevity by blocking 
CTLA-4 dependent costimulatory signals (Chu et al., 1996; Wang et al., 2002; Mihara et al., 
2000 ). These studies confirm the involvement of CTLA-4+ T cells in SLE disease 
pathogenesis and also suggest the participation of the increased numbers of CTLA-4+ DN T 
cells in the disease process.
A greater proportion of SLE DN T cells were also found to be CD45RA+(antigen 
naive) compared to DN T cells from HC. One explanation for this observation could be the 
recruitment of naive/resting DN T cells to the ongoing immune reaction to either contribute as 
helper T cells, or contain the autoimmune reaction as regulatory cells. Consistent with our 
results, studies following CD45 expression and disease progression in SLE T cells have shown 
the recruitment of nai've/resting T (CD45RA+) cells in active SLE, rather than the reactivation 
of existing memory (CD45R0+) clones (Gordon et al., 1996). Previous studies have shown that 
mice homozygous for the FasL (gld/gld) mutation cannot initiate apoptosis via the Fas/FasL 
pathway and develop an autoimmune disease characterized by the accumulation of CD4/CD8 
DN T cells and a progressive T cell anergy. These DN T cells expressed a high-molecular- 
weight isoform of CD45 (B220), the CD45RA (Brooks et al., 2001). When a FasL {gld/gld) 
mouse strain with only one functional CD45 allele (CD45 (+/-), FasL {gld/gld) was produced in 
order to explore the role that CD45 plays in the lymphoaccumulation and proliferative 
capacity of the DN T cells, the mice displayed a 10-fold reduction in the DN T cell population 
and had decreased levels of anti-DNA antibodies and total serum Ig.. These data indicate that 
CD45 is essential to the accumulation of DN T cells in FasL {gld/gld) mice and implicate 
CD45 as a component of the process of deletion that normally governs the composition of the 
T cell population. Thus, the increased numbers of CD45RA+ DN T cells in patients with SLE 
might contribute to the presence of expanded populations of ‘activated’ ap  TCR+ DN T cells 
shown by my studies.
The data in this thesis has also shown that the ap  TCR+ DN T cell compartment of 
patients with SLE contains more cells positive for intracellular IL-4 than the equivalent cells
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of RA autoimmue controls or HC. Recently, a regulatory/immunosupressive role has been 
suggested for IL-4 producing TCRV a24+ Vp 11+ NK T cells (a sub population of a p + DN T 
cells) in various autoimmune disorders including SLE (Kojo et al., 2001). Studies on double 
negative suppressor T cell clones in mice have also shown that they are resistant to apoptosis 
in the presence of exogenous IL-4 due to the upregulation of Bcl-xL anti-apoptotic protein 
(Khan et al., 1999). The greater numbers of IL-4+a p  TCR+DN T cells observed in patients 
with SLE might explain my observations of increased resistance to apoptosis and increased 
Bcl-x expression in these cells. The IL-4 produced by the cells might act in an autocrine or 
paracrine manner in prolonging the survival of these cells in vivo. Previous studies on the 
cytokine profile of ap  TCR+ DN T cells in healthy subjects have also revealed that they are 
capable of producing IL-4 and IL-10 thus indicating a potential regulatory function (Katsikis 
et al., 1995). It is possible that the DN T cell population is in fact, a heterogeneous pool of 
cells comprising compartments with distinct functions.
The antigen specificity of DN T cells in patients with SLE is unknown at present. 
However, DN T cells have recently been shown to respond to non-peptide antigens presented 
by the CD1 family of antigen presenting molecules (Porcelli et al., 1992). Unlike MHC 
antigen presentation, expression of CD4 or CD8 co-receptors or not essential to recognise 
antigens presented by this family of antigen presentation molecules. A well-defined 
autoantigen resposible for disease initiation and progression in SLE has yet to be identified. 
Nuclear material and phospholipids from apoptotic cell debris which escaped the normal 
clearence process are some of the candidates suggested for the role of autoantigens in SLE, 
leading to the production of anti-dsDNA and and anti-phospholipid autoantibodies associated 
with the disease. There is evidence to suggest that these unsual antigens might be presented by 
the CD1 family of antigen presentation molecules. CD 1-restricted T cells (particularly CD Id 
restricted cells) have been shown to be potent stimulators of humoural immunity, indicating 
their potential to participate in an autoantibody based autoimmune disease such as SLE 
(Schofield et al., 1999). It has been proposed that due to infection or trauma, the increased 
levels of apoptosis or defective clearance of apoptotic material seen in autoimmune diseases 
such as SLE, can result in apoptotic fragments taken up and presented to T cells by CD1+ 
dendritic cells (Albert et al., 1998). These apoptotic fragments express cellular phospholipids 
and antigens normally sequestered from the immune system and might activate T cells (DN T 
cells?) that recognise them and set an autoimmune response in motion. Identification of T cells
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reacting to nucleosomal autoepitopes, and C D lc restricted T cells (perhaps recognising 
cardiolipin and other self-glycolipids), in patients with SLE lend support to this theory (Shi et 
al., 1998; Sieling et al., 2000). A regulatory role has also been proposed for CD 1-restricted T 
cells, especially in autoimmune disease conditions. The pattern emerging from studies 
examining a regulatory role for CD 1-restricted DN T cells is that IL-4 production from these 
cells (especially the NKT cells) protects from self-recognition and that IFN-y production is 
associated with disease (Kojo et a l ,  2001).
7.4: DN  T cells in SLE: Apoptosis
In order to understand the mechanisms by which ap  TCR+ DN T cells accumulate in 
patients with SLE compared to healthy individuals, the process of apoptosis was studied. 
Lower levels of constitutive apoptosis in DN T cells of patients with SLE compared to 
autoimmune controls (RA) and healthy subjects were found. DN T cells in general, showed 
decreased numbers of apoptotic cells compared to the conventional (CD4 and CD8) 
compartment, although this phenomenon was more pronounced in SLE DN T cells. When DN 
T cells from SLE patients and healthy controls were cultured in, a lower rate of apoptosis was 
observed in SLE DN T cells at 24 hours. By 48 hours numbers of apoptotic cells in DN T 
cultures from both patients and controls were similar. The change in resistance to apoptosis in 
SLE DN T cells by 48 hours in culture might be due to absence of anti-apoptotic cytokines 
which maintain their survival in vivo. In fact, studies by Graninger et al., have shown that 
addition of cytokines such as IL-2, IL-4, IL-7 and IL-15 to in vitro cultures of SLE PBMC 
significantly reduced cell death rates (Graninger et al., 2000). Studies on DN T cells in mice 
have also shown that they are highly resistant to TCR crosslinking induced apoptosis in the 
presence of exogenous IL-4 (Khan et al., 1999).
The difference in the numbers of apoptotic cells in freshly isolated and cultured DN T 
cells, was not observed in the conventional (CD4 and CD8) T cell compartment of patients 
and controls. Although this result is in contradiction with some published data (Aringer et al., 
1994; Emlen et al., 1994; Kovacs et al., 1997) reporting a higher incidence of apoptosis in T 
cells from patients with SLE it is in agreement with a more recent and comprehensive study 
by Caricchio et al, who failed to find consistent abnormalities in spontaneous and induced
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apoptosis in lymphocytes from SLE patients (Caricchio and Cohen, 1999). Annexin V 
binding was used by the authors to identify apoptotic cells and the resulting numbers were 
similar to our results using the same technique (Caricchio and Cohen, 1999). It is not clear 
from these results whether the increased resistance to apoptosis seen in SLE DN T cells is a 
contributory cause, or a consequence of the disease process.
To understand the mechanism of resistance to apoptosis of DN T cells further, 
particularly those from SLE patients, I studied the expression of some pro- and anti- apoptotic 
proteins involved in the apoptotic process (Fas, Bcl-2, Bcl-x and Bax) in the DN T cell 
compartment of both patients with SLE and HC. I could detect no differences in the levels of 
expression of Bcl-2 and Fas proteins in both the CD4+/CD8+ and DN T cell compartments of 
patients with SLE, RA and HC in contrast to some previous reports (Graninger, 1992;
Gatenby and Irvine, 1994; Aringer et al., 1994). However, data has also been published which 
support my observations (Chan et al., 1997; Rose et al., 1995; Rose et al., 1997). Differences 
in the techniques used to detect Fas and Bcl-2 such as western blot analysis and flow 
cytometry and the disease activity of the patients studied, could account for differences in the 
results between my studies and others.
Further examination of the Bcl-2/Bax ratios in the DN T cells showed significantly 
higher values in freshly isolated DN T cells from patients with SLE compared to HC, which 
would explain the lower numbers of apoptotic cells detected. In addition, the expression of 
Bcl-x an anti-apoptotic protein, was significantly higher in DN T cells from patients with SLE 
compared to DN T cells from healthy subjects. The anti-Bcl-x antibody used in our studies has 
been previously shown to detect mainly the levels of B c 1 -x l  in immunofluorescence staining 
of cells (Dibbert et al., 1998).
Thus, the resistance to apoptosis of DN T cells from patients with SLE could be 
conferred by the increased expression of B c1-xl (anti-apoptotic) and decreased levels of Bax 
(pro-apoptotic) in these cells, although expression of Bcl-2 is unchanged compared to DN T 
cells from HC. Previous studies on DN T cells in mice have shown that they constitutively 
express high levels of BC L-xl but not Bcl-2 and Bcl-XLis further up-regulated following 
TCR-cross-linking and IL-4 stimulation (Khan et a l,  1999). Thus, the dysregulation of 
cytokine profile observed in patients with SLE could perhaps contribute to the prolonged 
survival of DN T cells by influencing the expression of pro- and anti-apoptotic proteins.
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7.5: The role o f Double N egative T cells in SLE: friends or foe?
My data together with other published data suggests a role for DN T cells, especially 
cells expressing the a p  TCR in the pathogenesis of SLE. The results in this thesis indicate the 
presence of an expanded population of a p  TCR+ DN T cells, with an activated phenotype, 
expression of intracellular IL-4 and resistance to apoptosis in the peripheral blood of patients 
with SLE. These results further support the participation of DN T cells in the autoimmune 
reaction in patients with SLE. The data in this thesis however, does not answer how these cells 
could participate in the autoimmune reaction. Two possibilities are:
a) DN T cells have a T helper function and augment the pathogenic autoantibody 
production in patients with SLE, or
b) DN T cells function as regulatory /supressor cells that act to contain the ongoing 
autoimmune reaction.
Evidence exists in the literature supporting both these possibilities and is as follows:
a) DN T cells as Helper T cells: Helper cell function has been identified in DN T 
cells from healthy subjects and DN T cells providing help for the production of pathogenic 
autoantibodies have been isolated from patients with SLE (Shivakumar et al., 1989; 
Rajagopalan et al., 1990; Sieling et al., 2000). DN T cells recognising nucleosomal and 
lipid autoepitopes have also been identified in patients with SLE (Shi et al., 1998; Sieling 
et al., 2000).
b) DN T cells as regulatory T cells: DN T cells in SLE resemble in many ways the 
recently described CD4+ CD25+ regulatory T cells— presenting a highly activated 
phenotype (HLA-DR+, CTLA-4+), apoptosis resistance and expressing higher levels of 
intracellular IL-4 (Horwitz et al., 2002 ). Recently, a population of extrathymically derived 
a p  TCR+ DN T cells with regulatory functions from the mouse female genital tract have 
also been reported (Johansson et al., 2003). Reduction in the numbers of Va24+ Vp 11 + 
NKT cells, defined as a regulatory T cell subset is associated with the occurrence of 
autoimmune diseases such as systemic sclerosis, SLE, RA and insulin-dependent diabetes 
mellitus (IDDM) (Kojo et al., 2001 ). Recently, it has also been suggested that the role of 
regulatory cells in general immunity may be two-sided, with both autoimmune effector cell 
function important in tissue maintenance, and regulatory cell function to control this 
autoimmunity from reaching disease proportions (Schwartz and Kipnis, 2002).
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At the start of this project, the available information suggested the possible 
participation of DN T cells as T helper cells in augmenting the production of pathogenic 
autoantibodies by B cells, in patients with SLE. The wealth of recently published data now 
also suggests a potential regulatory/suppressor role for these cells, perhaps attempting to 
contain the autoimmune reaction. Based on these theories and our results, I propose a 
model illustrating the possible roles o f the DN T cell population to the pathogenesis of 
SLE.
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7.6: Model fo r  the participation o f DN T cells in SLE disease pathogenesis. 
Figure 7.1 shows possible ways in which DN T cells could contribute to the pathogenesis of 
SLE.
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Figure 7.1: Proposed model describing the possible ways of DN T cell participation in 
SLE disease pathogenesis. Shaded areas denote results described in this thesis.
SLE is characterized by a spectrum of autoantibodies whose respective antigens are 
abundant in every cell of the body and include chromatin, ribonucleoprotein components of 
the spliceosome complex, and phospholipid components of the cell membrane, such as 
phosphatidylserine.
The initiating antigen in patients with SLE such as modified apoptotic cell debris may 
be presented by professional antigen presenting cells through the CD1 family of antigen 
presenting molecules to DN T cells leading to activation and cytokine secretion. Apoptotic and 
necrotic cells are strong candidates as the source of the autoantigens that drive the 
autoantibody response in SLE. Impairment of the normal physiological processes of disposal 
of cellular debris in patients with SLE could result in the accumulation of potential 
autoantigens (Baumann et al., 2002). The induction of of an immune response to autoantigens 
such as nucleosomes could be enhanced by modifications of histones or DNA during 
apoptosis or altered presentation by antigen presenting cells (Bums et al., 2000). Apoptotic 
fragments of cells might also express cellular phospholipids and antigens normally 
sequestered from the immune system.
The activated DN T cells along with conventional (CD4+) helper T cells could provide 
T cell help to B cells producing pathogenic autoantibodies. Conversely (or in addition), the 
DN T cells might act as regulatory/suppressor cells to contain the autoimmune reaction by 
influencing either the B cells or other T cells participating in the immune reaction. The 
autoantibody response in SLE has been shown to be mediated by an antigen-driven, T -cell- 
dependent mechanism in a number of studies.
Expression of the cytokine IL-4 or ligation of the CD28 molecule or other unknown 
factors might cause the upregulation of levels of anti-apoptotic proteins (e.g. B c1 -X l), leading 
to increased resistance to apoptosis, prolonged survival and consequently expanded population 
of cells in patients with SLE (Tang et al., 2003;Khan et al., 1999)). The factors resulting in 
B c 1 -x l  upregulation (IL-4 production and CD28 ligation) are discussed in detail in sections 7.4 
and 7.3.
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7.6.1: Regulatory / Suppressor role o f  DN  T cells.
Both recently published literature and the studies presented in this thesis on DN T cells 
in patients with SLE, suggest a regulatory role for all or a subset of the DN T cell population. 
Extensive studies indicating their regulatory role have been reported in mouse models of 
transplantation, autoimmune diseases (SLE, EAE, IDDM, SSc) and in normal mice where they 
are thought to suppress/regulate the function of conventional (CD4+/CD8+) T cells and B cells 
(Zhang et al., 2001, Johansson et ah, 2003, Kojo et al., 2001 ). Figure 7.2 illustrates some of 
the proposed mechanisms by which DN T cells and a subset of these, the NKT cells, are 
thought to mediate their regulatory activity. Studies of these cells have indicated that they 
mediate their regulatory function through rapid production of high levels of immunoregulatory 
cytokines such as IL-4, IFN-y, TNF and IL-10 (Godfrey et al., 2000). In mouse models of 
transplantation and in the Ipr or gld mice it has been shown that cell-cell contact is necessary 
for regulation of target cell activity by DN T cells (Young and Zhang, 2002, Hamad et al., 
2003). Studies on NKT cells have indicated that they mediate their regulatory function 
through rapid production of high levels of immunoregulatory cytokines such as IL-4, IFN-y, 
TNF and IL-10 (Godfrey et al., 2000). The regulation of levels of Thl/Th2 cytokines by NKT 
cells (especially those that are CD Id restricted) cells has been proposed to be significant in 
reducing inflammation and restricting the proliferation of C D ld+ marginal zone B cells (that 
are enriched in autoreactive cells) in mouse models of SLE, EAE (experimental autoimmune 
encephalomyelitis) and IDDM (Godfrey et a l, 2000, Chatenoud, 2002).
Thus DN T cells have the potential to regulate all the components of an autoimmune 
process including the CD8+ T cells involved in inflammation, CD4+T cells that provide help 
for autoantibody producing B cells and the autoreactive B cells themselves within the splenic 
marginal zone areas.
My studies on patients with SLE have shown expanded populations of DN T cells, 
with an activated phenotype, a large percentage of which constitutively produces IL-4 and are 
resistant to apoptosis. These results, in the context of recently published studies characterizing 
DN T cells indicate a similar potential immunoregulatory role for this population in patients 
with SLE. Expansion of the apoptosis-resistant DN T cell population could be a consequence 
of the disease process aimed at regulating the B cells and conventional T cells participating in 
the autoimmune response. Further studies on cytokine production by DN T cells from patients
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with SLE (IL-10, TGF-p, IFN-y) and functional studies are needed to verify their precise role 
in the autoimmune disease process.
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Figure 7.2: Model for the possible roles of DN T cells in autoimmune diseases.
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7.7: Future studies
The work in this thesis raises a number of further questions about the role of DN T 
cells; both as a distinct cell population and their role in the pathogenesis of SLE .
Although, the exact functional contribution of DN T cells to SLE disease pathogenesis 
has not been defined here, the data presented suggest that they are involved in the process. The 
work in this thesis shows the importance of the a p  TCR+ DN T cells in patients with SLE. 
However, to understand the complete picture of how they contribute to the pathogenesis, their 
frequency in the tissues of the various organ systems affected in each patient, needs to be 
evaluated (ideally in untreated patients). This presents practical difficulties since SLE patients 
do not often undergo biopsies of organs (other than kidney or skin) prior to commencement of 
treatment.
Presentation of potential SLE autoantigens such as nucleosomes and phospholipids by 
the CD1 family of antigen presenting molecules to DN T cells needs to be examined in detail. 
This should provide clues to the circumstances surrounding the initiation of anti-ds DNA and 
other autoantibody production in lupus. The response by DN T cells to antigen presented by 
CD1 in terms of activation, cytokine profile and proliferation also requires an in-depth study 
to further understand their significance in the immune system.
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System ic lupus erythematosus (SLE) is characterized by B cell hyperactivity and the production o f  
autoantibodies, some o f which (antibodies to dsDNA ) are thought to be pathogenic. T helper cells  
drive the production o f autoantibodies and the aim o f  this study is to characterize phenotypically a 
subpopulation o f  T cells (the CD3 + C D 4 _ CD8 “ , double negative (DN) T cells) previously  
identified as helping to enhance anti-DNA antibodies in patients with SLE. Data were obtained 
using FACS staining o f DN T cells that had been purified from PBMCs by magnetic bead 
separation.
The percentage of TCR a/iC DN T cells was found to be significantly higher in patients with 
SLE as compared with controls (P =  0 .02), although there was no significant increase in total 
percentage o f DN T cells, which includes TCR yS + cells. Activation markers HLA-DR and CD69, 
the costimulatory m olecule CD28 and CTLA-4 were all expressed on the surface o f a higher 
percentage o f DN T cells in patients with SLE than in patients with rheumatoid arthritis (RA) or 
healthy controls (HC). More DN T cells from patients with SLE were o f  CD45RA phenotype than 
was found in controls, while CD45RO -expressing cells were reduced. In addition, DN T cells from 
patients with SLE expressed significantly higher levels o f HLA-DR (P =  0.006), CD28 (P  =  0 .05), 
CTLA4 (P =  0.03) and CD45RA (P  =  0 .05) on the cell surface than those from the C D 4/8  
population. Correlation of expression o f the markers measured with various parameters o f  disease 
activity and severity showed that high levels o f HLA-DR expression correlated with high 
circulating serum C3 ( > 0 .9 I U /m l) ,  indicating that an activated phenotype is consistent with 
severe disease. Lupus  (2002) 11, 4 9 3 -5 0 0 .
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Introduction
System ic lupus erythem atosus (SLE) is an au to im m une 
rheum atic disease characterized  serologically  by B cell 
hyperactiv ity  and  a panoply  o f autoantibodies against 
nuclear, cy toplasm ic and cell surface antigens. Since 
these au toantibodies are m ainly o f the Ig G l subclass, it 
is likely that T  lym phocytes are essential in prov id ing  
help to the autoantibody  p roducing  B cells. E v idence
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for T cell involvem ent in disease pathogenesis is illu­
strated by the association o f SLE w ith  particu lar m ajor 
h istocom patability  com plex (M H C ) class II alleles and 
affinity m aturation  o f IgG  au toantibody  p ro d u c tio n .1 It 
is though t that T  helper (T h) cells d rive the production  
o f pathogenic anti-D N A  au toantibodies in SLE and it
has been show n, in vitro, that som e o f these are C D 4 ”  2
C D 8 , i.e. double  negative (D N ) T  cells, w hich have
been  show n to express either the a/? T cell receptor
(TC R ) or yd TCR. ’4 H ow ever, conflicting results have
been  obtained about w hether or not there is an increase
in D N  T cells in patients with S L E .5 -7
T o understand the contribution o f  D N  T  cells to 
d isease pathogenesis, we have determ ined  the p re ­
sence of D N  T cells in the b lood  o f patients with SLE 
and further characterized them  in term s o f activation
/Yndd23Q2 1011.91/C6612033Q2 u235oa
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state. O ur studies have show n that, although there was 
no significant increase in absolute circu lating  D N  T 
cells, there w as a g reater proportion  o f the a/? D N  T 
cell population  in SLE. Furtherm ore, these cells w ere 
m ore activated  than control D N  T cells as de term ined  
by a num ber o f activation  m arkers.
M aterials and methods
Patients and controls
T w enty  tw o patients w ith SLE (21 fem ales and  one 
male aged 1 7 - 6 7  years, m ean 42 years) w ere studied  
with inform ed consent. E ach  met four o r m ore o f  the 
revised criteria  o f the A m erican C ollege o f R h eu m a­
tology for the classification o f rheum atic  d ise a se .1 
D isease activity  w as assessed using the B ritish Isles 
L upus A ssessm ent G roup  (B ILA G ) com puterized  
index .8 T he index is based upon the ‘p h y sic ian ’s 
intention to trea t’ p rinciple and divides lupus activ ity  
into eight o rgans or system s which are scored from  A 
(m ost active) to E (never previously  active). A global 
score determ ined  using A = 9, B =  3, C =  1, D =  0, 
E — 0 has been successfully  com pared with o ther 
m ethods o f calculating  global scores,9 and in this 
study patients scoring >  6 w ere deem ed active 
and <  6 inactive. L evels o f  circulating  anti-dsD N A  
antibodies and C3 w ere m easured during  rou tine 
patient assessm ent. Serum  levels o f anti-dsD N A  an ti­
bodies in excess o f  5 0 IU /m l (Shield D iagnostics, 
D undee) and levels o f C3 less than 0 .9 IU /m l (by 
laser nephelom etry) are regarded as abnorm al. For 
statistical analysis in this study, antids-D N A  antibody 
levels o f lO O IU /m l or m ore w ere considered  to be 
high. Seventeen  patients with rheum ato id  arthritis 
(RA: 15 fem ale, three m ale, aged 3 5 - 8 2  years, 
m ean 59 years) w ho fulfilled four or m ore o f the 
ARA  criteria  for rheum atoid  a rth ritis10 and 18 healthy  
contro ls (HC: 17 fem ales, one m ale aged 1 8 - 4 5  
years, m ean 31 years) w ere also studied.
Preparation of double negative T cells
Peripheral b lood  m ononuclear cells (PB M C s) w ere 
separated from  venous blood by F ico ll-H ypaque 
(N ycom ed) gradients w ithin 6 0 m in  o f collection . T he 
C D 4 -  C D 8~  T cell population  was enriched  by n eg a ­
tive selection. Briefly, PB M C s were incubated  with 
m onoclonal an tibodies (M abs) to CD 4 (U C H T -8), CD 8 
(U C H T-4), the B cell m arker C D 19 (B U -12) and the 
m onocyte m arker CD  14 (M Y -23) for 3 0 m in  at 4°C  
under previously  established optim um  conditions. T he 
w ashed cells w ere then incubated w ith sheep an ti­
m ouse IgG  D ynabeads (D ynal) for 3 0 m in  at 4°C  and 
the non-C D 4~ C D 8~  T cells rem oved w ith a m agnet.
T he rem aining cells w ere tested for purity  and were 
alw ays > 9 5 %  pure D N  T cells.
Immunofluorescence staining and flow cytometry
Indirect th ree-co lour staining p rio r to FA CS analysis 
was carried  out. C ells were labelled  w ith the first anti­
body (30 m in, 4°C ), w hich w as e ither H L A -D R  (D ako- 
Patts D enm ark), C D 28 (gift from  D r Y L atchm ann), 
C T L A -4 (gift from  D r BM  B roker), C D 45R A  or 
C D 45R O  (gifts from  Professor BM  C hain) follow ed 
by FITC  con jugated  anti-m ouse F (ab ')2 (D akopatts A /S  
D enm ark), w ashed (PBS con tain ing  1 % BSA and 0.1%  
sodium  azide) and any free an ti-m ouse Ig b ind ing  sites 
blocked  w ith norm al m ouse serum . A direct staining 
m ethod was used for m easuring surface expression of 
C D 69 (Pharm ingen), and in every  case the cells were 
also stained using directly con jugated  C D 3-PE  or 
TCRa/?-PE, C D 4-C y and C D 8-C y (Pharm ingen) in 
order to identify  the double negative T  cells. Sam ples 
w ere then fixed for 10 min in 2%  parafo rm aldehyde 
before analysis o r storage at 4°C  in the dark. It is 
possible to distinguish  C D 4 “t" and C D 8 + cells from 
the rem aining PB M C s and from  each o ther using 
antibodies conjugated  with the sam e fluorochrom e 
(C ychrom e in this case) because the tw o different cell 
populations are o f  d ifferent density  and each can be 
visualized as a clearly  d istinguishable separate p o pu la­
tion on the screen. All an tibodies w ere used at optim al 
saturation concentrations. B ackground  staining was 
determ ined using isotype m atched  non-conjugated  
m onoclonal antibodies and F IT C  conjugated  an ti­
m ouse antibody for indirect staining and isotype 
m atched FITC , PE or Cy con jugated  m onoclonal 
antibodies (D akoPatts) for d irect staining. Cells were 
analysed on a FA C Scan flow cy tom eter (B ecton D ick­
inson) using a lym phocyte gate based on forw ard and 
side light scatter characteristics. A ll analyses were 
perform ed using W inM D I version 2.8 softw are.
Statistical analysis
D ata were analysed using the non-param etric  M ann -  
W hitney test and W ilco x o n ’s test for paired  sam ples. A 
tw o-tailed non-param etric (Spearm an) test w ith 95% 
confidence lim its was used to determ ine correlations.
Results
Quantitation of double negative T cells
D N  T cells w ere identified using three-co lour im m u­
nofluorescence staining with C D 3-PE , C D 4-C ychrom e 
and C D 8-C ychrom e used to d istinguish  the DN CD3 
positive cells from  total PB M C s (D N  T cells are
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F ig u re  1 T he percen tages o f b lood  DN T  cells are sim ilar in pa tien ts  
vcith SLE (n =  10), RA  (n =  8) and HC (n = 13). Total b lood  PB M C s w ere 
stained with fluorescent an tibod ies  to CD 3, CD4 and C D 8, for flow 
cstom etric  analysts, as described  in M aterials and m ethods.
C D S ’*', C D 4~  and C D 8 ~ ) and the third co lour being 
used to identify  the o ther param eter being m easured.
The percen tages o f D N  T  cells m easured in the 
total PB M C s o f  SL E  patients did not d iffer from  
control patients w ith RA  or HC (Figure 1). H ow ever, 
on further analysis o f the populations expressing 
either zfi or yS T  cell receptors, the percen tages of 
y.[J T C R + D N  T cells in SL E  patients w ithin the 
total D N  population  (59.81 ±  10.39) w ere signifi­
cantly  increased (P  =  0 .04) com pared w ith RA  
(53.08 ±  21 .91) and HC (4 8 .2 4 ±  15.23; F igure 2).
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D etailed  exam ination o f the treatm ent regim es at the 
tim e o f sam pling show ed that, w hile m any of the 
patients w ere on steroid therapy, e ither alone or in 
com bination  with o ther drugs, eigh t w ere receiving no 
m ajor drug therapy  (Table 1).
Expression of surface markers on DN T cells in 
patients with SLE
A num ber o f  surface m olecules w ere analysed  on the 
D N  T cells o f patients with SLE, RA  and HC (Figure 3).
HLA-DR. T he percentages o f H L A -D R  + DN T cells 
w ere increased in patients with SLE  com pared  with 
bo th  RA  patients (P  =  0.016) and  H C (P  =  0 .01; 
F igure 3a). In addition , there w ere significantly  m ore 
H L A -D R + D N  T  cells than C D 4 /8 + T cells in 
patien ts with SL E  (P = 0 .006; F igure 4a). H ow ever, 
there was neither any significant d ifference in p ercen ­
tages o f H L A -D R + D N  T cells nor o f  C D 4 /8  + T 
cells in patients w ith active d isease com pared  with 
inactive d isease (G lobal D isease A ctivity  Index). 
T here  was no correlation  betw een G lobal D isease 
A ctiv ity  Index and percentage o f H L A -D R + C D 4 / 
8 + T  cells (r  =  0 .21 , P  =  0.48) or H L A -D R +  DN T 
cells (r=  — 0.08 , P  =  0.78). W ith regard to anti- 
dsD N A  antibody  levels, there w ere no significant
T able 1 SLE patients and their treatments
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F ig u re  2 T he percen tages o f  a /J + DN T  cells are increased  in SL E 
patients (n — 15) com pared  w ith R A  ( n = 1 5 )  and H C (n = 1 5 ) .  B lood  
PB M Cs were trip le  s tained for C D 4 /C D 8 , CD3 and a/? as described  in 
the M aterials and m ethods. P ^ O .0 2  for increase in a /? +  D N  T  com pared  
w ith both RA and HC.
P a tien t No. D ate o f  B irth D rug Treatm ent
19 28 .08 .1928 N o m ajor d rugs
5 30.04.1941 No m ajor d rugs
20 31 .12 .1942 No m ajor d rugs
8 08 .0 5 .1 9 5 0 N o m ajor d rugs
16 10.08 .1950 N o m ajor d rugs
10 26 .09 .1959 N o m ajor d rugs
21 26 .0 9 .1 9 5 9 N o m ajor d rugs
1 18.07 .1964 N o m ajor d rugs
22 0 8 .12 .1973 No m ajor d rugs
18 0 7 .08 .1952 5 mg Predn iso lone
9 0 9 .02 .1970 4 0 0 m g  H ydroxych lo roqu ine
13 16.08 .1959 20 0 m g  Plaquan il
6 0 2 .09 .1949 2 mg Prednisolone
2 0 0 mg H ydro x y ch lo ro q u in e
17 1 1 .05.1952 2.5 mg P redn iso lone  
4 0 0 m g  P laquan il
4 20 .06 .1974 5 mg Prednisolone
4 0 0 mg H y d roxych lo roqu ine
7 04 .06 .1960 8 mg Predn iso lone
4 0 0 mg H ydroxych lo roqu ine
75 0 m g  quarte rly  C yclophospham ide  pulse
2 04 .05 .1962 10 mg P redn iso lone
4 0 0 mg H y d roxych lo roqu ine
12 2 6 .01 .1968 7.5 mg P redn iso lone 
25 mg A zath ioprine
15 19.12 .1969 7.5 mg P redn iso lone  
150 mg A zath ioprine
11 2 1 .1 2 .1 9 5 0 4 0 0 m g  H y droxyclo roqu ine  
125 mg m onth ly  D eltastab  pulse
3 2 8 .08 .1928 50 mg A zath ioprine
125 mg m onth ly  D eltastab  pulse
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CD28CTLA4
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F ig u re  3 E xpression  o f  su rface m arkers by DN T  cells from  patien ts  w ith SL E, R A  and HC. (a) H LA -D R expression is significantly  increased in DN T 
cells from  patients w ith SLE (n  =  17) com pared w ith e ither patien ts w ith  R A  (n =  14) or HC (n =  13). (b) C D 69 expression is significantly  increased in DN 
T  cells from  patients w ith SL E  (n =  11) com pared w ith patients w ith RA  (n =  11). In HC (n =  9), expression o f C D 69 is low er but the difference is not 
significant, (c) E xpression o f C TL A 4 is significantly increased in D N  T  cells from  patients w ith SL E  (n =  14) com pared w ith e ither patien ts w ith RA 
(n =  10) o r HC (n =  8). (d) C D 28 expression is significantly increased in D N  T  cells from  patients w ith SL E (n =  17) com pared w ith e ither patients w ith RA 
(n =  15) o r HC (n =  12). (e) E xpression o f C D 45R A  is significantly  increased in patients w ith SL E  (n =  8) com pared w ith HC (n =  6). T here was no 
d ifference in expression o f  C D 45R A  com pared w ith patients w ith RA (n  =  12). (0  Expression o f  C D 45R O  is significantly decreased in patients w ith SLE 
(n = 7) com pared w ith HC (n =  9). T here is no difference in expression  o f C D 45R A  com pared w ith patients with RA (n =  5).
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F ig u re  4 E xpression  o f  surface m arkers by C D 4 /8 + T  cells com pared  w ith D N  T  cells from  patien ts  w ith SLE. (a) E xpression  o f H LA -D R is 
significantly  h ig h er in DN T  cells than C D 4 /8  + T  cells (n =  17). (b) T here  is no significant d ifference in expression  o f CD 69 betw een C D 4 /8  + T  cells and 
DN T  cells (n =  11). (c) E xpression  o f  C T L A 4 is significantly h ig h e r in D N  T  cells than  C D 4 /8 + T  cells (n =  14). (d) C D 28 expression  is significantly 
h igher in DN T cells than C D 4 /8 + T  cells (n =  17). (e) C D 45R A  expression  is significantly  h igher in D N  T  cells than C D 4 /8  + T  cells (n -  8). (0 C D 45R O  
expression  is significantly  low er in D N  T  cells than C D 4 /8 + T  cells (n — 1).
differences in percentages o f H L A -D R + C D 4 /8 "1" T 
cells or H L A -D R + D N  T cells betw een patients w ith 
high vs low levels and no correlation betw een levels 
o f anti-dsD N A  antibody and percentage o f H LA -
D R + C D 4 /8 + T  cells (r  =  0 .35 , P  =  0 .25) or H LA- 
D R +  DN T cells (r=  - 0 .3 8 ,  P  =  0 .19). H ow ever, 
w hen high and low levels o f  c irculating C3 were 
related  to H L A -D R  expression, H L A -D R  expression
Lupus
D a d e negative T cells in
AAiandetal
was significantly  h igher in D N  T cells from  patients 
with high C3 (P  =  0.03). T here was a positive co rre la ­
tion betw een  C3 level and H L A -D R  expression  in 
both C D 4 /8 + T cells and DN T cells (r  =  0 .57 , 
P  =  0 .04 and r  =  0.58, P  =  0.04, respectively).
CD69. A lthough patients with SLE show ed an 
increased percen tage  o f DN T cells expressing 
C D 69 com pared  to HC, this was no t significant 
(P  =  0 .08; F igure 2b). H ow ever, there was a signifi­
cant increase in C D 6 9 + DN T cells in SL E  com pared  
with RA patients (P  =  0 .005). In addition, in the case 
o f RA there w as a significantly low er percen tage  o f 
C D 6 9 ’1' D N  T cells com pared with the C D 69 + 
C D 4 /8 + T  cell population  (P  =  0 .004 , data  not 
show n). In patients w ith SLE, the percen tages o f 
DN C D 6 9 4" cells w ere not significantly d ifferen t 
from the percen tages o f C D 4 /8 + C D 6 9 + T cells 
(Figure 4b). T here was no significant d ifference in 
C D 6 9 +  DN T cells or C D 6 9 + C D 4 /8 + T cells in 
those patients w ith active disease com pared  with 
inactive disease. In addition, there was no correlation  
betw een e ither C D 6 9 + DN or C D 6 9 + C D 4 /8 4" 
expression and G lobal D isease A ctivity Index 
(r — 0 .21 , P  =  0 .54 and r=  - 0 . 5 5 - 0 .5 2 ,  P  =  0 .95 , 
respectively). N o significant differences in pe rcen ­
tages o f 0 0 6 9 ^  D N  or C D 6 9 + C D 4 /8 + w ere seen 
betw een high and low levels o f serum  anti-dsD N A  
and no correlation  w as found betw een percen tage o f 
C D 69 + C D 4 /8 + T cells (r  =  0.05, P  =  0 .87) or 
C D 6 9 + D N  T cells (r  =  0.33, P  =  0 .31) and level o f 
an ti-dsD N A  antibody. No significant d ifferences w ere 
seen betw een  low and high levels o f serum  C3 and 
percen tage  o f  C D 6 9 + DN or C D 6 9 4" C D 4 /8 + and 
no corre la tion  betw een percentage o f e ither C D 69 + 
DN ( r  =  0 .49 , P  =  0 .12) or C D 6 9 +  C D 4 /8  +
(r=  —0.38, P  =  0 .25) and level o f anti-dsD N A  an ti­
body.
CTLA4. A lthough  few C T L A 4 + cells w ere detected  
(F igure 3c), there w ere significantly m ore in the D N  T 
cell population  o f the patients with SLE com pared  
with both the RA patients (P  =  0 .002) and H C 
(P =  0 .004). N um bers o f C T L A 4 +  C D 4 /8 + T cells 
also appeared  to be increased com pared  with contro l 
groups, but the increase w as not statistically signifi­
cant. T he percentages o f C T L A 4 4" D N  T cells w ere 
significantly h igher than the C T L A 4"1" C D 4 /8 + cells 
in both the SLE  patients (P  =  0 .03; F igure 4c) and HC 
(P  =  0 .001; data not show n).
CD28. T here  w ere m ore DN T cells expressing 
the costim ulatory  m olecule CD 28 in SLE patients 
than in e ither RA ( P =  < 0 .0 0 0 1 )  or H C  (P  =  0 .002; 
F igure 3d). H igher levels o f C D 2 8 + D N  T cells w ere
seen com pared  with CD 28"hC D 4 /8 + T cells p o pu la­
tions in SLE (P  =  0.05; F igure 4d).
CD45RA/RO. D N  T cells from  patients with SLE 
show ed significantly increased percentages of 
C D 4 5 R A '1' com pared  with HC (P  =  0 .007) but not 
w ith RA  controls (Figure 3e). C onversely , SLE patients 
had  significantly low er percentages of C D 4 5 R O + T 
cells in com parison with HC (P  =  0 .03), but not with 
RA  contro ls (Figure 30- In patients with SLE, the DN 
popu lation  w as significantly increased in C D 45R A  
com pared  with the C D 4 /8 4" population  ( P =  0 .048; 
F igure 4e), w hile it was significantly  decreased  in 
C D 45R O  (P  =  0 .03; Figure 4f).
W e had insufficient data to determ ine accurately  
w hether there w as any correlation  betw een disease 
activ ity , anti-dsD N A  or C3 and the levels o f exp res­
sion o f C D 28, C TLA 4, C D 45R A  or C D 45R O .
Discussion
In this study we show evidence for d ifferences in the 
D N  T cell population  in patients w ith SLE com pared  
w ith this population  in RA patients and HC. D ouble 
negative T  cells have been show n to express either the 
a/? T  cell receptor (TCR) or y<5TCR.3,11 A lthough 
there was no increase in the levels o f the total DN T 
cell populations in SLE, we found that T C R  DN 
T  cells w ere present in h igher levels in patients with 
SLE com pared  with HC (P =  0 .02). T here was no 
significant difference in num bers o f T C R  a /? + D N  T 
cells in patients with RA com pared  with SLE. O ther 
investigators have shown an increase in D N  T cells in 
various autoim m une diseases including in patients 
w ith SL E .6,12 It is unlikely that the observed increase 
w as a phenom enon induced by therapy because, 
although m any o f the patients w ere receiv ing steroids, 
either alone or in com bination w ith o ther drugs, eight 
patients w ere not receiving any m ajor drugs. The 
expression o f activation m arkers by the D N  T cells 
in patients w ith SLE could indicate that they are 
functionally  im portant in the d isease. The percentages 
o f  cells expressing CD69 in the D N  T cell population  
o f  patients with SLE was h igher com pared  with 
auto im m une (RA ) and healthy controls (P = 0 .005). 
C D 69 is one o f the earliest cell activation antigens 
that is expressed by activated lym phocytes and m ono­
c y te s13 and is involved in signal transduction, cell 
proliferation and cytokine sec re tio n .14 To our k now l­
edge, our studies are the first to investigate CD 69 
expression by DN T cells in SLE. O ther investigators 
have, how ever, show n that num bers o f C D 6 9 + cells 
are m arginally  increased in freshly isolated C D 4 + or 
C D S 4- T  cells from  patients w ith SLE, especially  in
lipus
D a d e  negativeT cdls in SLE
A/'rendetat
the C D 8 + T cell co m p artm en t.15-17 It has also been 
reported  that the C D 6 9 /C D 3  ratio, w hich detects T 
cell activation , is corre la ted  w ith disease activ ity  in 
patients w ith S L E .18 In ou r studies, the d ifferences 
betw een the D N  T cell popu la tions w ere m uch m ore 
significant than the d ifferences seen com paring  the 
C D 4 /C D 8 "1" popu la tions (P = 0A2) suggesting  that 
the level o f expression  o f  C D 69, a lthough increased 
on the overall T  cell popu lations, was h ighest for the 
DN T cells in SLE  patients.
H L A -D R  is m ainly expressed  by T cells 2 4 - 4 8 h  
after activation. Increased percentages o f D N  T  cells 
expressing H L A -D R  in patients with SLE com pared  
with the two contro l g roups (P = 0 .02 RA and P = 0.01 
HC), like the expression  o f  C D 69, indicates that there is 
a on-ongoing  activation  o f  these cells in the patients. 
A lthough we found no significant d ifferences in H L A - 
DR expression betw een  patients w ith SLE  and the 
control g roups in the C D 4 /8 + population , others 
have reported  a h igher proportion  of H L A -D R + T  
cells in both the C D 4 + and C D S '1" T cells in patients 
w ith S L E .1718 It is unclear why we did  not find 
d ifferences in expression o f the overall C D 4 /C D 8  + 
cells and unlikely that our findings are due to the 
disease activity  o f our patien t cohort as there does 
not appear to be any correlation  betw een G lobal D is­
ease A ctivity  Index and H L A -D R  expression. H ow ­
ever, we did find a positive correlation betw een  C3 
levels and H L A -D R  expression in both C D 4 /8 + T 
cells and DN T cells. H igher levels o f circu lating  C3 
are ind icative o f  less active disease and this finding 
m ight indicate that highly  activated DN T  cells could 
have a pro tective effect.
C D 28 has been show n to be present on the m ajority 
of C D 4 + T cells w ith few er C D 8 + T cells expressing 
this m o lecu le .19 It has been  reported  that patients w ith 
SLE have a p referen tia l decrease o f C D 2 8 + T cells, 
especially  in the C D 8 + T cell com partm en t.20’21 W e 
analysed the C D 4 + and C D 8 + cells together and 
found there to be significantly  m ore C D 2 8 + cells in 
the D N  com partm en t than in the C D 4 /8 "1’ population  
(P = 0 .045). W e also found  that m ore D N  T cells 
expressed C D 28 in patients w ith SLE com pared  to RA 
or HC. T he significance o f this is currently  unclear bu t 
engagem ent o f C D 28 on T  cells by its coun ter­
receptors B7-1 (C D 80) and B 7-2 (C D 86) on accessory 
cells is pivotal for T  cell activation  and in the absence 
o f this costim ulation  T  cells are ane rg ized .19 In terest­
ingly a defective C D 2 8 /B 7  costim ulatory  pathw ay
has also been described in SL E  T cells, w hich could
20  —  22contribu te  to the d isease pathogenesis. Follow ing 
activation via C D 28, C D 4 + and C D 8 + , T cells 
express C T L A -4 w hich has a h igher affinity for the 
same ligands as C D 28 (C D 8 0 /C D 8 6 ). T his is thought 
to deliver a negative signal to the T  ce lls .23-25 O ur
studies on C T L A -4 expression by C D 4 /C D 8  + T cells 
in SLE patients have show n increased percentages of 
C T L A -4 + T cells com pared w ith norm al controls, 
consisten t w ith that reported by o thers.26 In addition, 
we show ed a low but significantly increased p ercen ­
tage o f  D N  T cells expressing C T L A -4  in our patients 
w ith SLE. T h is concom itan t increase in the num ber of 
cells expressing both CD 28 and C T L A -4  confirm s the 
h ighly  activated  status o f som e D N  T  cells in patients 
w ith SLE. C T L A -4 is often detected  intracellularly . 
H ow ever, in this study we did no t stain for in tracel­
lu lar C T L A -4 routinely because in three patients 
studied  we found no significant d ifferences in the 
results for surface or in tracellu lar staining (data not 
show n). E xpression o f C D 45R O  usually m eans that 
the cells are ‘antigen exp erien ced ’ and those that are 
C D 45R A  are ‘antigen naive’. W e found that a sig­
nificantly h igher percentage o f D N  T cells but not 
C D 4 /C D 8 4’ T  cells expressed C D 45R A  in patients 
w ith SLE com pared  with HC (P = 0 .007). The 
patients also show ed a significantly h igher proportion  
o f  C D 4 5 R A +  cells to C D 4 5 R O + cells for C D 4 / 
C D 8 + T  cells (P  =  0 .05) and D N  T  cells (P  =  0.05). 
O ne explanation  for this could  be the recru itm ent of 
na iv e /restin g  D N  T cells to the ongoing  im m une 
reaction  in patients with SLE rather than the reactiva­
tion o f existing m em ory clones. T his finding is in 
agreem ent with the results o f studies follow ing the 
course o f d isease from  the onset of sym ptom s 
in patients w ith SL E .29 W e conclude  that the DN 
T  cell population  is heterogeneous, in that, while som e 
D N  T cells in SLE show increased expression o f a 
n um ber o f activation  m arkers, suggesting  som e in vivo 
activation, o thers do not. It is possible that the 
activated cells m ay provide help  for antibody and 
au toantibody  production , although this theory was not 
tested in the study. Interestingly, studies o f au to reac­
tive T cell lines or clones capable  o f inducing anti- 
dsD N A  production  in vitro w hich had been derived 
from  patients w ith SLE show ed these cells to be either 
C D 4 - C D 8 “ T C R a/?+ or C D 4 + T C R a/?+ (T helper 
ce lls).3,4 T hese cells could therefore  provide help for 
au toantibody  production  in addition  to the co n v en ­
tional C D 4 + helper T  cells. T his is consistent with the 
finding that D N  T cells are enriched  in IL4 producing 
cells in patients w ith SLE 28-30
W hat is activating som e D N  T  cells in patients with 
SLE is unclear. In terestingly , recen t studies have 
show n that D N  T cells from  SLE recognize C D lc  
expressed on B cells and can help  the B cells to 
develop into IgG  antibody producing  ce lls .31 C D lc  is 
capable o f p resen ting  unconventional antigens such as 
a variety o f foreign lipids and g lyco lip id s.32,33 This 
has led to speculation that the D N  T cells can co n ­
tribute to p roduction  o f autoan tibodies by recognizing
D atie restive T cells in SLE
Atoandetal
nucleosom es and could  contribute to the developm ent 
o f an ticard io lip in  antibodies. The recent finding that 
N K -T  cells w ithin the D N  T cell population  express a 
TC R  o f V a2 4 JaQ 34 has indicated that these cells m ay 
regulate p rogress o f the disease. Further studies will 
analyse the characteristics o f the V a24JaQ  T C R + D N  
T cells in contro ls and determ ine w hat role they have 
in patients w ith SLE.
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Characterization of CD3+CD4 CD8 (double negative) 
T cells in patients with systemic lupus erythematosus:
production of IL-4
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System ic lupus erythematosus (SLE) is a chronic autoimmune rheumatic disease that may affect 
every organ or system  in the body. W e have shown previously that the TCR subpopulation o f  
C D 3+CD4 ~ CD8 ~ , DN T cells is expanded in patients with SLE and that double negative T cells  
express increased levels of activation markers compared both with healthy people and with patients 
with rheumatoid arthritis, (RA) as autoimmune controls. The aim o f this study was to characterize 
these cells in terms o f their ability to produce IL4, a Th2 cytokine, both spontaneously and after 
mitogen stimulation. It was found that a higher percentage o f  TCR a/?+ double negative T cells from  
patients with SLE contained IL4 constitutively than did the same population o f  cells from healthy 
people or from those with RA. After m itogen stimulation, there was no significant difference in 
the amount of IL4 produced by each o f  the three groups. Further study o f  patients producing 
high levels o f IL4 (about one third o f the patients) indicated that they had a lower percentage o f  
T cells in the double negative compartment than did patients with fewer IL4 containing cells. 
Lupus  (2002) 11 , 501-507 .
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Introduction
SLE is a chronic  auto im m une rheum atic disease that 
is characterized  by B cell hyperactiv ity  and the 
production  o f a spectrum  o f autoantibodies. The 
m ost im portan t o f these autoantibodies (because 
som e are pathogenic), are the IgG  antibodies specific 
for doub le-stranded  D N A  (anti-dsD N A ). Several 
g roups have show n a link  betw een these an tibodies 
and kidney disease, one o f the m ost serious clin ical 
m anifestations o f S L E .1
D ouble negative T  cells (D N  T) are though t to be a 
separate lineage o f T  cells that develop  ex trathym i- 
cally in m an .2 W e have previously  characterized  these
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cells in term s o f  their expression  o f activation 
m arkers and CD 45 pheno type3 and have show n that 
the oe/?+ DN T cells are increased as a percen tage of 
total T  cells in patients with SLE. O ur w ork indicated 
that a /?+ D N  T cells in patients w ith SL E  expressed 
h igher levels o f early (C D 69) and late (H LA -D R ) 
activation m arkers than controls. T his subpopulation 
o f T  cells also appeared  to contain  a h igher proportion 
o f antigen naive cells (C D 45R A 4") in SLE than in 
controls. a/?+ D N  T cells appear to have a function 
in the developm ent o f au to im m une disease and it is 
thought that their apparen t au toreactive nature may be 
as a result o f avoidance o f the process o f thym ic 
selection that w ould delete au toreactive T  cells. 
T C R a/?+ D N  T cells have been im plicated  in the 
pathogenesis o f SLE and o ther au to im m une diseases 
in m an as well as in various au to im m une conditions in 
m ouse m odels.4 -6
T he aim  o f this study was to determ ine the percen ­
tage a/?+ D N  T cells from  patients with SLE 
and controls that contained in tracellu lar IL4 and to
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com pare these levels o f cy tokine p roduction  w ith those 
from  the C D 4 + and C D 8 + a/T^T  cell subpopulations.
Materials and methods
Patients and controls
Fifty patients w ith SLE (49 fem ale and one m ale, aged 
from  17 to 66 years, m ean age 37.2 years) w ere 
studied with in form ed consent. Each m et four or 
m ore o f the revised criteria  o f the A m erican  C ollege 
o f R heum atology (A C R ) for the c lassification  o f 
rheum atic d isease.7 D isease activity w as assessed 
using the British Isles Lupus A ssessm ent G roup  
(B IL A G ) com puterized  index .8 T he index  is based 
on the ‘p h ysic ian ’s in tention to trea t’ p rinc ip le  and 
divides lupus activ ity  into eight o rgans or system s 
w hich are scored from  A (m ost active) to E  (never 
previously  active). A B ILA G  global score (GS) 
determ ined  using A =  9, B =  3, C =  9, D  =  0, E =  0 
has been successfully  com pared with o ther m ethods 
ofcalcu lating  global scores,9 and in this study 
patients w ere d iv ided  arbitrarily  into tw o groups, 
active (GS >  6) and inactive (GS <  6). L evels o f  
circulating anti-dsD N A  antibodies and C3 w ere m ea­
sured during  routine patien t assessm ent. Serum  levels 
o f anti dsD N A  antibody levels in excess o f  5 0 IU /m l 
(Shield D iagnostics, D undee) and  levels o f  C3 less 
than 0 .9 IU /m l (by laser nephelom etry) w ere regarded  
as abnorm al. For statistical analysis in this study, 
anti dsD N A  antibody levels o f lO O IU /m l w ere 
considered  to be high. Fifteen patients w ith RA 
(eigh t m ale and seven fem ale, aged from  26 to 
77 years, m ean age 50.7 years) w ho fulfilled four or 
m ore o f the A C R  criteria  for rheum ato id  a rth ritis10 
and 16 healthy  controls (HC, 13 fem ale and three 
m ale, aged 2 1 - 5 7  years, m ean age 36.1 years) w ere 
also studied.
Preparation of PBMCs
B lood was taken by venepuncture and PB M C s 
isolated using grad ien t centrifugation  (L ym phoprep , 
N ycom ed). C ells w ere w ashed three tim es and stained 
for expression o f TCRa/J, C D 4, C D 8 and in tracellu lar 
IL4. Peripheral b lood  m ononuclear cells from  a 
statistical sam ple o f patients w ere incubated overn igh t 
at 37°C, 4 .5%  C O 2  in the presence o f  1 0 |ig /m l PH A  
(phytohaem agglu tin in , Sigm a). M onensin (0.05 M , 
S igm a) was added for the final 6 h  to facilitate 
accum ulation  o f cy tok ine  in the G o lg i11 and the 
cells w ere stained for surface m arkers and in tracellu ­
lar IL4 as before. All o f  the antibodies used w ere 
directly  conjugated  and w ere obtained from  Pharm in- 
gen or eB ioscience (TCRa/? (FITC ), C D 4 (C y-5),
CD 8 (C Y -5)) or R& D  System s (IL4 (PE)). Cells 
taken from  som e patients and  contro ls were also 
stained for the activation m arkers, C D 69 and H LA - 
D R  (Pharm ingen (PE)). D N  T  cells w ere iden ti­
fied by staining w ith TCRa/? PE  C D 4 and CD 8 CY-5 
(tw o colours) and the aj5+ C D 4 _ C D 8 _ population  
gated  to determ ine expression of IL 4  or surface 
m arkers using P E -conjugated  antibodies.
Immunofluorescence staining and flow cytometry
Surface staining was carried  ou t as previously 
described .3 Cells w ere then fixed and perm eabilized 
using C altag Fix and Perm  (C altag) in accordance 
with the m anufac tu rer’s instructions p rio r to in tracel­
lu lar staining for IL4. A fter stain ing, cells were 
resuspended  in 2%  parafo rm aldehyde p rio r to 
im m ediate analysis or storage at 4°C  in the dark. All 
an tibodies w ere used at p redeterm ined  optim al 
saturating concentrations. B ackground staining was 
determ ined using isotype and con jugate-m atched  
irrelevant an tibodies obtained  from  the appropriate 
m anufacturer. C ells w ere analysed  on a FA C Scan 
flow cytom eter (B ecton D ick inson) using a lym pho­
cyte live gate based on forw ard  and side light scatter 
and counting  a m inim um  o f  104 - 1 0 5 events. All 
analyses w ere perfo rm ed  using W inM D I version 2.8 
softw are.
Statistical analysis
D ata w ere analysed using the non-param etric  M ann -  
W hitney  test and the W ilcoxon non-param etric  paired 
test. C orrelation  coefficients w ere calculated  using a 
tw o-tailed non-param etric  (Spearm an) test w ith 95%  
confidence limits. C hi-squared  w as calcu lated  using 
F ischer’s exact test.
Results
Production ofIL4 by af+DN, CD4+ and CD8+ T cells
Constitutive levels of IL4. a/?+ D N  T  cells isolated 
from  patients w ith SL E  had significantly h igher 
percentages o f  IL 4-contain ing  cells than those from  
patients with RA  (P  =  0 .003 , F igure. 1). The 
d ifference betw een  patients w ith SLE and HC was 
not significant (P  =  0 .066). H ow ever, 12 of the 
patients w ith SLE w ere show n to have a percentage 
o f oc/?+ D N  T cells contain ing IL 4 o f m ore than twice 
the standard erro r o f the m ean o f  H C (Figure 1). The 
num ber o f  patients with SLE w ho show ed high 
percentages o f IL4 contain ing  cells was significantly 
d ifferen t from  H C  by F ischer’s exact test (P  =  0.025). 
In addition, it was observed that the percentage o f
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F ig u re  1 Percentage o f IL4 + a/?+ DN T cells in the b lood  o f  patients 
with SLE (n =  50). RA (n =  15) and HC (n =  16). PBM Cs w ere stained fo r 
CD4/CD8, a/? TCR and IL4 as described  in the M aterials and m ethods. 
The dotted  line represents +2 s.e.m . o f  patients with SLE.
IL4-positive cells was significantly higher in the a/?4- 
DN T cell subset than in either the C D 4 '1' or the C D 8+ 
T cell subsets o f patients with SLE both in w hole 
population analyses (P  <  0.0001 in each case) and in 
the 12 patients with IL4-positive cells greater than 
twice the standard error o f the m ean o f H C (P  =  0.006 
for C D 8+ and P  =  0.019 for C D 4+; data not show n). It 
was difficult to determ ine w hether increased num bers 
o f IL 44' a/C - D N  T cells in patients com pared with 
controls also show ed these individual cells to be 
producing m ore IL4 owing to variations in binding 
o f isotype controls and anti-IL4 antibody from  patient 
to patient.
IL4 production after PHA stimulation. W hen cells 
from  these experim ental groups w ere stim ulated by 
overnight incubation with PHA, the differences in 
frequency o f IL4-positive cells betw een the groups 
were no longer observable (Figure 2). A nalysis 
o f paired data from  constitutive and PH A -stim ulated 
cells showed a significant increase in percentage of 
IL4-positive a / ^ D N  T cells on stim ulation for 
SLE (P  =  0.03), RA (P  =  0.006) and HC (P  =  0.004). 
There was no significant difference in percentage of 
IL4-positive cells either betw een SLE and RA 
(P =  0.8) or betw een SLE and HC (P  =  0.9). It 
was noted that, w hile m ost individuals tested 
show ed an increase in IL4-positive cells follow ing
F ig u re  2 Effect o f PHA on expression  o f  IL4 by a /T 'D N  T  cells with 
SLE, RA and HC. PBM Cs were cultured  w ith PH A  for 24 h as described in 
the M aterials and m ethods (stim ulated) and stained as described in F igure 
1 (constitu tive expression).
PHA stim ulation, six o f  the patients with SLE 
decreased their percentages o f IL4-positive a/?4" cells 
after stimulation.
Quantitation of a  fi+ double-negative T cells
O ur previous w ork had indicated that the a/?+ DN T 
cell subpopulation was expanded w ithin the total DN 
population in patients with SL E .3 W hile the total 
lym phocyte population com prised approxim ately 
1 -1 2 %  DN T cells in all experim ental groups, an 
average o f 60% of these cells w ere a/?+ in patients 
with SLE com pared with an average o f 48%  in 
healthy people (P =  0 .0216). C om parison o f percen­
tages o f a/? DN T cells as a proportion of total a/?+ 
T  cells for those 15 patients w ho had the highest 
frequency of IL4-positive a/?+ DN T cells with per­
centage o f a/T^D N  T cells for those patients with low 
frequency o f IL4-positive cells, show ed that those 
patients with high percentages o f IL4-positive cells
Upus
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F ig u re  3 Patients w ith the h ighest percentages o f  IL 4 -con ta in ing  
x/iT DN T  cells had the low est levels o f  x/T^DN T  cells. Pa tien ts  were 
g rouped  into those w ith g reater than 2 s.d. from  the m ean percen tages o f  
constitu tive  IL4 con ta in ing  T  cells o f  the patients w ith S L E  (IL 4 h igh ) and 
those w ith percentages o f IL 4 -con ta in ing  T  cells less than  2 s.d. from  the 
mean (IL4 low).
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F ig u re  4  T here  is no  re la tionsh ip  betw een activation  m arker expression  
and h igh and low  IL4 expression  by x/?+ DN T  cells in patien ts w ith SLL 
PB M C s from  patien ts w ith SL E  w ere stained fo r expression  o f  H LA -D R 
and C D 69 as described  in the M aterials and  m ethods and grouped  into 
constitu tive  h igh  and  low  IL4 p roducers as described  in F igure  3.
had significantly few er a/?'1'  T  cells in the D N  
com partm ent than did the group w ith low  frequency  
o f  IL4-positive cells (P  =  0 .02; F igure 3). (Further 
analysis show ed that there was no overall correlation  
betw een percentages o f lL 4-positive a ^ + D N  T cells 
and total a/S+D N  T cells (r=  - 0 .1 5 ,  P =  0 .36)).
No correlation of IL4 production with cell surface 
markers
Levels o f the surface activation m arkers C D 69 and 
H L A -D R  w ere m easured on a/?+ D N  T  cells from  21 
patients w ith SLE, 17 o f w hom  had low frequencies 
o f IL 4-positive cells and four had high frequencies o f 
IL4 positive a/?+ D N  T cells. There was no significant 
difference in activation m arker expression betw een 
high and low producers o f IL4 (P = 0.51 for H L A -D R  
and P  =  0.58 for C D 69; F igure 4). In addition , there 
was no significant correlation betw een expression 
o f activation m arkers and high or low  frequency  o f 
IL 4-positive a/?+ D N  T cells (r= — 0 .12 , P =  0 .33 for 
H LA -D R  and r = 0 .78, P =  0 .39 for C D 69; F igure 4). 
In the above experim ents, D N  T cells w ere indepen ­
dently  evaluated for activation m arkers and IL4 
expression. It was no t possible to determ ine w hether 
the IL4 containing cells them selves expressed H L A - 
DR or C D 69 in this study ow ing to the technical 
lim itations o f th ree-co lour staining.
No correlation between constitutive IL4 production 
and disease activity
T here was no correlation  betw een  the B ILA G  Global 
D isease A ctivity Index and IL4 production  (r  =  0.07, 
P = 0 .6). S im ilarly, w hen the patients w ith SLE were 
d ivided into groups depending  on the specific organs 
o r system s affected, there w as no connection  betw een 
IL4 production  and the organ or system  involved. It 
w as not possible to calculate correlation  coefficients 
for each o f the specific organs or system s ow ing to the 
sm all sam ple size.
No association between constitutive IL4 production 
and disease duration
T he 12 patients in the high constitu tive IL4 group had 
a m ean disease duration o f  10.67 ± 2 .6 4  years. The 
low IL4 group consisted o f 29 patients o f mean 
disease duration 12.64 ± 1 .5 6  years. T here was no 
significant difference in d isease duration  betw een the 
tw o groups (P  =  0.6).
No association of constitutive IL4 production and 
drug treatment
All but one o f the patients w ith SL E  w ho show ed high 
levels o f IL 4-positive a/?+ D N  T  cells was receiving 
predniso lone therapy (dosage varying from  3 to 
10 m g). Five o f these patients w ere also being treated 
with A zath ioprine (dosage vary ing  from  50 to 100 mg).
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T he rem ain ing  patien t w as being  treated w ith antim a- 
larial d rugs (hyd roxych lo roqu ine , 4 0 0 m g). T w enty - 
four o f the low -IL 4 g roup  w ere also being treated  w ith 
p redn iso lone , 11 o f these in com bination  w ith 
azath ioprine and one in com bination  with antim alar- 
ials. O ne p a tien t w as receiv ing azath ioprine alone, 
seven were receiv ing  an tim alaria ls alone, and one 
patient w as being  treated  w ith a com bination  o f  an ti­
m alarials and azath ioprine. T here  w as no association 
betw een drug  treatm en t and levels o f  constitu tive 
p roduction  of IL4. W hen  the patients treated  w ith 
p redn iso lone w ere d iv ided  arbitrarily  on the basis o f 
steroid dosage into h igh and  low  dose g roups ( >  10 
and < 10 m g, respective ly ), no significant d ifferences 
in percen tages o f  IL 4-positive  a/?+ DN T cells or 
percen tages o f a/?+ D N  T betw een the tw o g roups 
w ere found  (P = 0 .77  and  P = 0 .84 , respectively).
No correlation between IL4 production and plasma C3
Plasm a C3 is m easured  routinely in all pa tien ts  
attending  the L upus clinic. Low  levels o f C3 o ften  
correlate w ith  active disease. H ow ever, in 47 patien ts 
for w hom  data  w ere availab le, percen tages o f  a/?+ D N  
T cells constitu tively  expressing  IL4 did no t co rre la te  
with p lasm a C3 (r = 0 .21 , P  =  0 .44).
No correlation between IL4 production and circulat­
ing anti-dsDNA antibodies
C ircu lating  an ti-dsD N A  an tibod ies are a characteristic  
o f SLE and h igh levels o f  an tibody  are a p red ic to r o f 
severe d isease. In the 47 patien ts for w hom  da ta  w ere 
availab le, there w as no corre la tion  b etw een  levels o f 
c ircu lating  an ti-dsD N A  an tibod ies and  the p e rcen ­
tages o f  IL 4-positive a /J^ D N  T  cells ( r  =  0 .07  
P = 0 .66). H ow ever, there w as a statistically  sign ifi­
cant negative correlation  betw een  C3 and an ti-dsD N A  
for the patien t sam ple considered  in th is study 
(r — — 0 .45 , P = 0 .01), confirm ing the know n re la tio n ­
ship betw een  high an ti-dsD N A  antibodies and low  C3.
No association of constitutive IL4 production with 
ethnic background
O f the 12 patien ts w ith SLE  show ing e levated  
frequency o f constitu tive IL 4-positive  aj?+ D N  T 
cells, n ine w ere C aucasian , one Indian , one A fro- 
C aribbean  and one C hinese. A ll o f  these patien ts 
w ere fem ale. T w en ty -fo u r o f  the g roup  w ith a low 
frequency  o f IL4 positive cells w ere C aucasian , four 
Indian, one A fro -C aribbean , one m ixed race C aucasian  
and A fro -C aribbean  and tw o C hinese; one  o f  these 
patients w as m ale. T here w as no association  betw een  
ethnic background  and levels o f  IL4 production .
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No association of 1LA production with HLA phenotype
T issue-typ ing  data  w ere not availab le  for all o f the 
patien ts bu t w ere obtained  for nine o f  the high- 
frequency  IL 4-positive group  and fo r 24 o f  the 
low -frequency  group. T here  w as a w ide variation  in 
H L A  expression, bu t it was noted  that several p h en o ­
types occurred  m ultiple tim es. F ive o f the 24 patients 
in the low -frequency  g roup  expressed  H LA  A l and 
H L A  B8 w hile ano ther five expressed  H LA  D Q 5. In 
the h igh-frequency  group, four o f the nine patients 
expressed  each o f these pheno types. F ischer’s exact 
test ind icated  that the d ifferences in expression 
betw een  the tw o g roups w ere not significantly  d iffer­
en t ( P = > 0 . 5 )  as m ight be expected , g iven the 
relatively  small sam ple num ber.
Discussion
In this study we have show n that the a/?+ DN T cell 
com partm en t o f patien ts w ith SL E  con tains m ore cells 
positive for in tracellu lar IL4 than the equ iva len t cells 
o f  RA  auto im m une con tro ls o r healthy  controls. O ur 
results are consisten t w ith the findings o f  o ther groups 
w ho  have reported  increased p roduc tion  of IL4 by 
T  cells from  patients w ith au to im m une and atopic 
diseases. Since we only looked  at IL4 and not IFNy in 
o u r study we w ere unable  to de term ine  w hether IL4 
p roducers w ere also IFN y+ . F unauch i et al. have 
dem onstrated  that the frequency  o f  IL 4-positive  cells 
is increased in SLE  com pared  w ith in terferon  gam m a 
(IFN y) p ro d u cers12 and it has been  show n that IL4 
enhances differentiation  o f  no t on ly  B cells bu t also T13cells, particularly  T h2 helper T  cells. A higher 
frequency  o f N K  T cells (a subpopu la tion  o f 
a/? D N  T cells) p roducing  IL4 in patien ts w ith SLE 
than controls, fo llow ing stim ulation  w ith PM A  and 
Ionom ycin  has been d esc rib ed .14 T his N K T  p o p u la­
tion m ainly utilizes V a2 4 Ja Q V /? ll +  T  cell receptor 
in healthy  subjects and these cells have been  show n to 
p roduce  m ostly IFNy on activation . T hen , p roduction  
o f  IFNy by these cells w ould  coun terbalance  the 
ac tion  o f  IL4 in augm enting  the d ifferen tia tion  o f 
naive T  cells into Th2 cells. T his population  of 
V a2 4 Ja  Q V jS ll+ D N  T  cells has been show n by 
o thers to be reduced  in patien ts w ith active SL E 6 and 
to have dysfunction  in abou t 50%  o f p a tie n ts ,1 
although  D N  V a2 4 + T cells are expanded  overall.
W hen  these patients becom e inactive w ith the help  of 
p redn iso lone  therapy, V a24JaQ V /?l 1 + D N  T cells 
becom e detectab le  once again , bu t it is unclear as to 
w hether the function is restored. T his finding w ould 
im plicate  V a24JaQ V /?l 1 + D N T  cells in control o f the 
p a thogenesis  o f S L E  possibly th rough  the production  
o f IFNy.
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It is unclear at p resen t w hy only a m inority  o f 
patien ts had an increased  frequency  o f  in tracellu lar 
IL4 in the a / ^ D N  subpopulation , suggesting that 
these patients are in som e w ay different from  o thers 
w ithin the group . In addition , a h igh frequency  o f 
in tracellu lar IL4 appeared  to be specific to the 
a / i+ D N  T cell popu la tion  and was not found  in the 
C D 4 ^  and C D 8 + popu lations. A ttem pts to correlate 
the increased  exp ression  o f  IL4 by the a/?+ D N  T cell 
popu lation  w ith a variety  o f  o ther criteria  failed to 
yield any re la tionsh ips. T hese patients w ere no t from  
a com m on ethnic  background , did no t share a 
com m on H L A  p h en o ty p e  and there w as no re la tio n ­
ship betw een  the severity  o f  their disease at the tim e 
o f sam pling and the percen tage  o f IL 4-positive  cells. 
T his latter o bserva tion  is in contrast to the w ork  o f 
ano ther g ro u p ,14 w ho  found that disease activ ity  w as 
low est in those patien ts who produced  the h ighest 
levels o f IL4. Indeed , the highest levels o f  IL 4  in the ir 
patien t co h o rt w ere produced  by patien ts  w ith a 
SL E D A I (system ic lupus ery them atosus d isease ac tiv ­
ity index9) G S o f  one. H ow ever, their da ta  w ere 
genera ted  from  only  the subpopulation  o f  D N  cells 
expressing  C D 57 not from  the w hole otjS+ D N  T  cell 
population  and so m ay not be com parab le  w ith ou r 
find ings.14 T here  appeared  to be no re la tionsh ip  
betw een levels o f p lasm a C3 and anti dsD N A  an ti­
bodies and IL 4 p roduced , suggesting that the h igh 
levels o f in tracellu lar IL4 in som e patien ts are not 
sim ply related  to disease activ ity  using these criteria. In 
addition , there appeared  to be no obv ious re lationsh ip  
betw een drug  therapy  and p roduction  o f  IL4. In terest­
ingly, alm ost all o f  o u r patients w ere being  treated  w ith 
predniso lone.
F urther analysis o f the data  show ed that the p e rcen ­
tages o f  a/?+ D N  T cells p resen t in the 15 patien ts with 
the h ighest frequency  o f  IL4 con ta in ing  cells was 
significantly  low er than that in the o ther pa tien ts with 
SLE. A lthough  the significance o f this observation  is 
not yet clear, it m ay lend w eight to the theory  that high 
levels o f IL4 w ithin the D N  T cell popu la tion  are seen 
in those patients w ho lack a regulatory  popu la tion  o f 
cells that w ould o therw ise contro l cy tokine production . 
A lternatively , it is possib le  that w hen the aj?+ D N  T 
cells are p resen t in low er num bers, they receive  m ore 
help to p roduce  cytokines. Such a possib ility  w ould  
suggest that the IL 4-producing  cells w ould  be m ore 
activated and m easurem ent o f  activation  m arkers on 
the w hole subpopu la tion  o f  a/?+ D N  T  cells appeared  to 
confirm  this theory , a lthough  the d ifference  w as not 
significant and num bers w ere too low  to draw  firm 
conclusions. T hese findings are consisten t w ith those o f 
our prev ious study, show ing  that a/?+ D N  T  cells 
express h igher than norm al levels o f  C D 69 and 
H L A -D R .3 H ow ever, it w as no t possib le to determ ine
w hether those cells positive for in tracellu lar IL4 w ere 
also activated  w ithin the constra in ts o f th ree-co lour 
staining and further w ork w ould  be needed  to clarify 
this point. S ince IL4 is under genetic  control and 
p o lym orph ism s have been show n to be related to its 
p ro d u c tio n ,15’16 it w ould be valuable  in fu ture studies to 
determ ine any d ifferences in the geno type in relation 
to IL4 p roduction . It is possib le  that the increased 
recep to r function  seen in som e patien ts with SLE 
m ay play a role in the developm en t o f  disease through 
induction  o f T h2  subset developm ent. T he observation  
that stim ulation with PH A  m asked the differences 
observed  betw een the experim en ta l g roups may be 
exp lained  by the fact that cells in patients w ith SLE 
are already in an activated  state and have been widely 
show n not to react strongly to m itogenic  s tim u la tio n .18 
S tim ulation with PH A  caused m ost o f the individuals 
tested to have a h igher p ercen tage  o f IL 4-positive 
a / ^ D N  T  cells a lthough  there appeared  to be a low er 
level o f  stim ulation in the patien ts w ith SLE. Indeed, 
six o f these patients could  be seen to have a low er 
percen tage  o f  IL4 positive D N  T  cells than they 
expressed constitu tively . It is u nclear as to w hy these 
six patients had reduced  levels o f  IL 4-con ta in ing  cells 
since there was no apparen t corre la tion  fo llow ing PHA 
stim ulation w ith disease activ ity , disease duration  or 
percentage o f a/?+ D N  T cells. In addition , these six 
patients were no t con co rd an t for d rug  treatm ent and did 
no t appear to be conco rdan t for H L A  phenotype.
In conclusion, ou r data  ind icate  that in about one 
third o f patients w ith SL E , there  is a h igher frequency 
o f  a/?+ D N  T cells that constitu tively  express IL4 than 
in control individuals. T his increase in IL4 was m ore 
accentuated  in the a/?+ D N  T  cells than in the C D 4^ 
and C D 8 4" T  cell populations, suggesting  that the DN 
T  cell com partm en t could  be functionally  m ore im por­
tant than the conven tional a/?+ T  cells in these patients 
w ith SLE. A lthough  there w as no d irect correlation 
w ith anti D N A  antibodies, o r indeed  w ith o ther p ara ­
m eters such as d isease activity  or d rug  treatm ent, it is 
possib le that this popu lation  cou ld  con tribu te  to au to ­
antibody  p roduction  but o ther popu la tions not m ea­
sured could  be regulating  the function  o f  the a /i+ DN 
T  cells in SLE.
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